A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
Phase: PHASE2
Conditions: Biliary Tract Cancer (BTC)
Sponsor: TerSera Therapeutics LLC

 
Title:   A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® 
(Telotristat Ethyl) plus First-line Chemotherapy in Patients with Locally Advanced, 
Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC) 
 
 
NCT Number: 03790111 
 
Protocol Approval Date:   November 23, 2020 
 
Certain information within this protocol has been redacted (ie, Specific content is 
masked irreversibly from view with a black bar) to protect either personally 
identifiable information or company confidential information. 
 
This may include, but is not limited to, redaction of the following: 
 
• Named persons or organizations associated with the study. 
 
• Proprietary information, such as scales or coding systems, which are 
considered confidential information under prior agreements with license 
holder. 
 
• Other information as needed to protect confidentiality of TerSera or 
partners, personal information, or to otherwise protect the integrity of the 
clinical study. 
 
The information contained in the following document is the property of TerSera 
Therapeutics LLC and should not be shared or used for any purpose other than for 
which it was provided. 
 
 

15 November 2020 
Page 1 of 117 
CLINICAL STUDY PROTOCOL 
Protocol Number: 
LX1606.1-207-BTC 
LX1606.207 (Abbreviated number) 
Investigational Phase: 
2a 
Protocol Title: 
A Phase 2, Multicenter, Open-label, Safety and Efficacy Study 
of XERMELO® (Telotristat Ethyl) plus First-line 
Chemotherapy in Patients with Locally Advanced, 
Unresectable, Recurrent or Metastatic Biliary Tract Cancer 
(BTC) 
Study Name: 
TELE-ABC (Telotristat Ethyl for Advanced Biliary Tract 
Cancer) 
Amendment 3 Date 
23 November 2020 
Administrative Change 
29 May 2020 
Amendment 2 Date 
08 August 2019 
Amendment 1 Date 
13 December 2018 
Original Version Date: 
24 October 2018 
Sponsor: 
TerSera Therapeutics LLC 
 520 Lake Cook Road, Suite 500 
Deerfield, IL 60015 
Medical Director: 
Co-Coordinating 
Investigators 
CCI
CCI
CCI
CCI
CCI
CC1
CCI
CCI
CC1
CCI

X E R M E L O ®  Pr ot oc ol N o. L X 1 6 0 6. 2 0 7 
1 5 N o ve m ber 2 0 2 0 
Pa ge  2 of 1 1 7  
I n vesti g at or Si g n at ure P a ge 
Pr ot oc ol N u m ber: 
L X 1 6 0 6. 1- 2 0 7- B T C 
L X 1 6 0 6. 2 0 7 ( A b bre viate d n u m ber) 
Pr ot oc ol Title: 
A P hase 2, M ultice nter, O pe n-la bel, Safet y a n d 
Efficac y St u d y of X E R M E L O ®  ( Tel otristat Et h yl) 
pl us First-li ne C he m ot hera p y i n Patie nts wit h L ocall y 
A d va nce d, U nresecta ble, Rec urre nt or Metastatic 
Biliar y Tract Ca ncer ( B T C) 
A me n d me nt 1 D ate 
1 3 Dece m ber 2 0 1 8 
A me n d me nt 2 D ate 
0 8 A u g ust 2 0 1 9 
A me n d me nt 3 D ate 
1 5 N o ve m ber 2 0 2 0 
Ori gi n al Versi o n D ate: 
2 4 Oct o ber 2 0 1 8 
S p o ns or: 
Ter Sera T hera pe utics L L C  
5 2 0 La ke C o o k R oa d, S uite 5 0 0  
Deerfiel d, I L 6 0 0 1 5  
B y m y si g nat ure bel o w, I here b y attest t hat I ha ve rea d a n d t hat I u n dersta n d a n d will a bi de 
b y all t he c o n diti o ns, i nstr ucti o ns, a n d restricti o ns c o ntai ne d i n t he attac he d pr ot oc ol a n d 
will c o n d uct t he st u d y i n acc or da nce wit h I nter nati o nal C o u ncil f or Har m o nisati o n (I C H) 
E 6 G o o d Cli nical Practice ( G C P) g ui da nce. 
A d diti o nall y, I will n ot i nitiate t his st u d y wit h o ut writte n a n d date d a p pr o val fr o m t he 
a p pr o priate I nstit uti o nal Re vie w B oar d (I R B)/ Et hic Re vie w C o m mittee ( E R C), a n d I 
u n dersta n d t hat a n y c ha n ges i n t he pr ot oc ol m ust be a p pr o ve d i n writi n g b y t he S p o ns or, 
t he I R B/ E R C, a n d, i n certai n cases t he U nite d States ( U S) F o o d a n d Dr u g A d mi nistrati o n 
( F D A) or ot her a p plica ble re g ulat or y a ge ncies, bef ore t he y ca n be i m ple me nte d, e xce pt 
w here necessar y t o eli mi nate hazar ds t o partici pa nts. 
Ter Sera E xec uti ve Vice Presi de nt R & D a n d 
C hief Me dical Officer ( Si g nat ure)
      Date 
Pri nci pal I n vesti gat or  
( Si g nat ure)    
      Date 
Pri nci pal I n vesti gat or ( Pri nte d Na me)          
Ter Sera E xec uti ve Direct or of Cli nical 
De vel o p me nt 
     Date 
, 7 1 9 0 4 3 6 Ā- 6: 2 5 7 8 2 Ā/,) Ā,"* $! &', Ȁ"!*" Ȁ # #-, Ȁ( +* & Ȁ"*. %,'! !.- 
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 3 of 117 
PROTOCOL AMENDMENT SUMMARY OF KEY CHANGES 
1. Replaced former Sponsor name (Lexicon) and contact details, including Medical
Director, Medical Monitor and Safety reporting contacts with new Sponsor (TerSera
Therapeutics LLC) and contact details throughout the protocol.
2. Added Amendment 3 date.
3. Clarified in the Synopsis and throughout the protocol that efficacy, based on progression-
free survival rate at Month 6 will also be assessed in the Per Protocol population and by
treatment cycle.
4. Clarified in the Synopsis and within the protocol that Cycle 10 Day 1 is considered the
Month 6 timepoint and Cycle 19 Day 1 is considered the Month 12 timepoint for analysis
purposes.
5. Clarified that enrollment into Stage 2 will continue if greater than or equal to (≥) 60% of
patients in the Safety Population and the Per-Protocol (PP) population survive and remain
progression-free at Month 6.
6. Clarified in the Synopsis and throughout the protocol that certain
7. Updated the synopsis and throughout the protocol which endpoints are exploratory
endpoints.
8. Added new exploratory efficacy endpoint
9. Added new exploratory subgroup analyses
10. Included that patients who prematurely discontinued from Treatment Period or withdrew
consent from Treatment Period prior to Month 6 of the Treatment Period, will be asked to
reconsent to allow for images and or imaging reports, obtained locally, to be submitted to
BICR.
11. Added a formal interim analysis to be conducted on the Stage 1 analysis group, i.e., the
first 20 patients enrolled in the study. The interim analysis results will include safety,
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 4 of 117 
efficacy (response rates) and pharmacodynamic (biomarker) data. These data will be used 
to help plan for future studies. 
12. Outlined that C1D1 images do not need to be collected and submitted to BICR when
images that were obtained within 6 weeks prior to Day 1 were submitted to BICR.
13. Clarified that Screening images obtained within 6 weeks prior to and including Cycle 1
Day 1 (C1D1), or whichever images were closest in date to C1D1, will be considered
Baseline.
14. Minor grammatical edits have been incorporated throughout the protocol.
15. Added Appendix K detailing each edit within the document, except minor grammatical
changes.
For a detailed summary of all changes, please refer to Appendix K. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 5 of 117 
1 
SYNOPSIS 
Name of Study Drug 
XERMELO® (telotristat ethyl) 
Protocol Number 
LX1606.1-207-BTC 
LX1606.207 (Abbreviated number) 
Protocol Title 
A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of 
XERMELO® (telotristat ethyl) plus First-line Chemotherapy in 
Patients with Unresectable, Locally Advanced, Recurrent or 
Metastatic Biliary Tract Cancer (BTC)  
Primary Objective 
The primary objective of the study is to assess the safety and 
efficacy (PFS rate at Month 6) in the Safety population receiving the 
combination of XERMELO plus 1L treatment with cis/gem 
combination chemotherapy. Efficacy (PFS rate at Month 6) will also 
be evaluated in the Per Protocol Population (PP) and by treatment 
cycle.   
Secondary Objectives 
To assess the effect of study treatment on the following: 
•
Overall survival (OS)
•
OS rate at Months 6 and 12
•
PFS rate at Month 12 and median PFS at Month 12
•
Disease control rate (DCR); defined as complete response (CR)
+ partial response (PR) + stable disease (SD) at Months 6 and
12 and End of Study (EOS)
•
Objective response rate (ORR) defined as CR + PR at Months 6
and 12 and EOS
•
Local radiologist’s assessment of PFS, ORR, and DCR
•
Change from Baseline in plasma 5-hydroxyindoleacetic acid (5-
HIAA) and serum carbohydrate antigen 19-9 (CA 19-9) at
Months 6 and 12 and EOS
•
Change from Baseline in body weight at Months 6 and 12 and
EOS
•
Change from Baseline in serum albumin at Months 6 and 12
and EOS
Note: Unless otherwise indicated, all radiologic endpoints will be 
based on Response Evaluation Criteria in Solid Tumors (RECIST) 
v1.1 as determined by blinded independent central review (BICR) 
and compared to published historical data of cisplatin/gemcitabine 
(cis/gem) alone. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 6 of 117 
Exploratory Objectives 
To assess the effect of study treatment on the following: 
•
Changes in health-related quality of life (HRQoL) as
measured by European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life
Questionnaire Core 30 (QLQ-C30) and Cholangiocarcinoma
and Gallbladder Cancer (QLQ-BIL21) items at Baseline,
Months 6 and 12;
•
Change from Baseline in carcinogenic embryonic antigen
(CEA) fragment at Months 6 and 12 and EOS;
•
Subgroup analyses of PFS, OS, ORR, and DCR using both
BICR and local radiologist’s assessment, based on
categorical group of Baseline and change from Baseline at
Months 6 and 12 and EOS in:
o
body weight
o
serum albumin
o
correlation between Baseline neutrophil:lymphocyte
ratio and OS
•
Subgroup analyses in:
o
Patients with changes in liver function tests
o
Patients with Biliary stents
o
Location of disease (intrahepatic, extrahepatic, or
gallbladder)
o
Extent of disease
o
Demographic groups
•
Efficacy analyses by treatment cycles (such as in patients
who completed 
 with combination
treatment)
Pharmacokinetic (PK) 
Objectives 
To identify intrinsic and extrinsic factors contributing to variability 
in exposure of XERMELO and the active metabolite, LP-778902, 
when dosed as a combination treatment with cisplatin and 
gemcitabine, including but not limited to, age, sex, race, body mass 
index (BMI), as compared to historical data  
Substudy Objectives 
•
To assess the effect of study treatment based on
characterization of tumor tissue by immunohistochemical (IHC)
staining (i.e., serotonin [5-HT] and tryptophan hydroxylase-1
[TPH-1])
•
To determine the population PK profile among patients who
participate in intensive PK sampling
Primary Safety Objectives 
Evaluation of overall safety will be assessed by means of the 
following: 
•
Incidence of treatment-emergent adverse events (TEAEs) and
severity assessment using National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events (CTCAE)
v5.0
CCI
CCI
CC1
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 7 of 117 
•
Change from Baseline in clinical laboratory results including
frequency of values meeting CTCAE severity Grades >1,
laboratory data toxicities as defined by NCI CTCAE v5.0,
physical examination (PE) findings, vital signs, and
electrocardiogram (ECG) findings
Phase of Development 
Phase 2a 
Methodology 
This study will be conducted as a multicenter, open-label, 2-stage 
study to assess the safety, tolerability, and efficacy of XERMELO in 
combination with first-line (1L) therapy (cisplatin plus gemcitabine) 
in patients with unresectable, locally advanced, recurrent or 
metastatic BTC (intrahepatic or extrahepatic cholangiocarcinoma, 
gallbladder cancer), who are naïve to tumor-directed therapy in the 
locally advanced or metastatic setting, and for which treatment with 
1L therapy (defined as a combination of cis/gem) is planned.  
Note: 1L therapy will not be provided for this study by the Sponsor.  
Note: Efficacy (PFS rate at Month 6) will also be assessed in the Per 
Protocol population and by treatment cycle. 
Note: For statistical purposes and most analyses, Cycle 1 Day 
1 is intended as Baseline, Cycle 10 Day 1 is intended as 
Month 6, and Cycle 19 Day 1 is intended as Month 12.  
Study Overview: 
Stage 1 
Stage 1 enrollment will include a Safety Run-in cohort. Safety and 
tolerability data of the combination treatment from the first 6 
patients who complete at least 21 days of safety follow-up after the 
first dose of combination treatment will be evaluated by the 
Coordinating Investigators, Sponsor, and Medical Monitor in 
accordance with established clinical stopping rules. This review will 
include all safety assessments from all patients obtained prior to the 
second chemotherapy cycle of the 6th patient enrolled. During this 
safety review, Stage 1 enrollment will continue as per the study 
schema outlined below. It is anticipated that a total of 20 patients 
will participate in Stage 1. If there are no clinically significant or 
unresolved Grade 3 or higher toxicities considered related to the 
study drug, and if efficacy in 12 (60%) or more of the 20 patients are 
deemed responders, in the Safety population, enrollment will 
continue to Stage 2. In addition, efficacy will be assessed in the Per-
Protocol (PP) population and by treatment cycle.  
Stage 2 
Stage 2 may initiate enrollment once Stage 1 enrollment has been 
completed, in the absence of significant or unresolved Grade 3 or 
higher toxicities considered related to the study drugs. 
Approximately 33 additional patients are anticipated to participate in 
Stage 2. Study duration and assessments in this stage will be 
identical to Stage 1.  
From a total of 53 accrued patients from Stage 1 + Stage 2, if 34 
(>60%) or more responses are observed (i.e., patients are alive and 
progression-free at Month 6) in the Safety population, the study will 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 8 of 117 
be declared successful. Efficacy will also be assessed in the PP 
population and by treatment cycle. 
Study Treatment (Stage 1 and Stage 2) 
On Day 1 (D1), eligible patients are to initiate Cycle 1 (C1), a 21-
day cycle of XERMELO plus 1L therapy (herein referred to as 
“combination treatment”) as follows:  
o
XERMELO 250 mg (1 x 250-mg tablet) given as an oral
dose 3 times daily (tid) for 7 days, plus
o
Cisplatin 25 mg/m2 administered intravenously (iv) over 60
to 90 minutes, followed by
o
Gemcitabine 1000 mg/m2 administered iv over 30 minutes
On Day 8, patients will receive combination treatment as follows: 
o
XERMELO 500 mg (2 x 250-mg tablets) tid for 14 days,
plus
o
Cis/Gem as described above
Every 21 days thereafter, patients will initiate a new 21-day cycle 
(eg, Cycle 2 [C2], Cycle 3 [C3]) and will receive combination 
treatment, administered as  
o
XERMELO 500 mg tid, plus
o
Cis/Gem regimen as described above on Day 1 and Day 8 of
each cycle
Dose modification(s) and/or delay in treatment may be permitted as 
described in the sections described below. During the Treatment 
Period, patients may discontinue cisplatin and continue treatment 
with XERMELO plus gemcitabine alone at the Investigator’s 
discretion. Gemcitabine should be administered on the same 
schedule as described above. 
Active symptom control will be permitted during the study as 
clinically indicated.  
Radiological assessment of the tumor by computed tomography (CT) 
or magnetic resonance imaging (MRI) will be conducted prior to 
initiating treatment on Cycle 1 Day 1 (C1D1), then every 9 weeks (3 
cycles) for the remaining duration of the Treatment Period. Note: If 
a radiological assessment has performed within 6 weeks prior to Day 
1, a Day 1 assessment will not be required. 
All imaging will be evaluated by the local radiologist (or designee) 
for clinical management. If a change in response is noted by the local 
radiologist or Investigator at any time during the study a second 
radiological assessment should be performed within 4-6 weeks to 
confirm.    
All images will be sent to a central review facility for 
blinded, independent-parallel reading (i.e., BICR) for assessments of 
study endpoints. No information regarding results of progressive 
disease (PD) determination will be shared between central radiologic 
review and the local radiologist/Principal Investigator at any time 
during the study. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 9 of 117 
Note: Management of biliary obstruction and/or ascending 
cholangitis will not be considered as PD in the absence of 
radiologically confirmed PD. 
Patients may continue to receive combination treatment as described 
above for as many cycles as possible until PD as determined by local 
review, unacceptable toxicity, or the patient withdraws from 
treatment. At this time, chemotherapy will be discontinued, the End-
of-Treatment (EOT) assessments should occur, and the patient 
should enter the Follow-up Period. Visit dates for the Follow-up 
period are based off the EOT date.  
Follow-up Periods: 
All patients are expected to be followed for a total duration of 24 
months after the Treatment Period unless they prematurely 
discontinue or voluntarily withdraw consent from future study visits 
or assessments. This 24-month phase is divided into 2 periods; the 
Post-treatment Follow-up Period (PTFP) where onsite visits occur 
every 3 months, and the Survival Follow-up Period, where survival 
status will be collected by phone and no onsite visits are required. 
Post-treatment Follow-up 
All patients are expected to enter a Post-treatment Follow-up Period 
(PTFP) at the time PD is confirmed locally or the patient experiences 
unacceptable toxicity, or the patient withdraws from chemotherapy 
in the absence of PD. During the Post-treatment Follow-up Period, 
patients may continue treatment with XERMELO at the discretion of 
the treating physician. 
Patients will complete scheduled study visits every 3 months for a 
total of 24 months or until the patient begins a new tumor-directed 
therapy, prematurely discontinues, declines further treatment after 
progression, or withdraws consent from future study visits or 
assessments. At this time, the End of Study (EOS) procedures should 
be performed and the patient should enter the Survival Follow-up 
(unless 24 months of follow-up after the last dose of chemotherapy 
has already occurred). 
Note: For those patients who enter the PTFP prior to PD confirmed 
locally (i.e., those who experience an unacceptable toxicity or 
withdraw from chemotherapy), routine imaging assessments will 
continue to be performed every 3 months until PD is confirmed by 
local review. 
Note: For those patients who enter PTFP prior to having their 6-
month imaging assessment in the Treatment Period, will be asked to 
consent to provide their local scans and/or local scan report closest to 
the Treatment Period 6-month timepoint. This includes the possible 
reconsenting of patients previously prematurely discontinued or 
withdrew consent from the Treatment Period of the study. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 10 of 117 
Survival Follow-up 
Once a new tumor-directed therapy begins, or a patient declines 
further treatment after progression, patients will enter the Survival 
Follow-up Period. All patients will be monitored until death, 
withdrawal of consent, loss to follow-up, or for a period of 24 
months following the last dose of chemotherapy, whichever comes 
first.   
Note: Patients who enter SFP without entering or completing PTFP 
and who entered SFP prior to having their 6-month imaging 
assessment in the Treatment Period, will be asked to consent to 
provide their local scans and/or local scan report closest to the 
Treatment Period 6-month timepoint. This includes the possible 
reconsenting of patients previously prematurely discontinued or 
withdrew consent from the Treatment Period of the study. 
The study scheme is as follows: 
Enroll Safety 
Cohort n=6
TE
1 + 1L
1 Cycle (21 days)
Enroll additional 
cohort n=6
TE
1 + 1L Reduced 
Dose
1 Cycle (21 Days)
Enroll remaining 
Stage 1 n=20
TE
1 + 1L
Terminate Study
Enroll remaining 
Stage 1 n=20
TE
1 + 1L Reduced 
Dose
If Clinically Significant AE*
 seen in ≥2 Patients
Treatment Period
Post Treatment 
Follow-up Period
Survival Follow-up 
Period
LX1606.207 
TE
1 + 1L in 
Patients with BTC 
N= 53
Enroll Stage 2 n=33
TE
1 + 1L Reduced 
Dose
If Clinically Significant AE* 
seen in ≤1 Patient
Enroll Stage 2 
n=33
TE
1 + 1L
If Clinically Significant AE*
 seen in ≤1 patient
If Clinically Significant AE*
 seen in ≥2 Patients
*Clinically Significant AE defined as unresolved, ≥Grade 3 non 
hematological toxicity related to study drug (See Exclusions in 
Protocol).
1 TE = Telotristat Ethyl
Number of Patients 
A total of 20 patients are anticipated to be enrolled in Stage 1 and 33 
patients in Stage 2, for a total of 53 patients enrolled in the study.  
Patients 
Eligible patients are defined as, adults of either sex (≥18 years of 
age) with unresectable, locally advanced, recurrent, or metastatic 
BTC (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder 
cancer) naïve to tumor-directed therapy in the locally advanced or 
metastatic setting and are candidates to receive 1L therapy. 
Number of Study Sites 
Approximately 15 sites in the United States 
Study Treatments 
XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 
250-mg tablet) tid for the first 7 days, then 500 mg (2 x 250-mg
tablets) tid plus 1L therapy for the duration of the study
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 11 of 117 
Route of Administration 
XERMELO is administered orally, cisplatin and gemcitabine are 
administered intravenously. 
Duration of Treatment 
Approximately 6 months of combination treatment (XERMELO plus 
1L therapy).  
Note: Patients may continue to receive treatment for as many cycles 
possible, until progressive disease (PD) (up to 19 cycles during the 
Treatment Period), and during the Post Treatment Follow-up Period 
(up to an additional 24 months) at the discretion of the Investigator. 
Inclusion Criteria 
Patients must meet all of the following criteria at Screening, or as 
otherwise indicated, to be considered eligible to participate in the 
study: 
1.
Adults of either sex, ≥18 years of age. Patients of
childbearing potential must agree to use an adequate method
of contraception during the study and for 30 days after the
last dose of XERMELO.
a.
Childbearing potential is defined as those who have
not undergone surgical sterilization (eg, documented
hysterectomy, tubal ligation, or bilateral salpingo-
oophorectomy) or those who are not considered
postmenopausal (defined as 12 months of
spontaneous amenorrhea). If necessary, follicular-
stimulating hormone (FSH) results >35 IU/L at
Screening are confirmatory in the absence of a clear
postmenopausal history.
b.
Adequate methods of contraception, defined as
having a failure rate of <1% per year, for patients or
their partner include the following: condom with
spermicidal gel, diaphragm with spermicidal gel,
intrauterine device, surgical sterilization, vasectomy,
oral contraceptive pill, depo-progesterone injections,
progesterone implant (i.e., Implanon®), patch
(Ortho Evra®), NuvaRing®, and abstinence. If a
patient is not sexually active but becomes active,
they or their partner should use medically accepted
forms of contraception.
2.
Histopathologically or cytologically-confirmed,
unresectable, locally advanced, recurrent, or metastatic BTC
(intrahepatic or extrahepatic cholangiocarcinoma,
gallbladder cancer)
3.
Naïve to tumor-directed therapy in locally advanced,
unresectable, or metastatic setting. Note: Previous treatment
with chemotherapy in the adjuvant setting (including
previous exposure to 1L therapy) will be permitted if PD is
confirmed >6 months following treatment.
4.
Measurable disease, defined as the presence of at least 1
measurable lesion as determined by RECIST v1.1 using
conventional imaging with CT or MRI
5.
Eastern Cooperative Oncology Group (ECOG) performance
status 0-1
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 12 of 117 
6.
Plans to initiate treatment with 1L therapy; defined as
cis/gem: cisplatin 25 mg/m2 administered iv over 60 to 90
minutes followed by gemcitabine1000 mg/m2 administered
iv over 30 minutes as standard of care
7.
Ability to provide written informed consent prior to
participation in any study-related procedure
Exclusion Criteria 
Patients who meet any of the following criteria at Screening, or as 
otherwise indicated, will be excluded from participating in the study:  
1.
Prior exposure to XERMELO, telotristat ethyl, telotristat
etiprate, LX1032, or LX1606
2.
Primary tumor site in the ampulla of Vater
3.
Treatment with photodynamic therapy for localized disease
or to relieve biliary obstruction in the presence of metastatic
disease within the past 30 days
4.
Hematology laboratory values of:
a.
Absolute neutrophil count (ANC) ≤1,500 cells/mm3;
or
b.
Platelets ≤100,000 cells/mm3; or
c.
Hemoglobin (Hgb) ≤9 g/dL; or
d.
White blood count (WBC) ≤3,000 cells/mm3
5.
Hepatic laboratory values of aspartate transaminase (AST)
or alanine aminotransferase (ALT):
a.
>5 x upper limit of normal (ULN) if patient has
documented history of hepatic metastases; or
b.
>2.5 x ULN if no liver metastases are present
6.
Serum albumin <2.8 g/dL
7.
Total bilirubin >1.5 x ULN or >1.5 mg/dL
8.
Prothrombin time (PT) or international normalized ratio
(INR) >1.5 x ULN. Note: Patients receiving therapeutic
doses of anticoagulant therapy may be considered eligible if
PT and INR are within the acceptable therapeutic limits for
the institution.
9.
Serum creatinine or serum urea >1.5 x ULN
10. Estimated glomerular filtration rate (eGFR) <50 mL/min
11. Positive pregnancy test, pregnant, or breastfeeding (female
patients only)
12. Any other clinically significant laboratory abnormality that
would compromise patient safety or the outcome of the
study
13. Any clinically significant and/or uncontrolled cardiac-related
abnormality that would compromise patient safety or the
outcome of the study including, but not limited to:
a.
Arrhythmia
b.
Bradycardia
c.
Tachycardia
d.
Symptomatic valvular disease
e.
Symptomatic congestive heart failure classified by
New York Heart Association (NYHA) as Class III
or IV
f.
Evidence of ischemia on ECG
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 13 of 117 
g.
Unstable angina pectoris
14. Myocardial infarction within the past 6 months
15. Active bleeding diathesis
16. Life expectancy ≤3 months
17. Current complaints of persistent constipation or history of
chronic constipation, bowel obstruction or fecaloma within
the past 6 months
18. Receiving chronic treatment with corticosteroids, ≥5 mg/day
of prednisone (or equivalent), or other immunosuppressive
agent(s)
19. Known history and/or uncontrolled hepatitis B surface
antigen (HBsAg), hepatitis C antibody (HCV Ab), or human
immunodeficiency virus (HIV)-1 or HIV-2
Note:  Because of the possibility of spontaneous resolution
of and success of treatment for hepatitis C, a clarification is
being provided. Patients who have a history of hepatitis C
will be allowed if their HCV RNA load is below the range
that reflects infection with the virus at a time point that is at
least 12 weeks after a spontaneous remission or 24 weeks
after the end of treatment for hepatitis C.
Hepatitis B patients will continue to be excluded based on having 
history of the disease. 
20. History of substance or alcohol abuse (Diagnostic and
Statistical Manual of Mental Disorders 5th edition [DSM-V]
Criteria for Substance-Related Disorders) within the past 2
years
21. History of galactose intolerance, deficiency of Lapp lactase,
or glucose-galactose malabsorption
22. History of malignancy or active treatment for malignancy
(i.e., radiation or chemotherapy, including monoclonal
antibodies) within 5 years. Note: Patients with squamous or
basal cell carcinomas of the skin, carcinomas in situ of the
cervix or uterus, ductal breast cancer in situ, resected low-
grade prostate cancer, or other malignancies that in the
opinion of the Investigator and the Medical Monitor are
considered cured, may participate.
23. Receipt of live, attenuated vaccine (eg, intranasal influenza,
measles, mumps, rubella, varicella) or close contact with
someone who has received a live, attenuated vaccine within
the past 1 month. Note: Influenza vaccine will be allowed if
administered >21 days prior to planned Day 1.
24. Receipt of any investigational agent or study treatment (i.e.,
any treatment or therapy not approved by the FDA for the
treatment of BTC) within the past 30 days
25. Receipt of any protein or antibody-based therapeutic agents
(eg, growth hormones or monoclonal antibodies) within the
past 3 months
26. Treatment with any tumor-directed therapy including, but
not limited to, chemotherapy or radiotherapy within the past
6 months with curative intent. Note: Treatment (i.e.,
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 14 of 117 
radiation, chemoembolization, radioembolization, or other 
local ablative therapies, or hepatic resection) is permitted if 
received ≥4 weeks from Screening and the patient has 
recovered to severity ≤Grade 1 toxicities as defined by NCI 
CTCAE v5.0. 
27. Existence of any surgical or medical condition that, in the
judgment of the Investigator, might compromise patient
safety or the outcome of the study
28. Presence of any clinically significant findings (relative to the
patient population) during review of medical history or upon
PE that, in the Investigator’s or Medical Monitor’s opinion,
would compromise patient safety or the outcome of the
study (e.g., psychiatric illness/social situations that would
limit compliance with study requirements)
29. Evidence of brain metastases
30. Unable or unwilling to communicate or cooperate with the
Investigator for any reason
31. Employee of Sponsor or clinical site, or relative of any
member of a clinical site’s staff
Interim Analysis 
A formal statistical interim analysis will be performed on patients 
included in the Stage 1 analysis. The interim analysis results will 
include safety, efficacy (PF responder rates), and pharmacodynamic 
(biomarker) data. These data will be used to help plan for future 
studies. 
Interim Analysis will be conducted: 
•
In addition to (Stage 1 + Stage 2) analysis, after all 53 patients
complete Month 6
•
In addition to (Stage 1 + Stage 2) analysis after, all 53 patients
complete Month 12
Statistical Methods 
Three patient populations will be used for analyses. A Per-protocol 
(PP) population will consist of those patients that 
and who have no major protocol 
violation(s) that would interfere with the collection or interpretation 
of the efficacy data. A Safety population will consist of all patients 
receiving any fraction of a dose of study drug. A PK population will 
be made up of all patients treated with at least 1 dose of study drug 
and who have adequate samples taken to reliably estimate the 
parameters of interest. 
The primary and secondary efficacy endpoints will be analyzed 
based on the Safety population. Additional analyses for the primary 
and secondary efficacy endpoints will be performed using the PP 
population.  
A Simon’s 2-stage design algorithm will be used to assess whether 
the study is successful at each stage of the analysis. In the Stage 1 
Safety population, if there are no clinically significant or unresolved 
Grade 3 or higher toxicities considered related to the study drug and 
if 12 or more (≥60%) of the 20 patients enrolled are deemed 
responders per the definition below after the 20th patient is censored, 
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 15 of 117 
is alive and progression-free at the Month 6 assessment, or has 
discontinued for any reason, the first stage of the study will be 
declared successful and enrollment will continue in Stage 2. Efficacy 
will also be assessed in the PP populations and by treatment cycle. 
Note: Patients are considered responders if they are alive and 
progression-free at the Month 6 assessment; otherwise, they are 
considered non-responders. 
In Stage 2, an additional 33 patients will be enrolled. If 34 (>60%) or 
more of the 53 patients enrolled (Stage 1 + Stage 2) are deemed 
responders, the study will be considered successful. Efficacy will 
also be assessed in the PP populations and by treatment cycle. 
For the primary endpoint, the distribution of PFS will be estimated 
using the Kaplan-Meier (KM) approach. The distribution of PFS 
from KM will be used to estimate the PFS rates and corresponding 
95% confidence intervals (CI) at Month 6. In addition, the PFS rate 
at Month 12 and EOS visit along with their corresponding 95% CI 
will be presented. The median PFS value computed from this study 
will be compared with the historical/published median PFS time of 
cis/gem alone. Patients without PD or death will be censored at the 
last centrally confirmed radiographic assessment prior to study 
completion. In addition, patients who are lost to follow-up or 
discontinued from the study after receiving study treatment will be 
censored at the last date of contact prior to lost to follow-up or date 
of discontinuation, respectively. The same model will be applied to 
analyze the median OS and the OS rate at Months 6 and 12. 
Subgroup analyses may be performed based on the primary tumor 
site, prior therapy(ies), performance status, major demographic and 
prognostic subgroups, extent of disease, and Baseline biomarker 
levels. 
Descriptive statistics will be used to summarize the data for the 
response rates and pharmacodynamic endpoints. Continuous 
variables will be summarized by n, mean, standard deviation (SD), 
median, minimum, and maximum values. Categorical variables will 
be summarized by patient counts and percentages.  
All imaging for study endpoints will be assessed by the local 
radiologist and BICR. The BICR will supersede the local 
radiologist’s assessment for the purpose of primary analysis of all 
applicable study objectives. A secondary analysis will be performed 
to further evaluate study objectives using the local radiologist 
assessments.  
For binary endpoints, such as ORR and DCR, the frequency and 
proportion of patients achieving the outcome in association with 
Fishers exact test will be presented at each assessed study time point. 
Other efficacy endpoints will be summarized descriptively by study 
time point. Change from Baseline for plasma 
will be summarized descriptively and 1-sample t-tests 
may be performed to test for significance. In addition, descriptive 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 16 of 117 
summaries of these endpoints will also be reported for responder and 
non-responder subgroups with respect to ORR and DCR. 
Efficacy Assessments 
Efficacy assessments include radiological study by CT or MRI and 
measurement of the tumor by RECIST v1.1 for the determination of 
PFS, ORR (CR+PR), and DCR (CR + PR + SD). In addition, 
HRQoL will be evaluated by EORTC QLQ-30 and QLQ-BIL21. 
Safety Assessments 
Safety and tolerability will be evaluated through the collection and 
review of TEAEs, including out-of-range laboratory parameters as 
graded by the CTCAE v5.0, vital signs measurement, 12-lead ECG 
findings, PE findings, and clinical laboratory parameters (chemistry, 
hematology, and urinalysis) including changes from Baseline and 
frequency of values meeting CTCAE Grades >1 for severity. 
Pharmacodynamic and 
Pharmacokinetic 
Assessments 
Pharmacodynamic assessments include the determination of 
Pharmacokinetic (PK) assessments include the determination of 
concentrations of XERMELO and the active metabolite, LP-778902. 
Dose Modification - 
XERMELO 
In general, the following dose modification rules will be used with 
respect to potential toxicity and management of TEAEs believed to 
be related to XERMELO. Toxicity will be assessed according to the 
NCI CTCAE v5.0. 
Grade of 
Event 
Management/Next XERMELO Dose2 
Grade 1 
No change in dose 
Grade 2 
Hold until ≤Grade 1. Resume at same dose level. 
Grade 3 
Hold until ≤Grade 1. Resume at 1 dose level 
lower (250 mg tid).1
Grade 4 
Discontinue treatment. 
1Patients unable to tolerate 250 mg tid should be discontinued from 
XERMELO.
2Rechallenge may be permitted upon consultation with the Medical Monitor.
Recommended management for the following AEs: 
•
Nausea and/or vomiting: treat with antiemetics
•
Diarrhea: treat as indicated for underlying cause
•
Gastrointestinal toxicity:
o
Monitor concomitant medication usage
o
Constipation (Grade 1 and above): initiate treatment as
clinically indicated; examples of therapy(ies) include:
laxatives, enemas, suppositories, psyllium hydration, over-
the-counter (OTC) agents
o
Abdominal pain (Grade 1 and above): initiate treatment as
clinically indicated; examples of therapy(ies) include:
analgesics, anti-gas/bloating agents
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 17 of 117 
o
Hold XERMELO for Grade 2 constipation or abdominal
pain until ≤Grade 1. Resume at 1 dose level lower (250 mg
tid).
o
Discontinue XERMELO for Grade 3 constipation or
abdominal pain.
•
Suicidal ideation: discontinue XERMELO
Dose Modification- 
Cisplatin/Gemcitabine 
In general, the following dose modification rules will be used with 
respect to potential toxicity and management of any TEAEs believed 
to be related to cisplatin or gemcitabine. Toxicity will be assessed 
according to the NCI CTCAE v5.0. 
ANC 
Platelet Count 
Gemcitabine/Cisplat
in 
≥1,000/mm3
and 
≥100,000/mm3
Treat as scheduled 
<1,000/mm3
or/ 
and 
<100,000/mm3
Defer treatment by 1 
week. Reduce dose 
by 1 level for next 
treatment. 
The following dose modification rules will be used with respect to 
hematologic toxicity on Day 8 of each treatment cycle believed to 
be related to cisplatin or gemcitabine: 
ANC 
Platelet Count 
Gemcitabine/Cisplatin 
≥1,000/mm3
and 
≥75,000/mm3
Treat as scheduled 
<1,000/mm3
or/ 
and 
<75,000/mm3
Defer for 1 week. 
Reduce dose by 1 level 
for next treatment. If 
second deferral is 
needed, treatment will 
be omitted.
Note: Administration of granulocyte-colony stimulating factor (G-
CSF) is allowed, but discontinuation is required at least 2 days prior 
to the next administration of chemotherapy. If symptoms do not 
resolve after 28 days of uninterrupted G-CSF, chemotherapy 
treatment should be stopped. 
The following dose modification rules will be used with respect to 
nonhematologic toxicity on Day 1 of each treatment cycle 
believed to be related to cisplatin or gemcitabine. 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 18 of 117 
Nonhematologic 
Toxicity1 
Gemcitabine/Cisplatin 
Grade 1 or 2 
Treat as scheduled 
Grade 3 or 4 
Defer treatment until resolves to ≤Grade 
1. Reduce dose by 1 level for next
treatment.
1Permissible exceptions to this rule are Grade 3 nausea, vomiting, 
hypertension, diarrhea, constipation, and transient electrolyte 
abnormalities that resolve within 72 hours following institution of 
appropriate supportive care, and alopecia.  
The following dose modification rules will be used with respect to 
nonhematologic toxicity on Day 8 of each treatment cycle 
believed to be related to cisplatin or gemcitabine. 
Nonhematologic 
Toxicity1 
Gemcitabine/Cisplatin 
Grade 1 or 2 
Treat as scheduled 
Grade 3 or 4 
Defer treatment until resolves to ≤Grade 1. 
Reduce dose by 1 level for next treatment. 
If deferral is needed for more than 1 week, 
treatment will be omitted. 
1Permissible exceptions to this rule are Grade 3 nausea, vomiting, 
hypertension, diarrhea, constipation, and transient electrolyte 
abnormalities that resolve within 72 hours following institution of 
appropriate supportive care, and alopecia. 
Clinical Stopping Rules 
While the combination treatment in this study is assumed safe due to 
minimal overlapping toxicities, untoward side effects may occur. 
Therefore, assessment of the safety and tolerability data of all 
enrolled patients will occur once the 6th patient has completed 21 
days of combination treatment and will include all safety 
assessments for all patients obtained prior to the second 
chemotherapy cycle of the 6th patient enrolled. The subsequent 
approach will be followed: 
•
If ≤1 patient has a clinically significant (CS) adverse event
(AE), the study will continue without a dose adjustment.
•
If ≥2 patients have CS AE, the dose level will be decreased to
the Reduced Dose level in accordance with the table below, and
6 additional patients will be enrolled and treated with the
Reduced Dose for 1 full cycle.
o
If ≤1 of these patients has a CS AE at the Reduced Dose for
the 1st cycle, the Reduced Dose will be used for the study.
o
If ≥2 patients have a CS AE at the Reduced Dose, the study
will be stopped.
Note: A CS AE is considered an unresolved ≥Grade 3 
nonhematological toxicity, which is related to the study drugs, 
excluding: controllable nausea, vomiting, hypertension, diarrhea, 
constipation, transient electrolyte abnormalities and alopecia; Grade 
3 or higher febrile neutropenia.  
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 19 of 117 
Dose Level 
Gemcitabine 
Cisplatin 
XERMELO 
Starting Dose 
1000 mg/m2
25 mg/m2
500 mg tid 
Reduced Dose 
800 mg/m2
20 mg/m2
250 mg tid 
Note: If any patient experiences a Grade 4 toxicity during the Safety 
Run-in, the Sponsor, in consultation with the Investigator, will 
determine if additional patients should be enrolled at the Reduced 
Dose level. 
Safety Data Analysis 
Safety analysis will involve examination of the descriptive statistics 
and individual patient listings for any effects of XERMELO on 
clinical tolerability and safety. All safety data will be listed by 
patient. 
Summaries will be prepared by CTCAE grade for severity and, as 
needed, by cycle. The TEAE summaries will include the overall 
incidence (by System Organ Class [SOC] and Preferred Term [PT]), 
events by maximum intensity, event by relationship to each study 
drug, TEAEs by study drug exposure time, events leading to 
discontinuation of study drug, and serious adverse events (SAEs). 
Vital signs, ECG findings, PE findings, and laboratory variables 
(hematology, chemistry, and urinalysis) will be summarized 
descriptively at each time point. Actual and change from Baseline 
data will be calculated and summarized. In addition, shift tables will 
be generated for the laboratory variables including changes from 
Baseline and frequency of values meeting CTCAE Grades >1 for 
severity. 
Pharmacokinetic Analysis 
PK data will be summarized by n, arithmetic and geometric mean, 
standard deviation, median, minimum, and maximum values at 
various time points. Regression models may be used to evaluate the 
type and magnitude of associations between trough concentrations 
and clinical outcomes at selected time points. 
Based on intensive PK sampling from a subset of patients and sparse 
PK sampling (eg, trough concentrations) from the study population, 
population PK analyses will explore the effects of covariates 
including, but not limited to, age, sex, race, and body mass index 
(BMI) on the systemic exposure of XERMELO and the active 
metabolite, LP-778902, when dosed as a combination treatment with 
cisplatin and gemcitabine. PK data from this study may be integrated 
with PK data from other clinical trials to further enhance the 
population PK analysis. Details of population PK analysis plan will 
be prepared in a separate document. 
The data analysis plan and results from the population (cumulative) 
PK analysis will be documented in a separate report. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 20 of 117 
TABLE OF CONTENTS 
1 
SYNOPSIS ........................................................................................................................ 5 
2 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS .................................. 24 
3 
INTRODUCTION .......................................................................................................... 27 
3.1 Background on XERMELO and Biliary Tract Cancer .......................................... 27 
3.2 XERMELO Pharmacology .................................................................................... 29 
3.3 XERMELO Toxicology ......................................................................................... 29 
3.4 Clinical Trials of XERMELO in Humans .............................................................. 29 
3.5 Rationale for Current Study ................................................................................... 29 
3.6 Rationale for Selection of Dose ............................................................................. 30 
3.7 Rationale for Study Design .................................................................................... 31 
4 
STUDY OBJECTIVES ................................................................................................... 32 
4.1 Primary Objective .................................................................................................. 32 
4.2 Secondary Objectives ............................................................................................. 32 
4.3 Exploratory Objectives .......................................................................................... 32 
4.4 Pharmacokinetic (PK) Objective ........................................................................... 33 
4.5 Substudy Objectives............................................................................................... 33 
4.6 Safety Objectives ................................................................................................... 33 
5 
INVESTIGATIONAL PLAN ......................................................................................... 34 
5.1 Overall Study Design ............................................................................................. 34 
5.1.1 
Screening .................................................................................................. 34 
5.1.2 
Study Overview ........................................................................................ 34 
6 
STUDY POPULATION .................................................................................................. 39 
6.1 Inclusion Criteria ................................................................................................... 39 
6.2 Exclusion Criteria .................................................................................................. 40 
6.3 Criteria for Stopping Treatment/Study Withdrawal ............................................... 43 
6.3.1 
End-of-Treatment (EOT)/End-of-Study (EOS) Procedures ..................... 43 
6.4 Criteria for Termination of the Study ..................................................................... 45 
6.5 Clinical Stopping Rules ......................................................................................... 45 
6.6 Method of Assigning Patients to Treatment ........................................................... 46 
6.7 Blinding and Unblinding of Study Drug ................................................................ 46 
6.8 Replacement of Patients ......................................................................................... 46 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 21 of 117 
6.9 Rescreening of Patients .......................................................................................... 46 
7 
TREATMENT ................................................................................................................. 47 
7.1 XERMELO (telotristat ethyl) ................................................................................ 47 
7.1.1 
Identity ...................................................................................................... 47 
7.1.2 
Packaging, Labeling, and Storage ............................................................ 47 
7.2 Prior and Concomitant Medications ...................................................................... 47 
7.2.1 
Prior Medication ....................................................................................... 47 
7.2.2 
Concomitant Medication .......................................................................... 47 
7.3 Prohibited Medication or Concomitant Therapy ................................................... 48 
7.4 Administration of Study Drug ............................................................................... 48 
7.4.1 
Treatment Compliance ............................................................................. 48 
7.5 Dose Adjustment/Modification .............................................................................. 49 
7.5.1 
XERMELO (telotristat ethyl) ................................................................... 49 
7.5.2 
Cisplatin/Gemcitabine .............................................................................. 51 
8 
STUDY PROCEDURES ................................................................................................ 53 
8.1 Restrictions during Study ....................................................................................... 53 
8.2 Description of Study Assessments ......................................................................... 53 
8.2.1 
Efficacy Assessments ............................................................................... 53 
8.2.2 
Clinical Laboratory Assessments ............................................................. 54 
8.2.3 
Pharmacodynamic and Pharmacokinetic Assessments ............................ 55 
8.2.4 
Safety Assessments ................................................................................... 55 
8.3 Other Assessments ................................................................................................. 57 
8.3.1 
Performance Status Based on Eastern Cooperative Oncology Group 
(ECOG) .................................................................................................... 57 
8.3.2 
Health-related Quality of Life (HRQoL) .................................................. 58 
8.3.3 
Characterization of the Tumor - Substudy ............................................... 58 
8.4 Appropriateness of Assessments ............................................................................ 58 
9 
SAFETY REPORTING .................................................................................................. 59 
9.1 Definitions and Special Considerations ................................................................. 59 
9.1.1 
Adverse Events ......................................................................................... 59 
9.1.2 
Serious Adverse Events ............................................................................ 60 
9.1.3 
Unexpected Adverse Events ..................................................................... 61 
9.2 Assessment of Adverse Events .............................................................................. 61 
9.2.1 
Severity ..................................................................................................... 61 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 22 of 117 
9.2.2 
Causality ................................................................................................... 61 
9.3 Special Situations ................................................................................................... 62 
9.3.1 
Pregnancy ................................................................................................. 62 
9.3.2 
Adverse Events of Special Interest (AESIs) ............................................. 63 
9.4 Reporting of Serious Adverse Events and Pregnancies ......................................... 64 
9.5 Follow-up of Adverse Events ................................................................................. 65 
9.6 Safety Oversight..................................................................................................... 65 
10 
STATISTICAL METHODOLOGY ................................................................................ 66 
10.1 Determination of Sample Size ............................................................................... 66 
10.2 Analysis Populations .............................................................................................. 66 
10.3 Study Endpoints ..................................................................................................... 67 
10.3.1 Efficacy Endpoints ................................................................................... 67 
10.3.2 Safety Endpoints ....................................................................................... 68 
10.3.3 Pharmacokinetic Endpoints ...................................................................... 68 
10.3.4 Characterization of Tumor Substudy Endpoint ........................................ 69 
10.4 Statistical Methods ................................................................................................. 69 
10.4.1 Efficacy Analyses ..................................................................................... 69 
10.4.2 Safety Analyses ........................................................................................ 71 
10.4.3 Pharmacodynamic Analyses ..................................................................... 72 
10.4.4 Pharmacokinetic Analyses ........................................................................ 72 
10.4.5 Analysis of Health-related Quality of Life (HRQoL) .............................. 73 
10.4.6 Baseline Characteristics and Other Summaries ........................................ 73 
10.4.7 Interim Analysis ....................................................................................... 73 
10.4.8 Protocol Deviations .................................................................................. 74 
11 
STUDY MANAGEMENT ............................................................................................. 75 
11.1 Monitoring ............................................................................................................. 75 
11.2 Protocol Deviations ................................................................................................ 76 
11.3 Audits and Inspections ........................................................................................... 76 
11.4 Amendments .......................................................................................................... 76 
11.5 Record Keeping ..................................................................................................... 77 
11.5.1 Drug Accountability ................................................................................. 77 
11.5.2 Health Insurance Portability Accountability Act of 1996 and Subsequent 
Updates ..................................................................................................... 77 
11.5.3 Financial Disclosure ................................................................................. 77 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 23 of 117 
11.5.4 Access to Original Records ...................................................................... 78 
11.5.5 Retention of Study Documents ................................................................. 78 
12 
ADMINISTRATIVE STRUCTURE OF THE STUDY ................................................. 79 
13 
APPENDIX A – SCHEDULE OF EVENTS: ................................................................. 80 
14 
APPENDIX B – INTENSIVE PK SUBSTUDY SCHEDULE ...................................... 85 
15 
APPENDIX C – ESTIMATED AMOUNT OF BLOOD TO BE COLLECTED FROM 
EACH PATIENT ............................................................................................................. 86 
16 
APPENDIX D – ETHICAL STANDARDS ................................................................... 87 
17 
APPENDIX E – INVESTIGATOR OBLIGATIONS ..................................................... 89 
18 
APPENDIX F – CALCULATIONS ............................................................................... 94 
19 
APPENDIX G – ECOG AND KARNOFSKY PERFORMANCE SCALE 
CONVERSION TABLE ................................................................................................. 95 
20 
APPENDIX H – NATIONAL CANCER INSTITUTE (NCI) COMMON 
TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) V5.0 .................. 96 
21 
APPENDIX I – EORTC QUALITY OF LIFE QUESTIONNAIRE CORE 30 (QLQ-
C30) AND CHOLANGIOCARCINOMA AND GALLBLADDER CANCER (QLQ-
BIL21) MODULE ........................................................................................................... 97 
22 
APPENDIX J – RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
(RECIST) ...................................................................................................................... 100 
23 
APPENDIX K - DETAILED SUMMARY OF PROTOCOL CHANGES ................... 101 
24 
REFERENCES ............................................................................................................. 114 
List of Tables 
Table 6-1 Safety Run-In Dose Reduction .............................................................................. 46 
Table 7-1  Xermelo Dose Modifications ................................................................................. 49 
Table 7-2 Dose Reduction ...................................................................................................... 51 
Table 7-3 Dose Reduction For Hematologic Toxicity On Day 1 ........................................... 51 
Table 7-4 Dose Reduction For Hematologic Toxicity On Day 8 ........................................... 51 
Table 7-5 Dose Reduction For Nonhematologic Toxicity On Day 1 ..................................... 52 
Table 7-6 Dose Reduction For Nonhematologic Toxicity On Day 8 ..................................... 52 
List of Figures 
Figure 5-1 Treatment Schema .................................................................................................. 38 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 24 of 117 
2 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
1L 
first-line 
2L 
second-line 
5-HIAA
5-hydroxyindoleacetic acid
5-HT
serotonin
AE
adverse event
ALKP
alkaline phosphatase
ALT
alanine aminotransaminase
ANC
absolute neutrophil count
AST
aspartate aminotransaminase
BICR
blinded independent central review
BMI
body mass index
BTC
biliary tract cancer
C1
Cycle 1
C1D1
Cycle 1, Day 1; Baseline (Baseline value is defined as the last non-
missing data on or before the first dose of the study drug, unless
otherwise specified)
C10D1 
Cycle 10, Day 1 is intended as Month 6
C19D1 
Cycle 19 Day 1 is intended as Month 12
CA 19-9 
carbohydrate antigen 19-9
CBC 
complete blood count
CCA 
cholangiocarcinoma
CEA 
carcinogenic embryonic antigen
CFR 
Code of Federal Regulations
CI 
confidence interval
cis 
cisplatin
cis/gem 
cisplatin/gemcitabine: cisplatin 25 mg/m2 administered intravenously (iv)
over 60 to 90 minutes followed by gemcitabine iv 1000 mg/m2
administered iv over 30 minutes (also referred to as 1L therapy)
CMP 
complete metabolic profile
CR 
complete response
CRFg 
Case Report Form guideline
CS 
carcinoid syndrome or clinically significant
CT 
computed tomography
CTCAE 
Common Terminology Criteria for Adverse Events (v 5.0)
D1 
Day 1
DCR 
disease control rate defined as CR+PR+SD
DSM-V 
Diagnostic and Statistical Manual of Mental Disorders 5th edition
ECG 
electrocardiogram
ECOG 
Eastern Cooperative Oncology Group
eCRF 
electronic Case Report Form
eGFR 
estimated glomerular filtration rate
EORTC 
European Organisation for Research and Treatment of Cancer
EOS 
End-of-Study
EOT 
End-of-Treatment
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 25 of 117 
Abbreviation 
Definition 
ERC 
Ethics Review Committee 
FDA 
US Food and Drug Administration 
FSH 
follicle stimulating hormone 
G-CSF
granulocyte-colony stimulating factor 
GBC
gall bladder carcinoma 
GCP
Good Clinical Practice 
gem
gemcitabine 
GGT
gamma-glutamyltransferase 
GINA
Genetic Information Nondiscrimination Act of 2008 
GLP
Good Laboratory Practice 
HbsAg
hepatitis B surface antigen 
HCV Ab
hepatitis C virus core antibody 
HDL
high-density lipoprotein 
HEENT
head, eyes, ears, nose, and throat 
Hgb
hemoglobin 
HIPAA
Health Insurance Portability and Accountability Act 
HIV
human immunodeficiency virus 
HRQoL
health-related quality of life 
IAC
Independent Adjudication Committee 
IB
Investigator Brochure 
ICH
International Council for Harmonisation 
IHC
immunohistochemical  
IND
Investigational New Drug 
INR
international normalized ratio 
IRB
Institutional Review Board 
iv
intravenously 
KPS
Karnofsky Performance Scale 
LDL
low-density lipoprotein 
MAO-A
monoamino-oxidase A 
MedDRA
Medical Dictionary for Regulatory Activities 
MRI
magnetic resonance imaging 
NCCN
National Comprehensive Cancer Network® 
NCI
National Cancer Institute 
NCS
not clinically significant 
NYHA
New York Heart Association 
ORR
objective response rate defined as CR+PR 
OTC
over-the-counter 
OS
overall survival 
PD
progressive disease 
PE
physical examination 
PFS
progression-free survival 
PHI
protected health information 
PK
Pharmacokinetic 
PP
per-protocol population 
PR
partial response 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 26 of 117 
Abbreviation 
Definition 
PT 
Preferred Term or prothrombin time 
QLQ-BIL21 
Cholangiocarcinoma and Gallbladder Cancer Module 
QLQ-C30 
Quality of Life Questionnaire Core 30 
QoL 
quality of life 
QTc 
corrected QT interval 
QTcB 
corrected QT interval using Bazett’s formula 
QTcF 
corrected QT interval using Fridericia’s formula 
RECIST 
Response Evaluation Criteria in Solid Tumors 
SAE 
serious adverse event 
SD 
stable disease or standard deviation 
SFP 
Survival Follow-up Period 
SI 
Le Système international d'unités (The International System of Units) 
SOC 
System Organ Class 
SSA 
somatostatin analog(s) 
TEAE 
treatment-emergent adverse events 
TE 
telotristat ethyl 
tid 
3 times daily 
TPH 
tryptophan hydroxylase  
TPH-1 
tryptophan hydroxylase-1  
TTP 
time to tumor progression 
ULN 
upper limit of the normal reference range 
US 
United States 
v 
version 
WBC 
white blood cell 
Definitions of Investigational Product Terms 
Term 
Definition 
LX1606 Hippurate or telotristat 
etiprate 
salt form of the drug substance, LX1606 or telotristat 
ethyl 
LP-778902 or telotristat or 
LX1033 
active metabolite of LX1606 or telotristat ethyl 
telotristat ethyl or LX1606 
ethyl ester prodrug of the active metabolite 
LP-778902; XERMELO 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 27 of 117 
3 
INTRODUCTION 
3.1 
Background on XERMELO and Biliary Tract Cancer 
Biliary tract cancer (BTC) is a group of malignancies that arise from the epithelium of the 
biliary tract. Classified by anatomical location, BTC includes cholangiocarcinoma (CCA), 
identified as intrahepatic or extrahepatic based on their location in relation to the liver, and 
gall bladder carcinoma (GBC) (Zhao, 2017). Approximately 10,000 new cases of BTC are 
diagnosed each year in the United States (US). Patients generally present with nonspecific 
abdominal symptoms that are bothersome, but not significantly burdensome for them to seek 
timely medical care. This most often results in a locally advanced, likely metastatic, BTC at 
the time of diagnosis (Marks, 2016). Demographically, the incidence of BTC increases with 
age. Patients are diagnosed later in life (between ages 40-70); there is a slight gender 
predominance in females for GBC and in males for CCA. A patient’s geographic location 
plays a significant role in associated risk. The incidence of BTC is relatively rare in the 
Western world as compared to Asian countries where the liver fluke (a risk factor for BTC) is 
endemic but the overall incidence of BTC is rising; possibly due to increased recognition of 
the disease by physicians, improved diagnostic capabilities, and active screening of patients 
at high risk (Bergquist, 2015; Kanthan, 2015; Razumilava, 2014). 
Management of risk factors and early detection of are key to improving survival in patients 
with BTC. Five years after diagnosis, 10% of patients with CCA and <5% with GBC remain 
alive. The 1-year survival rate for patients diagnosed with Stage 3 or 4 BTC is even lower. 
Only 10-15% of BTCs are amenable to surgery at initial presentation, and postresection 
recurrence rates remain at 50-60%. Given these statistics, it is apparent that these tumors are 
very aggressive malignancies with a very poor prognosis. Due to the rarity of this disease, 
evidence to support the role of adjuvant therapy is limited and available treatment options are 
not sufficient to address the poor survival rates in patients with locally advanced, recurrent, or 
metastatic BTC (Marks, 2016; Zhao, 2017).  
Available Treatment Options 
For patients presenting with unresectable BTC (locally advanced, recurrent, or metastatic) the 
current standard first-line (1L) therapy is a combination of cisplatin (cis) and gemcitabine 
(gem). The combination treatment (cis/gem) was found superior to gemcitabine alone in a 
randomized Phase 2 study (ABC-01) in 86 patients conducted in the United Kingdom 
(Valle, 2009). Treatment with cis/gem was associated with an improved disease control rate 
(DCR; complete response [CR] + partial response [PR] + stable disease [SD]; 75.0% vs 
58.0%), time to tumor progression ([TTP]; 8.0 months vs 4.0 months) and 6-month 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 28 of 117 
progression-free survival ([PFS]; 57.1% vs 45.5%) when compared to gemcitabine alone. 
Following the positive results, the ABC-01 trial was extended into a randomized, Phase 3 
study (ABC-02) and powered to determine the effect of cis/gem or gemcitabine alone on 
overall survival (OS) and quality of life (QOL) (Valle, 2010).  
In the ABC-02 study, the treatment regimens and eligibility criteria mirrored the ABC-01 
study. A total of 410 patients were randomized (n=204 cis/gem vs. n=206 gem alone) and 
followed for a median of 8.2 months. Again, the combination treatment (cis/gem) was shown 
to be statically superior to gemcitabine alone; the median OS was 11.7 months vs 8.1 months, 
median PFS was 8.0 months vs 5.0 months, and DCR (CR + PR + SD) was 81.4% vs. 71.8%. 
Adverse events (AEs) were similar in the 2 groups with the exception of neutropenia, which 
was increased in the cis/gem group, although the number of neutropenia-associated infections 
was similar in the 2 groups (Valle, 2010). 
A second randomized Phase 3 study (BT-22) was conducted in Japan and enrolled 84 
Japanese patients (41 cis/gem vs 42 gem alone) with advanced BTC. For this study, the 
median OS was 11.2 vs 7.7 months, median PFS was 5.8 vs 3.7 months, and DCR (CR + PR 
+ SD) was 68.3% vs 50.0% (Okusaka, 2010).
Treatment options for patients with unresectable BTC following the failure of 1L therapy 
remain limited and are not supported by Phase 3 data. Other chemotherapy combinations (eg, 
oxaliplatin, 5-FU, capecitabine) have demonstrated only marginal improvements in survival 
and targeted therapies, such as antiEGFR or antiVEGF antibodies, have produced limited 
success in early stage studies. As such, second-line (2L) treatment regimens are highly 
variable and are influenced by the physician’s knowledge of available treatment options or, 
more likely, the availability of clinical trials (Zhao, 2017).  
In February 2017, the US Food and Drug Administration (FDA) approved the oral drug 
telotristat ethyl (XERMELO) as a 2L therapy to be used in combination with somatostatin 
analogs (SSAs) to help address inadequate control of diarrheal symptoms in patients with 
carcinoid syndrome (CS). XERMELO has been shown to lower serotonin (5-HT) levels in 
the peripheral system by inhibiting tryptophan hydroxylase (TPH). Through inhibition of 
TPH, XERMELO reduces the production of peripheral 5-HT and the frequency of CS 
diarrhea. This intracellular mechanism of action complements the extracellularly mediated 
action of SSAs, providing a more complete inhibition of 5-HT overproduction than SSA 
therapy alone (Lexicon Pharmaceuticals, Inc., 2017). 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 29 of 117 
3.2 
XERMELO Pharmacology 
A complete package of safety pharmacology has been conducted for XERMELO. Details 
may be found in the Investigator's Brochure (IB). 
3.3 
XERMELO Toxicology 
A complete package of toxicology studies including Good Laboratory Practice (GLP)-
compliant mammalian toxicology, genetic toxicology, and safety pharmacology has been 
conducted with XERMELO. Details may be found in the IB. 
3.4 
Clinical Trials of XERMELO in Humans 
Detailed information regarding clinical studies may be found in the IB. 
3.5 
Rationale for Current Study 
While XERMELO is indicated for the treatment of CS diarrhea in combination with SSA 
therapy in adults inadequately controlled by SSA therapy, its mediation of 5-HT may provide 
a larger benefit. Serotonin (5-HT) plays a critical role in regulating several major 
physiological processes including cell proliferation. Literature suggests cell proliferation is 
autoregulated by endogenously produced 5-HT and that high levels of circulating 5-HT may 
exert a direct mitogenic effect on tumor cells, leading to tumor growth. Further, by 
modulating the amount of 5-HT exposure, tumor growth may be inhibited through 
vasoconstrictive action on the arterioles feeding the malignant growth, an antiangiogenic 
effect (Sarrouilhe, 2015).  
In vitro and in vivo studies have shown increased expression of TPH 1 and decreased 
expression of monoamino-oxidase A (MAO-A), the enzyme responsible for the degradation 
of serotonin, indicating that the metabolism of 5-HT is dysregulated. The result of this type of 
dysregulation is an increase in the production and secretion of 5-HT (Alpina, 2018; 
Huang, 2012; Sarroulilhe, 2015). In addition, treatment with 5-HT increased CCA cell 
growth in vivo and inhibition of 5-HT synthesis significantly blocked the growth of CCA in 
vivo and in vitro (Alpina, 2018; Huang, 2012; Sarroulilhe, 2015).  
A novel treatment approach that inhibits 5-HT production may provide clinical benefit to the 
significant number of patients with unresectable BTC. Adding a TPH inhibitor, like 
XERMELO to the treatment paradigm in combination with 1L therapy, may improve the 
physician’s armamentarium and fulfill the unmet medical need for patients with advanced 
BTC.  
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 30 of 117 
The AE profiles of XERMELO and the cis/gem combination are largely distinct and do not 
overlap, except for events related to elevations of liver function tests (LFTs). This is not 
surprising, as liver involvement occurs often in the setting of advanced BTC and in patients 
with advanced NETs. In order to address a potential risk to patients with liver involvement, 
the study will exclude patients with aspartate transaminase (AST) or alanine 
aminotransaminase (ALT) levels >5 x upper limit of normal (ULN) who have a documented 
history of hepatic metastases. Moreover, a Safety Run-in has been included in the design of 
the study since this will be the first time that these 3 agents will be used concomitantly in 
patients. A total of 6 patients with advanced BTC will be enrolled and treated with 
XERMELO plus 1L therapy for 1 cycle (21 days) to assess the safety of the triple 
combination before enrolling additional patients. Liver function will be closely monitored 
throughout the study and dose adjustment/modification rules are described in Section 7.5. 
The known and largely nonoverlapping safety profiles of XERMELO and the combination 
chemotherapy (cis/gem) suggest concomitant use is a rational approach to investigate the 
potential additive clinical benefit of XERMELO to 1L treatment, the current standard of care 
in eligible patients with advanced BTC. 
This study is intended to assess the effect of XERMELO in combination with 1L 
chemotherapy on PFS in patients with locally advanced, unresectable, recurrent or metastatic 
BTC who are naïve to tumor-directed therapy in the locally advanced or metastatic setting 
and for which treatment with 1L therapy is planned. 
3.6 
Rationale for Selection of Dose 
The dose level of XERMELO selected for this study is consistent with prior clinical study 
experience and is based upon clinical safety and pharmacodynamic (PD) data from Phase 2 
and Phase 3 multiple ascending-dose studies in patients with symptomatic CS. Dosages of 1L 
therapy are consistent with standard of care established by the ABC-02 trial (Valle, 2010). 
Based upon clinical study results, information for the XERMELO 500 mg tid dose level is 
more robust in terms of patient years of exposure and has an improved efficacy profile than 
the marketed dosage of 250 mg tid.  
As such, it is anticipated that the combination of therapies, at the dose levels proposed in this 
protocol, will be safe and well tolerated and may provide clinical benefit to patients with 
BTC. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 31 of 117 
3.7 
Rationale for Study Design  
An open-label study will allow for the assessment of the safety, tolerability, and efficacy 
XERMELO plus 1L therapy, herein referred to as “combination treatment” in a transparent 
manner. Should an efficacy signal be identified, additional studies may be undertaken to 
further assess the effect of the combination treatment in a larger patient population. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 32 of 117 
4 
STUDY OBJECTIVES 
4.1 
Primary Objective 
The primary objective of the study is to assess the safety and efficacy (PFS rate at Month 6) 
in the Safety population receiving the combination of XERMELO plus 1L treatment with 
cis/gem combination chemotherapy. Efficacy (PFS rate at Month 6) will also be evaluated in 
the Per Protocol Population (PP) and by treatment cycle. 
4.2 
Secondary Objectives 
To assess the effect of study treatment on the following: 
•
Overall survival (OS)
•
OS rate at Months 6 and 12
•
PFS rate at Month 12 and median PFS at Month 12
•
Disease control rate (DCR); defined as complete response (CR) + partial response
(PR) + stable disease (SD) at Months 6 and 12 and End of Study (EOS)
•
Objective response rate (ORR) defined as CR + PR at Months 6 and 12 and EOS
•
Local radiologist’s assessment of PFS, ORR, and DCR
•
Change from Baseline in
 Months 6 and 12 and EOS 
•
Change from Baseline in body weight at Months 6 and 12 and EOS
•
Change from Baseline in serum albumin at Months 6 and 12 and EOS
Note: Unless otherwise indicated, all radiologic endpoints will be based on Response 
Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by blinded independent 
central review (BICR) and compared to published historical data of cisplatin/gemcitabine 
(cis/gem) alone. 
4.3 
Exploratory Objectives 
To assess the effect of study treatment on the following: 
•
Changes in health-related quality of life (HRQoL) as measured by European
Organisation for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire Core 30 (QLQ-C30) and Cholangiocarcinoma and Gallbladder Cancer
(QLQ-BIL21) items at Baseline, Months 6 and 12
•
Change from Baseline in 
 fragment at Months
6 and 12 and EOS
•
Subgroup analyses of PFS, OS, ORR, and DCR using both BICR and local
radiologist’s assessment, based on categorical group of Baseline and change from
Baseline at Months 6 and 12 and EOS in:
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 33 of 117 
o
body weight
o
serum albumin
o
correlation between Baseline neutrophil:lymphocyte ratio and OS
•
Subgroup analyses in:
o
Patients with changes in liver function tests
o
Patients with Biliary stents
o
Location of disease (intrahepatic, extrahepatic, or gallbladder)
o
Extent of disease
o
Demographic groups
•
Subgroup analyses of patients by treatment cycles (such as patients who completed
 with combination treatment
4.4 
Pharmacokinetic (PK) Objective 
The pharmacokinetic (PK) objective is to identify intrinsic and extrinsic factors contributing 
to variability in exposure of XERMELO and the active metabolite, LP-778902, when dosed 
as a combination treatment with cisplatin and gemcitabine, including but not limited to, age, 
sex, race, and body mass index (BMI), as compared to historical data. 
4.5 
Substudy Objectives 
•
To assess the effect of study treatment based on characterization of tumor tissue by
immunohistochemical (IHC) staining (i.e., serotonin [5-HT] and tryptophan
hydroxylase-1 [TPH-1])
•
To determine the population PK profile among patients who participate in intensive
PK sampling
4.6 
Safety Objectives 
Evaluation of overall safety will be assessed by means of the following: 
•
Incidence of treatment-emergent adverse events (TEAEs) and severity assessment
using National Cancer Institute (NCI) Common Terminology Criteria for Adverse
Events (CTCAE) v5.0
•
Change from Baseline in clinical laboratory results including frequency of values
meeting CTCAE severity Grades >1, laboratory data toxicities as defined by NCI
CTCAE v5.0, physical examination (PE) findings, vital signs, and electrocardiogram
(ECG) findings
CCI
CCI
CCI
CCI
CCI
CCI
C

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 34 of 117 
5 
INVESTIGATIONAL PLAN 
5.1 
Overall Study Design 
This study will be conducted as a multicenter, open-label, 2-stage study to assess the safety , 
tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin 
plus gemcitabine) in patients with unresectable, locally advanced, recurrent or metastatic 
BTC (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer), who are naïve to 
tumor-directed therapy in the locally advanced or metastatic setting, and for which treatment 
with 1L therapy (defined as a combination of cis/gem) is planned.  
Note: 1L therapy will not be provided for this study by the Sponsor. 
5.1.1 Screening 
All patients are allowed a Screening Period of up to 21 days prior to Cycle 1 Day 1 (C1D1) 
when assessments for determining eligibility will be conducted per Appendix A. Written 
informed consent will be obtained from all patients before beginning any study related 
screening procedures. The collection of SAEs will begin after the patient has signed informed 
consent.  
Note: If radiological assessments have been completed within 6 weeks prior to Day 1, they 
are not required to be repeated at Day 1. 
5.1.2 Study Overview 
5.1.2.1 Treatment Period 
Stage 1 
Stage 1 enrollment will include a Safety Run-in cohort. Safety and tolerability data of the 
combination treatment from the first 6 patients who complete at least 21 days of safety 
follow-up after the first dose of combination treatment will be evaluated by the Coordinating 
Investigators, Sponsor, and Medical Monitor in accordance with established clinical stopping 
rules. This review will include all safety assessments from all patients obtained prior to the 
second chemotherapy cycle of the 6th patient enrolled. During this safety review, Stage 1 
enrollment will continue as per the study schema (Figure 5-1). It is anticipated that a total of 
20 patients will participate in Stage 1. 
Stage 2 
Stage 2 may initiate enrollment once Stage 1 enrollment has been completed, in the absence 
of significant or unresolved Grade 3 or higher toxicities considered related to the study drugs. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 35 of 117 
Approximately 33 additional patients are anticipated to participate in Stage 2. Study duration 
and assessments in this stage will be identical to Stage 1. From a total of 53 accrued patients 
from Stage 1 + Stage 2, if 34 or more (>60%) responses are observed (i.e., patients are alive 
and progression-free at Month 6), the study will be considered successful. 
Study Treatment (Stage 1 and Stage 2) 
On Day 1 (D1), eligible patients are to initiate Cycle 1 (C1), a 21-day cycle of XERMELO 
plus 1L therapy (herein referred to as “combination treatment”) as follows:  
•
XERMELO 250 mg (1 x 250-mg tablet) given as an oral dose 3 times daily (tid) for 7
days, plus
•
Cisplatin 25 mg/m2 administered intravenously (iv) over 60 to 90 minutes, followed
by
•
Gemcitabine 1000 mg/m2 administered iv over 30 minutes
On Day 8, patients will receive combination treatment as follows: 
•
XERMELO 500 mg (2 x 250-mg tablets) tid for 14 days, plus
•
Cis/Gem as described above
Every 21 days thereafter, patients will initiate a new 21-day cycle (eg, Cycle 2 [C2], Cycle 3 
[C3]) and will receive combination treatment, administered as:  
•
XERMELO 500 mg tid, plus
•
Cis/Gem regimen as described above on Day 1 and Day 8 of each cycle
Dose modification(s) and/or delay in treatment may be permitted as described in Section 7.5. 
During the Treatment Period, patients may discontinue cisplatin and continue treatment with 
XERMELO plus gemcitabine alone at the Investigator’s discretion. Gemcitabine should be 
administered on the same schedule as described above. 
Active symptom control will be permitted during the study as clinically indicated. 
Radiological assessment of the tumor by computed tomography (CT) or magnetic resonance 
imaging (MRI) will be conducted prior to initiating treatment on Cycle 1 Day 1(C1D1), then 
every 9 weeks (3 cycles) for the remaining duration of the Treatment Period. Note: If a 
radiological assessment has not been performed within 6 weeks prior to Day 1, a Screening 
assessment will also be required. 
All imaging will be evaluated by the local radiologist (or designee) for clinical management. 
If a change in response is noted by the local radiologist or Principal Investigator at any time 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 36 of 117 
during the study a second radiological assessment should be performed within 4-6 weeks to 
confirm.    
All images will be sent to a central review facility for blinded, independent-parallel reading 
(i.e., BICR) for assessments of study endpoints (Section 8.2.1). No information regarding 
results of PD determination will be shared between central radiologic review and the local 
radiologist/Principal Investigator at any time during the study. 
Note: Management of biliary obstruction and/or ascending cholangitis will not be considered 
as PD in the absence of radiologically confirmed PD. 
Patients may continue to receive treatment as described above for as many cycles possible 
until progressive disease (PD) as determined by local review, unacceptable toxicity, or the 
patient withdraws from treatment. At this time, chemotherapy will be discontinued, End-of-
Treatment (EOT) assessments should occur, and the patient should enter the Follow-up 
Period. The Follow-up visit dates will be based off of the EOT date. 
5.1.2.2 Follow-up Periods  
All patients are expected to be followed for a total duration of 24 months after the Treatment 
Period unless they prematurely discontinue or voluntarily withdraw consent from future study 
visits or assessments. This 24-month phase is divided into 2 periods; the Post-treatment 
Follow-up Period (PTFP) where onsite visits occur every 3 months, and the Survival Follow-
up Period (SFP), where survival status will be collected by phone and no onsite visits are 
required. 
Post-treatment Follow-up Period 
All patients are expected to enter a PTFP at the time PD is confirmed locally or the patient is 
no longer able to tolerate chemotherapy plus XERMELO in the absence of PD. During the 
Post-treatment Follow-up Period, patients may continue treatment with XERMELO at the 
discretion of the treating physician. 
Patients will complete scheduled study visits every 3 months for a total duration of 24 months 
or until the patient begins a new tumor-directed therapy, prematurely discontinues, declines 
further treatment after progression, or withdraws consent from future study visits or 
assessments. At this time, the End of Study (EOS) procedures should be performed and the 
patient should enter the SFP (unless 24 months of follow-up after the last dose of 
chemotherapy has already occurred). 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 37 of 117 
Note: For those patients who enter the PTFP prior to PD confirmed locally (i.e., those who 
experience an unacceptable toxicity or withdraw from chemotherapy), routine imaging 
assessments will continue to be performed every 3 months during the Post-treatment Follow-
up Period until PD is confirmed by local review. 
Note: Patients who enter PTFP prior to having their 6-month imaging assessment in the 
Treatment Period, will be asked to consent to provide their local scans and/or local scan 
report closest to the Treatment Period 6-month timepoint. This includes the possible 
reconsenting of patients previously prematurely discontinued or withdrew consent from the 
Treatment Period of the study. 
Survival Follow-up 
Once a new tumor-directed therapy begins, or a patient declines further treatment after 
progression, patients will enter the SFP. During this period, all patients (or caregivers, where 
appropriate) will be contacted by phone every 3 months to obtain the patient’s survival status 
until death, prematurely discontinue, withdrawal of consent, loss to follow-up, or for a period 
of 24 months following the last dose of chemotherapy, whichever occurs first. The site should 
make every attempt to document the date of death, if appropriate. 
Note: Patients who enter SFP without entering or completing PTFP and who entered SFP 
prior to having their 6-month imaging assessment in the Treatment Period, will be asked to 
consent to provide their local scans and/or local scan report closest to the Treatment Period 
6-month timepoint. This includes the possible reconsenting of patients previously
prematurely discontinued or withdrew consent from the Treatment Period of the study.
Note: The total duration of the PTFP and SFP combined should be no more than 24 months. 
Reconsent 
In cases when a patient has prematurely discontinued from the study and/or withdrawn 
consent from conducting further study assessments, these patients may be asked to re-consent 
to provide permission for their local imaging and imaging reports to be submitted to BICR.  
The treatment schema is summarized in Figure 5-1. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 38 of 117 
Figure 5-1 Treatment Schema 
Enroll Safety 
Cohort n=6
TE
1 + 1L
1 Cycle (21 days)
Enroll additional 
cohort n=6
TE
1 + 1L Reduced 
Dose
1 Cycle (21 Days)
Enroll remaining 
Stage 1 n=20
TE
1 + 1L
Terminate Study
Enroll remaining 
Stage 1 n=20
TE
1 + 1L Reduced 
Dose
If Clinically Significant AE*
 seen in ≥2 Patients
Treatment Period
Post Treatment 
Follow-up Period
Survival Follow-up 
Period
LX1606.207 
TE
1 + 1L in 
Patients with BTC 
N= 53
Enroll Stage 2 n=33
TE
1 + 1L Reduced 
Dose
If Clinically Significant AE* 
seen in ≤1 Patient
Enroll Stage 2 
n=33
TE
1 + 1L
If Clinically Significant AE*
 seen in ≤1 patient
If Clinically Significant AE*
 seen in ≥2 Patients
*Clinically Significant AE defined as unresolved, ≥Grade 3 non
hematological toxicity related to study drug (See Exclusions in
Protocol).
1 TE = Telotristat Ethyl
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 39 of 117 
6 
STUDY POPULATION 
It is anticipated that a total of 53 adult (>18 years of age) patients will be enrolled in 2 stages 
(n1=20 patients enrolled in Stage 1 and n2 = 33 patients enrolled in Stage 2) with 
unresectable, locally advanced, recurrent, or metastatic BTC (intrahepatic or extrahepatic 
cholangiocarcinoma, gallbladder cancer) naïve to tumor-directed therapy in the locally 
advanced or metastatic setting and are candidates to receive 1L therapy from approximately 
15 centers in the United States over an 18-month period.  
6.1 
Inclusion Criteria 
Patients must meet all of the following criteria at Screening, or as otherwise indicated, to be 
considered eligible to participate in the study: 
1. Adults of either sex, ≥18 years of age. Patients of childbearing potential must
agree to use an adequate method of contraception during the study and for 30 days
after the last dose of XERMELO.
a.
Childbearing potential is defined as those who have not undergone surgical
sterilization (eg, documented hysterectomy, tubal ligation, or bilateral
salpingo-oophorectomy) or those who are not considered postmenopausal
(defined as 12 months of spontaneous amenorrhea). If necessary, follicular-
stimulating hormone (FSH) results >35 IU/L at Screening are confirmatory in
the absence of a clear postmenopausal history.
b. Adequate methods of contraception, defined as having a failure rate of <1%
per year, for patients or their partner include the following: condom with
spermicidal gel, diaphragm with spermicidal gel, intrauterine device, surgical
sterilization, vasectomy, oral contraceptive pill, depo-progesterone injections,
progesterone implant (i.e., Implanon®), patch (Ortho Evra®), NuvaRing®,
and abstinence. If a patient is not sexually active but becomes active, they or
their partner should use medically accepted forms of contraception.
2. Histopathologically or cytologically-confirmed, unresectable, locally advanced,
recurrent, or metastatic BTC (intrahepatic or extrahepatic cholangiocarcinoma,
gallbladder cancer)
3. Naïve to tumor-directed therapy in locally advanced, unresectable, or metastatic
setting. Note: Previous treatment with chemotherapy in the adjuvant setting
(including previous exposure to 1L therapy) will be permitted if PD is confirmed >6
months following treatment.
4. Measurable disease, defined as the presence of at least 1 measurable lesion as
determined by RECIST v1.1 using conventional imaging with CT or MRI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 40 of 117 
5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
6. Plans to initiate treatment with 1L therapy; defined as cis/gem: cisplatin 25 mg/m2
administered iv over 60 to 90 minutes followed by gemcitabine1000 mg/m2
administered iv over 30 minutes as standard of care
7. Ability to provide written informed consent prior to participation in any study-related
procedure
6.2 
Exclusion Criteria 
Patients who meet any of the following criteria at Screening or as otherwise indicated, will be 
excluded from participating in the study:   
1. Prior exposure to XERMELO, telotristat ethyl, telotristat etiprate, LX1032, or
LX1606
2. Primary tumor site in the ampulla of Vater
3. Treatment with photodynamic therapy for localized disease or to relieve biliary
obstruction in the presence of metastatic disease within the past 30 days
4. Hematology laboratory values of:
a.
Absolute neutrophil count (ANC) ≤1,500 cells/mm3; or
b. Platelets ≤100,000 cells/mm3; or
c.
Hemoglobin (Hgb) ≤9 g/dL; or
d. White blood count (WBC) ≤3,000 cells/mm3
5. Hepatic laboratory values of aspartate transaminase (AST) or alanine
aminotransferase (ALT):
a.
>5 x upper limit of normal (ULN) if patient has documented history of
hepatic metastases; or
b. >2.5 x ULN if no liver metastases are present
6. Serum albumin <2.8 g/dL
7. Total bilirubin >1.5 x ULN or >1.5 mg/dL
8. Prothrombin time (PT) or international normalized ratio (INR) >1.5 x ULN. Note:
Patients receiving therapeutic doses of anticoagulant therapy may be considered
eligible if PT and INR are within the acceptable therapeutic limits for the institution.
9. Serum creatinine or serum urea >1.5 x ULN
10. Estimated glomerular filtration rate (eGFR) <50 mL/min
11. Positive pregnancy test, pregnant, or breastfeeding (female patients only)
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 41 of 117 
12. Any other clinically significant laboratory abnormality that would compromise patient
safety or the outcome of the study
13. Any clinically significant and/or uncontrolled cardiac-related abnormality that would
compromise patient safety or the outcome of the study including, but not limited to:
a.
Arrhythmia
b. Bradycardia
c.
Tachycardia
d. Symptomatic valvular disease
e.
Symptomatic congestive heart failure classified by New York Heart
Association (NYHA) as Class III or IV (Criteria Committee of the NYHA,
1994)
f.
Evidence of ischemia on ECG
g. Unstable angina pectoris
14. Myocardial infarction within the past 6 months
15. Active bleeding diathesis
16. Life expectancy ≤3 months
17. Current complaints of persistent constipation or history of chronic constipation, bowel
obstruction or fecaloma within the past 6 months
18. Receiving chronic treatment with corticosteroids of ≥5 mg/day of prednisone (or
equivalent), or other immunosuppressive agent(s)
19. Known history and/or uncontrolled hepatitis B surface antigen (HBsAg), hepatitis C
antibody (HCV Ab), or human immunodeficiency virus (HIV)-1 or HIV-2
Note:  Because of the possibility of spontaneous resolution of and success of 
treatment for hepatitis C, a clarification is being provided. Patients who have a 
history of hepatitis C will be allowed if their HCV RNA load is below the range that 
reflects infection with the virus at a time point that is at least 12 weeks after a 
spontaneous remission or 24 weeks after the end of treatment for hepatitis C. 
Hepatitis B patients will continue to be excluded based on having history of the 
disease. 
20. History of substance or alcohol abuse (Diagnostic and Statistical Manual of Mental
Disorders 5th edition [DSM-V] Criteria for Substance-Related Disorders) within the
past 2 years (American Psychiatric Association, 2013)
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 42 of 117 
21. History of galactose intolerance, deficiency of Lapp lactase, or glucose-galactose
malabsorption
22. History of malignancy or active treatment for malignancy (i.e., radiation or
chemotherapy, including monoclonal antibodies) within 5 years. Note: Patients with
squamous or basal cell carcinomas of the skin, carcinomas in situ of the cervix or
uterus, ductal breast cancer in situ, resected low-grade prostate cancer, or other
malignancies that in the opinion of the Investigator and the Medical Monitor are
considered cured, may participate.
23. Receipt of live, attenuated vaccine (eg, intranasal influenza, measles, mumps, rubella,
varicella) or close contact with someone who has received a live, attenuated vaccine
within the past 1 month. Note: Influenza vaccine will be allowed if administered >21
days.
24. Receipt of any investigational agent or study treatment (i.e., any treatment or therapy
not approved by the FDA for the treatment of BTC) within the past 30 days
25. Receipt of any protein or antibody-based therapeutic agents (eg, growth hormones or
monoclonal antibodies) within the past 3 months
26. Treatment with any tumor-directed therapy including, but not limited to,
chemotherapy or radiotherapy within the past 6 months with curative intent. Note:
Treatment (i.e., radiation, chemoembolization, radioembolization, or other local
ablative therapies, or hepatic resection) is permitted if received ≥4 weeks from
Screening and the patient has recovered to ≤Grade 1 toxicities as defined by NCI
CTCAE v5.0.
27. Existence of any surgical or medical condition that, in the judgment of the
Investigator, might compromise patient safety or the outcome of the study
28. Presence of any clinically significant findings (relative to the patient population)
during review of medical history or upon PE that, in the Investigator’s or Medical
Monitor’s opinion, would compromise patient safety or the outcome of the study (eg,
psychiatric illness/social situations that would limit compliance with study
requirements)
29. Evidence of brain metastases
30. Unable or unwilling to communicate or cooperate with the Investigator for any reason
31. Employee of Sponsor or clinical site, or relative of any member of a clinical site’s
staff
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 43 of 117 
6.3 
Criteria for Stopping Treatment/Study Withdrawal 
A patient may be discontinued from the study treatment and/or withdrawn from the study for 
the following medical or administrative reasons: 
•
Withdrawal of consent by the patient or legal guardian
•
Noncompliance, including failure to adhere to the study requirements as in the study
protocol, and/or lost to follow-up 
•
Investigator decides that, in the interest of the patient, it is not medically acceptable to
continue participation in the study 
•
The Sponsor terminates the study (Section 6.4)
•
Pregnancy (Section 9.3.1)
•
Progressive disease based on RECIST v1.1
•
Patient is unable to tolerate XERMELO following dosage reduction to 250 mg tid
•
Patient experiences:
○
Unresolved Grade 3 constipation as graded by the NCI CTCAE v5.0; or
○
Development of severe, persistent, or worsening abdominal pain
○
Continuing or recurrent Grade 4 toxicity (with the exception of alopecia, inadequately
treated nausea, vomiting, diarrhea, and transient electrolyte abnormalities that resolve
within 72 hours following institution of appropriate supportive care)
○
Suicidal ideation
○
Death
6.3.1 End-of-Treatment (EOT)/End-of-Study (EOS) Procedures 
6.3.1.1 End-of-Treatment Procedures 
The EOT procedures should occur as close to the last day of combination treatment whenever 
possible for all patients. Any assessments that have occurred <3 weeks prior to this visit will 
not be required to be repeated. See Appendix A for a list of all required EOT assessments. If a 
patient voluntarily withdraws consent from the study during the Treatment Period, or is 
discontinued prior to progressing, every attempt should be made to have the patient return to 
the clinic to complete all required EOT assessments and ask if the patient wishes to remain in 
the study by continuing into either Follow-up Period; PTFP where clinic visits occur every 3 
months, or SFP where phone calls occur instead of on-site visits. The date the patient 
discontinues the treatment, the treatment(s) discontinued, the primary reason for 
discontinuation (eg, AE, PD, protocol deviation, withdrawal of consent, lost to follow-up, 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 44 of 117 
death) and whether they will continue in either Follow-up Period must be recorded on the 
electronic case report form (eCRF). The patient must agree to report any AEs, including 
serious adverse events (SAEs), see Section 9.4, for 30 days following their last dose of any 
study drug.  
Note: If the patient does not wish to enter the PTFP, EOS procedures should occur in the 
place of EOT procedures; see Appendix A for a list of all required EOS and EOT procedures. 
For those patients who enter PTFP prior to having their 6-month imaging assessment in the 
Treatment Period, will be asked to consent to provide their local scans and/or local scan 
report closest to the 6-month timepoint. 
6.3.1.2 End-of-Study Procedures 
The EOS procedures should occur at the final Post-treatment Follow-up visit whenever 
possible. Any assessments that have occurred ≤8 weeks prior to this visit will not be required 
to be repeated. See Appendix A for a list of all required EOS procedures. If a patient 
voluntarily withdraws or is discontinued from the study prior to completing the 24-month 
Follow-up Period, every attempt should be made to have the patient return to the clinic to 
complete the EOS assessments. Patients who enter PTFP prior to having their 6-month 
imaging assessment in the Treatment Period, will be asked to consent to provide their local 
scans and/or local scan report closest to the 6-month timepoint.  See Appendix A for a list of 
all EOS assessments required. In addition, if a patient voluntarily ends participation in the 
study at any time, the primary reason for discontinuation (e.g., AE, PD, protocol deviation, 
withdrawal of consent, lost to follow-up, death)   must be recorded on the eCRF and 
document whether the patient  agrees to attend future study visits, allow contact by study 
personnel, and/or continued access to information and/or images about disease status and 
potential SAEs. The date the patient discontinues participation and the primary reason for 
discontinuation of participation (eg, AE, PD, protocol deviation, withdrawal of consent, lost 
to follow-up, death), must be recorded on the eCRF. 
After the EOS visit occurs, patients who have not completed 24 months of follow-up will 
enter the SFP where all patients (or caregivers, where appropriate) will be contacted by phone 
every 3 months to obtain their survival status until death, premature discontinuation, 
withdrawal of consent, loss to follow-up, or for a total duration of 24 months after the last 
dose of chemotherapy (including the duration of the PTFP), whichever occurs first. 
Note: Patients who enter SFP without entering or completing PTFP and who entered SFP 
prior to having their 6-month imaging assessment in the Treatment Period, will be asked to 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 45 of 117 
consent to provide their local scans and/or local scan report closest to the 6-month timepoint. 
This includes the possible reconsenting of patients previously prematurely discontinued or 
withdrew consent from the Treatment Period of the study. 
6.3.1.3 Lost to Follow-up 
If a patient does not return to the clinic, attempts should be made to contact the patient (or a 
previously approved designee such as a caregiver, partner, or family member) to determine 
the reason for discontinuation. At minimum, 3 documented attempts, including 1 via certified 
mail, should be made to contact the patient before considering the patient lost to follow-up. If 
a patient is deemed lost to follow-up, every attempt should be made to obtain survival status 
through public records (eg, social security death index, obituaries) every 3 months for up to 
24 months after the last documented patient visit and record this data in the eCRF.  
6.4 
Criteria for Termination of the Study 
If the Sponsor, Investigator, study monitor, DSMB (if applicable), or regulatory officials 
discover conditions arising during the study that indicate that the study should be halted or 
that a study site’s participation in the study should be terminated, this action may be taken 
after appropriate consultation between the Sponsor and Investigator. Conditions that may 
warrant such action include, but are not limited to, the following: 
•
The discovery of an unexpected, serious, or unacceptable risk to the patients enrolled in
the study
•
A decision on the part of the Sponsor to suspend or discontinue testing, evaluation, or
development of the product
•
Failure of the Investigator to enroll patients into the study at an acceptable rate
•
Failure of the Investigator to comply with pertinent FDA regulations
•
Submission of knowingly false information from the research facility to the Sponsor,
study monitor, or the FDA
•
Insufficient adherence to protocol requirements
Study termination and follow-up would be performed in compliance with the conditions set 
forth in the following sections of the Code of Federal Regulations (CFR): 21 CFR 312.50 and 
21 CFR 312.56. 
6.5 
Clinical Stopping Rules 
While the combination treatment in this study is assumed safe due to minimal overlapping 
toxicities, untoward side effects may occur. Therefore, assessment of the safety and 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 46 of 117 
tolerability data of all enrolled patients will occur once the 6th patient has completed 21 days 
of combination treatment and will include all safety assessments for all patients obtained 
prior to the second chemotherapy cycle of the 6th patient enrolled. The subsequent approach 
will be followed: 
•
If ≤1 patient has a clinically significant (CS) AE, the study will continue without a dose
adjustment.
•
If ≥2 patients have a CS AE, the dose level will be decreased to the Reduced Dose level
in accordance with Table 6-1, and 6 additional patients will be enrolled and treated with
the Reduced Dose for 1 full cycle.
○
If ≤1 of these patients has a CS AE at the Reduced Dose for the 1st cycle, the Reduced
Dose will be used for the study.
○
If ≥2 patients have a CS AE on the Reduced Dose, the study will be stopped.
Note: A CS AE is considered an unresolved ≥Grade 3 nonhematological toxicity, which is 
related to the study drugs, excluding: controllable nausea, vomiting, hypertension, diarrhea, 
constipation, transient electrolyte abnormalities, and alopecia; Grade 3 or higher febrile 
neutropenia.  
Table 6-1 Safety Run-in Dose Reduction 
Dose Level 
Gemcitabine 
Cisplatin 
XERMELO 
Starting Dose 
1000 mg/m2 
25 mg/m2 
500 mg tid 
Reduced Dose 
800 mg/m2 
20 mg/m2 
250 mg tid 
Note: If any patient experiences a Grade 4 toxicity during the Safety Run-in, the Sponsor, in 
consultation with the Investigator, will determine if additional patients should be enrolled at 
the Reduced Dose level. 
6.6 
Method of Assigning Patients to Treatment 
This is a nonrandomized study. Eligible patients will be assigned to treatment once eligibility 
has been confirmed.  
6.7 
Blinding and Unblinding of Study Drug 
This is an open-label study. 
6.8 
Replacement of Patients 
Patients who do not complete the study will not be replaced. 
6.9 
Rescreening of Patients 
Patients who are excluded during the Screening Period may be allowed to rescreen once. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 47 of 117 
7 
TREATMENT 
The concomitant chemotherapy (cis/gem) will not be supplied by TerSera. Initial dosing will 
be as defined in Section 5.1. Any dosage modification(s) should be performed in accordance 
with Section 6.3 and Section 7.5. 
7.1 
XERMELO (telotristat ethyl) 
For complete details on drug administration and storage, please refer to the IB. 
7.1.1 Identity 
Telotristat ethyl 250-mg tablets are white to off-white, coated, and oval with “T-E” debossed 
on 1 side and “250” debossed on the other side. 
7.1.2 Packaging, Labeling, and Storage 
Patients will receive 250-mg telotristat ethyl tablets packaged in 100-cc high-density 
polyethylene bottles with child-resistant polypropylene screw caps and heat-induction seal 
liners, as 100 tablet count per bottle. The drug product bottle contains desiccants. 
Telotristat ethyl should be stored at 25°C (77°F); excursions are permitted 15°C to 30°C 
(59°F to 86°F). 
7.2 
Prior and Concomitant Medications 
7.2.1 Prior Medication 
All medications and other treatments taken within 30 days prior to Screening will be recorded 
on the eCRF. 
7.2.2 Concomitant Medication 
All concomitant medications and other treatments taken during the study, including 
modifications to dosage and/or frequency, will be recorded on the eCRF, including 1L 
therapy. Each component of the combination chemotherapy, (i.e., cisplatin, gemcitabine) for 
each cycle should be recorded as a separate entry. 
Medical management of patients and their concomitant medications is allowed at the 
discretion of the Investigator. The list of concomitant medication therapy should be reviewed 
at each visit and continuance and/or adjustment of dosages should be evaluated based upon 
the patient’s clinical presentation and contraindication(s) of the assigned treatment. Specific 
attention should be paid to additive effects of concomitant therapies that may increase a 
patient’s risk of constipation and/or abdominal pain. Dosages of such concomitant treatments 
should be reduced or stopped, as appropriate, during the patient’s participation on study. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 48 of 117 
7.3 
Prohibited Medication or Concomitant Therapy 
Medication and other treatments are prohibited if they are: 
•
Identified as contraindicated in the package insert for XERMELO (TerSera Therapeutics
LLC, 2020), gemcitabine (Lilly USA, LLC, 2018), or cisplatin (Bristol-Myers Squibb
Company, 2010) or in best practice during the administration of 1L therapy; respectively.
•
Intended to produce an effect on tumor growth. No other tumor-directed therapy(ies) is
(are) permitted while taking combination treatment.
•
Chronic treatment with corticosteroids, ≥5 mg/day of prednisone (or equivalent), or other
immunosuppressive agent(s)
7.4 
Administration of Study Drug 
All patients will be instructed to take XERMELO with food. “With food” means taking 
XERMELO tablets within 15 minutes before or within 1 hour after a meal or large snack. 
Patients will be instructed to take XERMELO tid during waking hours, with doses spaced 
approximately 6 hours apart. 
Bottles of XERMELO and dosing instructions will be dispensed to patients on Day 1 of each 
cycle during the Treatment Period and at each visit during the Post-treatment Follow-up 
Period (if applicable), as described in Appendix A. Patients should be reminded to bring their 
bottles to the clinic on Day 8 of each cycle for dosing. 
Cisplatin and/or gemcitabine will be administered iv as described in Section 5.1.2 in 
accordance with institutional practice guidelines. 
7.4.1 Treatment Compliance  
Patients will be asked to bring their unused or unopened bottles of XERMELO to each visit 
(Appendix A). At each visit and in the presence of the patient, study site personnel will count 
returned tablets and reconcile the counts against planned number of doses for that interval. 
All dosages prescribed and dispensed to the patient, dose modification(s), and missed dose(s), 
including planned dose interruptions during the study must be recorded. Site personnel are to 
clarify any discrepancy and record this information within the eCRF.  
Patients will be asked to keep a Medication Diary on an electronic, hand-held device 
provided for the study. The patients will enter the number of tablets of XERMELO taken at 
breakfast, lunch, and dinner on the device. 
Patients must maintain at least 75% compliance in dosing to be deemed as compliant. In the 
event of a missed or vomited XERMELO dose, patients will take their subsequent dose at the 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 49 of 117 
next scheduled time point, following the tid dosing regimen of approximately every 6 hours. 
A dose outside of a 3-hour window for XERMELO should be considered missed. A dose 
delay of more than 1 week for cis and gem should also be considered missed. Missed or 
vomited doses of XERMELO will not be made up. 
7.5 
Dose Adjustment/Modification 
For the purposes of this study the following definitions apply: 
•
Interruption: temporary stoppage of 1 or both treatments of the assigned combination
treatment (XERMELO and/or 1L) but then resuming the treatment(s) within 3 weeks for
XERMELO or at the next treatment cycle for 1L chemotherapy.
•
Discontinuation: premature withdrawal from 1 or both treatments of the assigned
combination treatment (XERMELO and/or 1L) defined as a dose interruption lasting for
>3 weeks (XERMELO) or a missed cycle (cis/gem)
•
Note: Discontinuation of cisplatin, but continuing treatment with gemcitabine alone, will
not be classified as a discontinuation.
Note: If gem is deferred, cis will also be deferred. Day 8 treatment may be deferred for toxic 
effect by 1 week only. If a second deferral is needed, the treatment will be omitted, and the 
patient will move on to the next treatment cycle.  
7.5.1 XERMELO (telotristat ethyl) 
XERMELO reduces bowel movement frequency and constipation was observed in clinical 
studies in patients with CS diarrhea. Monitor for the development of constipation and/or 
severe, persistent, or worsening abdominal pain in patients taking XERMELO. 
In general, 
 Toxicity will be 
assessed according to the NCI CTCAE v5.0 (Appendix G). 
Table 7-1  XERMELO Dose Modifications 
Grade of Event Management/Next XERMELO Dose2 
Grade 1 
No change in dose 
Grade 2 
Hold until ≤Grade 1. Resume at same dose level. 
Grade 3 
Hold until ≤Grade 1. Resume at 1 dose level lower (250 mg tid).1 
Grade 4 
Discontinue treatment 
1Patients unable to tolerate 250 mg tid should be discontinued from XERMELO. 
2Rechallenge may be permitted upon consultation with the Medical Monitor. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 50 of 117 
Recommended management for the following AEs: 
•
Nausea and/or vomiting: treat with antiemetics
•
Diarrhea: treat as indicated for underlying cause; examples of therapy(ies) include:
antidiarrheal agents (eg, loperamide, over-the-counter [OTC]), pancrealipase for
steatorrhea, cholestyramine for short gut syndrome
•
Gastrointestinal toxicity:
o
Monitor concomitant medication usage as described in Section 7.2.2.
o
Constipation (Grade 1 and above): initiate treatment as clinically indicated; examples
of therapy(ies) include: laxatives, enemas, suppositories, psyllium, hydration, OTC
agents
o
Abdominal pain (Grade 1 and above): initiate treatment as clinically indicated;
examples of therapy(ies) include: analgesics, anti-gas/bloating agents
o
Hold XERMELO for Grade 2 constipation or abdominal pain until ≤Grade 1. Resume
at 1 dose level lower (250 mg tid).
o
Discontinue XERMELO for Grade 3 constipation or abdominal pain
•
Suicidal ideation: Discontinue XERMELO
These dose modification rules should be followed for clinical laboratory abnormalities that 
are Clinically Significant as determined by the Investigator; the Investigator assessment can 
differ from the CTCAE severity grading stated on the laboratory report. 
Clinical interpretation is especially important for hepatic enzyme abnormalities. These may 
be elevated at Baseline, and CTCAE severity grades provided on the laboratory report may 
not account for this. Furthermore, GGT changes have been commonly observed with 
telotristat ethyl in patients with carcinoid syndrome, and these have been of uncertain clinical 
significance. 
Mean GGT changes in an oncology study were +130 U/L and +242 U/L on 250 mg tid and 
500 mg tid, respectively, of telotristat ethyl at Week 12. Increases in GGT were observed 
soon after telotristat initiation, and values remained elevated throughout the course of 
treatment (Kulke, 2017). 
In the same study, elevations in ALT were only +7 U/L and +17 U/L, respectively on these 
doses. No increase from Baseline in mean value of bilirubin levels was observed in any 
treatment group. Most adverse events of hepatic enzyme elevation were mild or moderate in 
intensity, the rate did not increase with long-term treatment, and a review concluded that 
these increases did not lead to Clinically Significant outcomes (Lexicon, 2018). 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 51 of 117 
If there are laboratory changes without Clinical Significance, the Investigator can maintain 
treatment and continue to monitor. The drug may be interrupted at the Investigator's 
discretion in consultation with the Medical Monitor. 
7.5.2 Cisplatin/Gemcitabine 
In general, 
Toxicity will be assessed according to the NCI CTCAE v5.0. 
Table 7-2 Dose Reduction 
Dose Level 
Gemcitabine 
Cisplatin 
Starting Dose 
1000 mg/m2 
25 mg/m2 
Reduced Dose 
800 mg/m2 
20 mg/m2 
The following dose modification rules (Table 7-3) will be used with respect to hematologic 
toxicity on Day 1 of each treatment cycle believed to be related to cisplatin or gemcitabine: 
Table 7-3 Dose Reduction for Hematologic Toxicity on Day 1 
ANC 
Platelet Count 
Gemcitabine/Cisplatin 
≥1,000/mm3 
and 
≥100,000/mm3 
Treat as scheduled 
<1,000/mm3 
or/ 
and 
<100,000/mm3 
Defer treatment by 1 week. Reduce 
dose by 1 level for next treatment. 
The following dose modification rules will be used with respect to hematologic toxicity on 
Day 8 of each treatment cycle believed to be related to cisplatin or gemcitabine: 
Table 7-4 Dose Reduction for Hematologic Toxicity on Day 8 
ANC 
Platelet Count 
Gemcitabine/Cisplatin 
≥1,000/mm3 
and 
≥75,000/mm3 
Treat as scheduled 
<1,000/mm3 
or/ 
and 
<75,000/mm3 
Defer treatment 1 week. Reduce dose 
by 1 level for next treatment. If a 
second deferral is needed, treatment 
will be omitted 
Note: Administration of granulocyte-colony stimulating factor (G-CSF) is allowed, but 
discontinuation is required at least 2 days prior to the next administration of chemotherapy. If 
symptoms do not resolve after 28 days of uninterrupted G-CSF, chemotherapy treatment 
should be stopped.  
The following dose modification rules will be used with respect to nonhematologic toxicity 
on Day 1 of each treatment cycle believed to be related to cisplatin or gemcitabine.  
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 52 of 117 
Table 7-5 Dose Reduction for Nonhematologic Toxicity on Day 1 
Nonhematologic Toxicity1 
Gemcitabine/Cisplatin 
Grade 1 or 2 
Treat as scheduled 
Grade 3 or 4 
Defer treatment until resolves to ≤Grade 1. Reduce dose by 
1 level for next treatment.  
1Permissible exceptions to this rule are Grade 3 nausea, vomiting, hypertension, diarrhea, constipation, and 
transient electrolyte abnormalities that resolve within 72 hours following institution of appropriate supportive 
care, and alopecia. 
The 
Table 7-6 Dose Reduction for Nonhematologic Toxicity on Day 8 
Nonhematologic Toxicity1 
Gemcitabine/Cisplatin 
Grade 1 or 2 
Treat as scheduled 
Grade 3 or 4 
Defer treatment until resolves to ≤Grade 1. Reduce dose by 1 
level for next treatment. If deferral is needed for more than 1 
week, treatment will be omitted. 
1Permissible exceptions to this rule are Grade 3 nausea, vomiting, hypertension, diarrhea, constipation, and 
transient electrolyte abnormalities that resolve within 72 hours following institution of appropriate supportive 
care, and alopecia.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 53 of 117 
8 
STUDY PROCEDURES 
A schedule of study assessments is provided in Appendix A.  
8.1 
Restrictions during Study 
Patients should be advised to adhere to restrictions as described in the package insert for 
cisplatin (Bristol-Myers Squibb Company, 2010), gemcitabine, (Lilly USA, LLC, 2018) and 
XERMELO (TerSera Therapeutics LLC, 2020). 
8.2 
Description of Study Assessments 
8.2.1 Efficacy Assessments 
8.2.1.1 Imaging Assessment 
Each study site must have a designated radiologist or qualified individual who is responsible 
for the interpretation and evaluation of required images for this study according to RECIST 
v1.1 (Appendix J). If possible, the same radiologist/qualified individual should perform the 
evaluation for the entire duration of the study. All radiology evaluations will be performed 
initially by the local radiologist (or designee) with all images sent to a central reviewer.  
Independent central radiology review includes radiology assessments by BICR and an 
Independent Adjudication Committee (IAC). All scans will be reviewed and adjudicated as 
set forth in the Independent Review Charter. 
8.2.1.1.1 Computed Tomography (CT)/ Magnetic Resonance Imaging (MRI) 
Patients who have received previous treatment with chemotherapy in the adjuvant setting will 
be required to provide documentation of PD prior to study entry. This documentation requires 
least 2 evaluable CT or MRI studies performed ≥4 weeks apart and within 6 months prior to 
planned C1D1. For the purpose of this study, images submitted to BICR within 6 weeks prior 
to and including C1D1, i.e., which ever set was closest to C1D1 will be referred to as 
Baseline imaging. Copies of these images are to be sent to a central reviewer to use in the 
final analysis.  
All patients should have at least 1 measurable lesion by CT or MRI as determined by 
RECIST v1.1. For the purposes of this study, CT refers to a contrast enhanced image by CT 
of the chest, abdomen, pelvis, and/or other areas of known disease. The preferred method of 
imaging for this study is CT with contrast; MRI of the abdomen and/or pelvis with 
noncontrast CT of the chest will be acceptable for patients with medical contraindications to 
either the procedure itself or contrast agent used (eg, allergy to the contrast agent). Suspected 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 54 of 117 
or known central nervous system involvement should be followed with MRI unless 
contraindicated. 
The same imaging technology and the same technique should be used to characterize each 
identified and reported lesion at Baseline and throughout the duration of the study. During the 
study, imaging studies will be performed as outlined in Appendix A.  
8.2.1.1.1.1 Measurement Technique 
All measurements should be taken and recorded in metric notation, using a ruler or calipers. 
8.2.1.1.1.2 Tumor Response by Response Evaluation Criteria in Solid Tumors 
(RECIST) 
Measurable disease lesions must be accurately measured in at least 1 dimension in 
accordance with RECIST v1.1 (Appendix J). Changes in tumor measurements must be 
confirmed by repeat assessments within 4-6 weeks after the criteria for response, or 
progression, are first met. 
8.2.2 Clinical Laboratory Assessments  
Clinical laboratory assessments will include, at a minimum, blood chemistry (complete 
metabolic profile [CMP], liver function tests [alkaline phosphatase (ALKP), ALT, AST, total 
bilirubin], lipid panel [high-density lipoprotein (HDL), low-density lipoprotein (LDL), total 
cholesterol, triglycerides], coagulation parameters [PT, INR]), hematology (complete blood 
count [CBC] with differential, and platelet counts), and urinalysis.  
Additional assessments such as serum and urine pregnancy tests will be performed on 
females of childbearing potential only. Urine pregnancy tests will be performed by the site 
staff and will not be sent to the central laboratory. 
All other laboratory assessments will be performed by a central laboratory. Note: Central 
laboratory assessments for Day 8 are not required; sites may perform local laboratory 
assessments on Day 1 and/or Day 8 for patient management of chemotherapy infusion 
according to their practiced standard of care. In rare cases, laboratory results obtained from 
the local laboratory may be used to assess eligibility when the central laboratory lab result is 
unavailable. Authorization to use local laboratory results for determining eligibility must be 
obtained from the Sponsor prior to initiating study drug. 
Out of range values should be assessed by the Investigator for clinical significance relevant to 
the patient population. For this protocol, assessments will be defined as not clinically 
significant (NCS) or clinically significant (CS). The incidence of clinically significant 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 55 of 117 
laboratory values, as well as clinically significant shifts in laboratory values, should be 
reported as an AE in the eCRF (Section 9.1.1) and followed as described in Section 9.5; 
retests should be performed as frequently as clinically indicated. 
8.2.3 Pharmacodynamic and Pharmacokinetic Assessments 
8.2.3.1 
Fasting (≥6 hours) blood samples for 
in plasma will be collected at 
the study sites and analyzed by Frontage Laboratories, Inc. All sample processing 
information will be supplied by the laboratory in a separate document. Efforts should be 
made to schedule these visits in the morning, with instructions to the patient to arrive in a 
fasted state and not dose prior to the blood draw. 
8.2.3.2 Other Tumor Biomarkers: Carbohydrate Antigen 19-9 (CA 19-9) and 
Carcinogenic Embryonic Antigen (CEA) 
Blood samples will be collected for measurement of 
throughout the 
duration of the study. 
Note: 
 Patients should be advised to avoid multivitamins or dietary 
supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail 
supplements and multivitamins, for 12 hours prior to sample collection. 
8.2.3.3 Pharmacokinetic (PK) Assessments 
Blood samples for the purposes of determining trough levels of XERMELO and LP-778902 
concentrations in plasma will be collected for all patients as indicated in Appendix A. Efforts 
should be made to schedule these visits in the morning, with instructions to the patient to 
arrive in a fasted state and not dose prior to the blood draw.  
A separate, optional substudy will be conducted to collect additional samples from a subset of 
patients over a 6-hour timeframe as indicated in Appendix B for the purposes of a population 
PK analysis.  
Detailed procedures for the drawing, preparation, storage, and shipping of samples will be 
provided in a separate laboratory manual. 
8.2.4 Safety Assessments 
In addition to the clinical laboratory assessments described in (Section 8.2.2) and monitoring 
of AEs described in detail in Section 9.5, safety of patients will be monitored through vital 
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 56 of 117 
sign measurements (Section 8.2.4.1), PE findings (Section 8.2.4.2), and ECG findings 
(Section 8.2.4.3).  
Findings outside of the normal range and/or expectation should be assessed by the 
Investigator for clinical significance relevant to the patient population. For this protocol, 
assessments will be defined as NCS or CS. Clinically significant changes compared with 
Baseline (C1D1) findings for these variables should be reported as AEs on the eCRF and 
followed as described in Section 9.5; additional testing and/or retests should be performed as 
frequently as clinically indicated. 
8.2.4.1 Vital Sign Measurements 
Measurement of vital signs will include assessment of blood pressure, respiratory rate, pulse 
rate, and temperature. Vital sign measurements should not be conducted within the 
30 minutes immediately following any phlebotomy. 
Efforts should be made to standardize blood pressure collection across all patients and visits. 
Patients should be seated for at least 5 minutes prior to collection. All measurements should 
be assessed on the same arm, using the same equipment, and by the same technician where 
possible. 
Additional measurements may be obtained if clinically indicated. 
8.2.4.2 Physical Examination (PE), Height, and Weight 
A complete PE will be performed at specific time points as outlined in Appendix A. Physical 
examinations will include a minimum of a review of the patient’s general appearance and 
mental status; visual assessment of the head, eyes, ears, nose, and throat (HEENT), back, 
extremities, musculoskeletal, and skin; palpitation of the abdomen and neck including 
thyroid, and auscultation of the heart and lungs.  
Symptom-oriented PEs will be performed at all other time points and as clinically indicated. 
In addition, body weight will be captured at each clinic visit. Efforts should be made to 
standardize weight collection across all patients and visits. Patients should be instructed to 
remove shoes and heavy clothing (eg, heavy coats, jackets) prior to measurement. For weight 
collection, an effort should be made to use the same scale throughout the study where 
possible. In instances where multiple scales may be used, efforts should be made to reset the 
scale to zero prior to collection of weight measurement.  
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 57 of 117 
Height (without shoes) will be measured once, during Screening. Body Mass Index (BMI) 
will be calculated by the eCRF once height and weight have been entered (see Appendix F 
for calculation details). 
8.2.4.3 Electrocardiogram (ECG) 
Electrocardiograms (12-lead ECGs) will be performed to monitor cardiac function. Tracings 
must include a documented assessment of clinical significance (eg, NCS or CS), as applicable 
and the assessment must be signed and dated by the Investigator (or designee). 
8.2.4.4 Depression Detection 
Patients will be evaluated prior to initiating treatment on Day 1, then periodically throughout 
the remaining duration of the Treatment Period as outlined in Appendix A. During the 
Baseline visit, the patient will first be asked to respond to the question “During the past 
month, have you often been bothered by feeling down, depressed, or hopeless?” followed by 
“During the past month, have you often been bothered by little interest or pleasure in doing 
things?”. A positive response prior to Day 1 dosing will be evaluated by the Investigator in 
order to assess if the response is clinically significant. Positive responses assessed as 
clinically significant will be captured on the medical history CRF page.  
At all other timepoints, the patient will be asked to provide a response in relation to the last 
visit. “Since the last visit, have you often been bothered by feeling down, depressed, or 
hopeless?” followed by “Since the last visit, have you often been bothered by little interest or 
pleasure in doing things?”. A positive response following Day 1 dosing will be evaluated by 
the Investigator to determine if the response is clinically significant. Positive responses 
assessed as clinically significant are to be reported as an AE and captured on the AE page, 
additional reporting requirements are discussed in Section 9.3.2.  
The depression detection questions will automatically populate on the patient’s electronic 
device for them to complete on the evening prior to each study visit. A positive response to 
any question will send an automatic email to the site alerting them of the response so follow-
up with the patient can occur and clinical significance assessed. 
8.3 
Other Assessments 
8.3.1 Performance Status Based on Eastern Cooperative Oncology Group (ECOG) 
Performance status will be assessed throughout the duration of the study, the ECOG score 
will be recorded in the eCRF. Appendix G  provides scoring criteria and a conversion table 
for Investigators using the Karnofsky Performance Scale (KPS) scoring system. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 58 of 117 
8.3.2 Health-related Quality of Life (HRQoL) 
Health-related quality of life (HRQoL) will be evaluated using the 
 Module (Appendix I) at specific time points as outlined in 
Appendix A. These questionnaires will be completed by the patient at the clinic during the 
visit using the electronic device provided for the study; therefore, patients should be 
reminded to bring their electronic diaries with them to each study visit. 
8.3.3 Characterization of the Tumor - Substudy 
Baseline characterization of tumor tissue will be completed for a subset of patients in an 
optional substudy. Previously archived patient tumor biopsy samples will be requested, where 
available. These samples will be analyzed by IHC methods for 5-HT, TPH-1, and tumor 
fibrosis on patients who consent to participate. Additional markers may be added to this list if 
suggested by internal or external data. The purpose of these studies will be to further 
characterize the patient population. 
Specific requirements for tissue preparation and submission will be supplied by the 
laboratory in a separate document. 
8.4 
Appropriateness of Assessments 
The assessments used in this study conform to accepted clinical and laboratory assessments 
of patients with BTC in clinical trials and are typical of a Phase 2a study. 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 59 of 117 
9 
SAFETY REPORTING 
It is the responsibility of the Investigator to document all AEs and special situations that 
occur during the study. 
Adverse events will be collected at all study visits as outlined in Appendix A. Each AE 
should be recorded using the medical diagnosis; if a diagnosis is not established at the time of 
the reporting, a symptom or sign described by standard medical terminology may be used. 
Adverse events should not be solicited with leading questions that suggest specific signs or 
symptoms. Rather, AEs should be solicited by asking the patient a nonleading question such 
as: “Do you feel different in any way since receiving the dose or since the last assessment?” 
Adverse events that occur after the signing of informed consent and before the first dose of 
study drugs should be recorded as medical history unless the event is an SAE that could be 
associated with the trial procedures and could modify the conduct of the trial, or as otherwise 
specified. 
9.1 
Definitions and Special Considerations 
9.1.1 Adverse Events 
An AE is defined as any untoward medical occurrence associated with the use of a drug in 
humans, whether or not it is considered drug related.  
An AE includes any noxious, pathological, or unintended change in anatomical, 
physiological, or metabolic functions as indicated by physical signs or symptoms occurring 
after a patient has provided informed consent, whether or not it is considered related to the 
study drugs.  
This definition includes an exacerbation of preexisting medical conditions or events, 
historical conditions not present prior to study treatment, which reappear following study 
treatment, intercurrent illnesses, hypersensitivity reactions, drug-drug or drug-food 
interactions, medication errors, overdose (both intentional or unintentional), drug 
misuse/abuse, false positive laboratory test, or the significant worsening of the disease under 
investigation.  
Anticipated day-to-day fluctuations of preexisting conditions that do not represent a clinically 
significant exacerbation or worsening need not be reported as AEs. 
Treatment-emergent AEs are defined as any AEs reported after the first dose of study drugs 
and for 30 days following the last dose of study drugs. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 60 of 117 
Any treatment-emergent abnormal laboratory result should be reported as an AE if it meets 1 
or more of the following conditions: 
•
Fulfills any of the criteria for an SAE (Section 9.1.2),
•
Results in discontinuation of study treatment,
•
Requires treatment, or
•
Is considered by the Investigator to be clinically significant.
9.1.2 Serious Adverse Events 
An SAE is defined as any AE that results in any of the following outcomes: 
1. Death;
2. A life-threatening AE - defined as an event, in the view of the Investigator, the
occurrence of which places the patient at immediate risk of death. It does not include
an AE that, had it occurred in a more severe form, might have caused death;
3. Hospitalization or prolonging of an existing hospitalization;
4. A persistent or significant incapacity or substantial disruption of the ability to conduct
normal life functions, or,
5. A congenital anomaly/birth defect.
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, 
they may jeopardize the patient and may require medical or surgical intervention to prevent 
one of the outcomes listed above. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of 
drug dependency or drug abuse. 
Hospitalization is defined as any inpatient overnight stay in a hospital. This does not include 
an emergency room visit or admission to an outpatient facility. 
A hospitalization in and of itself should not be reported as an SAE. 
Hospitalizations for preplanned or elective surgery or routine clinical procedures without 
worsening of the underlying condition, or for administrative/social reasons (such as 
convenience, logistics) should not be reported as SAEs; however, if an elective procedure has 
to be performed sooner than planned due to a worsening of the underlying medical condition 
and the patient is hospitalized for the procedure, the worsening medical condition should be 
reported as an SAE. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 61 of 117 
Any laboratory abnormality fulfilling any of the criteria for an SAE should be reported as 
such. 
9.1.3 Unexpected Adverse Events 
An unexpected AE is an AE that is not listed in the Reference Safety Information (eg, the IB) 
or is not listed at the specificity or severity that has been observed. “Unexpected” also refers 
to the AEs that are mentioned in the Reference Safety Information as occurring with the class 
of study drugs or as anticipated from the pharmacological properties of the study drugs but 
are not specifically mentioned as occurring with the study drugs. 
For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater 
severity) if the IB referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral 
thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater 
specificity) if the IB listed only cerebral vascular accidents. 
It the responsibility of the Sponsor to assess whether an AE is expected or unexpected. 
9.2 
Assessment of Adverse Events 
The Investigator will evaluate all AEs with regards to the severity and relationship to each of 
the study drugs; XERMELO, cisplatin, and gemcitabine. 
9.2.1 Severity 
The Investigator will assess the severity of each AE using their clinical expertise and 
judgment using NCI CTCAE v5.0 criteria (Appendix H). 
9.2.2 Causality 
Causality assessment is a determination of whether there is a reasonable possibility that the 
study drug caused an AE. Factors that should be considered in causality assessment include, 
but are not limited to, temporal relationship, dechallenge/rechallenge information, association 
(or lack of association) with underlying disease or concomitant medication, biological 
plausibility, and previous observation or lack of with study drug or other medication(s) in the 
same class. 
For each AE, the Investigator will assess the causal relationship between each of the study 
drugs and the AE using their clinical expertise and judgment according to the most 
appropriate description as follows: 
Note: In cases of elevated LFT(s), it may not be possible to differentiate which drug is 
causing the AE. If, based on clinical judgement, an increase in LFT(s) is attributed to drug 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 62 of 117 
treatment, causality could be assigned to each of the study drugs. Dose modification should 
be performed in accordance with Section 7.5. 
•
Not related: The AE does not follow a reasonable temporal relationship to
administration of the study drug, or an alternative etiology (eg, underlying disease,
complications, concomitant drugs, or concurrent treatment) is more likely
•
Unlikely related: The AE has an improbable temporal relationship to administration
of the study drug, or an alternative etiology (eg, underlying disease, complications,
concomitant drugs, or concurrent treatment) is more likely
•
Possibly related: The AE follows a reasonable temporal relationship to
administration of the study drug (including the course after withdrawal of the drug),
and an alternative etiology (eg, underlying disease, complications, concomitant drugs,
or concurrent treatment) is equally or less likely
•
Probably related: The AE follows a reasonable temporal relationship to
administration of the study drug (including the course after withdrawal of the drug),
and an alternative etiology (eg, underlying disease, complications, concomitant drugs,
or concurrent treatment) is unlikely
•
Definitely related: The AE follows a plausible temporal relationship to
administration of the study drug (including the course after withdrawal of the drug)
and alternative etiology (eg, underlying disease, complications, concomitant drugs, or
concurrent treatment) can be ruled out. Positive rechallenge (i.e., reappearance or
worsening of the AE after study drug is reintroduced) or a response pattern known to
be associated with administration of the study drug provides further evidence of a
definitive causality assessment.
9.3 
Special Situations 
9.3.1 Pregnancy 
Any patient who becomes pregnant during the study must be discontinued from the study 
immediately. 
Any pregnancy during the study that occurs after administration of combination treatment, 
where the embryo or fetus may have been exposed to the study drugs (either through 
maternal exposure or transmission of a medicinal product via semen following paternal 
exposure), should be followed-up in order to collect information on the outcome of the 
pregnancy and development of the child after birth.  
The pregnancy exposure should be reported on the Pregnancy Questionnaire and captured on 
the eCRF page for AEs. The pregnant woman (patient or partner) should be followed for 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 63 of 117 
pregnancy outcome through delivery or termination of the pregnancy. In any pregnancy that 
progresses to term, the infant should be followed until 6 months after birth and any 
congenital abnormalities/birth defects in the infant should be reported as an SAE.  
The outcome of a pregnancy, and the presence or absence of a congenital abnormality should 
be reported on the Pregnancy Outcome Form.  
After the study period, pregnancies should be collected by requesting that study patients 
notify the Investigator if a female patient or a female partner of a male patient becomes 
pregnant within 30 days after last dose of XERMELO. These pregnancies should be reported 
and followed in the same manner as pregnancies occurring during the study. 
9.3.2 Adverse Events of Special Interest (AESIs) 
Based on the mechanism of action of telotristat etiprate, and observations in the clinical 
studies, events described in this section are considered AESIs. Monitoring of these AEs will 
be the responsibility of the Sponsor.  
Additional information will be collected if clinically significant episodes of events described 
in this section occur. 
9.3.2.1 Depression 
Refer to the Section 8.2.4.4 for additional details regarding depression detection. Below is a 
list of terms that will be considered a depression-related AESI if deemed clinically significant 
by the Investigator:  
•
Adjustment disorder with depressed
mood with or without mixed anxiety
•
Feeling guilty or feelings of despair,
worthlessness
•
Agitated depression
•
Helplessness
•
Anhedonia
•
Mixed anxiety and depressive
disorder
•
Antidepressant therapy
•
Assisted or completed suicide,
including suicide attempt or threat
•
Depressive symptom
•
Columbia suicide severity rating
scale abnormal
•
Decreased interest or depressed
mood
•
Depression suicidal
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 64 of 117 
•
Depression, including major,
menopausal, perinatal
•
Intentional overdose or self-injury
•
Depression postoperative
•
Poisoning deliberate
•
Dysphoria
•
Self-injurious ideation
•
Electroconvulsive therapy
•
Suicidal behavior or ideation
9.4 
Reporting of Serious Adverse Events and Pregnancies 
All SAEs, regardless of causal relationship to study drug, and pregnancies must be reported 
to the Sponsor within 24 hours of investigational site awareness of the event. Investigators 
should not wait for complete information on an event before notifying the Sponsor of an 
SAE. All SAEs, pregnancies, and other special situations should be recorded on the study 
participant’s eCRF page for AEs. 
Investigational site personnel must use the approved method of notification (eg, SAE Report 
form, Pregnancy Questionnaire form, eCRF page) provided by the Sponsor to report these 
events. Where applicable, information from relevant hospital records and autopsy reports 
should be obtained. 
If paper report forms are used or to provide redacted supporting documents, they, should be 
sent to:  
Safety Data Facsimile: 
or  
Email address (in case of fax failure): 
In case of failure of/lack of access to eCRF, email, or fax, the event can be reported to the 
TerSera Call Center 
If an SAE is reported via telephone, the telephone report should be followed by a written 
report using a reporting method described above (i.e., completion of eCRF or paper form). 
For questions on safety reporting, please contact TerSera Pharmacovigilance at 
For questions on study participant management related to AE, the Medical Monitor of the 
study should be contacted. 
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 65 of 117 
Additional information received after the initial SAE has been reported to the Sponsor should 
be reported as follow-up information following the same procedure and timeline as the initial 
SAE. 
An SAE that occurs after completion of the study and, in the opinion of the Investigator is 
related to study drug, should be reported following the same procedure and timeline as an 
SAE that occurs during the study. 
9.5 
Follow-up of Adverse Events 
All AEs should be followed until the event has resolved, the condition has stabilized, the 
patient is lost to follow-up, or at least 30 days following the last dose of any study drug (i.e., 
XERMELO, cisplatin, gemcitabine), whichever comes first. Final known outcome must be 
reported whenever possible.  
Medically significant abnormal laboratory test results should be repeated and followed until 
the test results have returned to the normal range or Baseline value, and/or an adequate 
explanation of the abnormality is determined.  
9.6 
Safety Oversight 
Safety review and oversight of this study will be the responsibility of the Sponsor according 
to the Sponsor’s Standard Operating Procedures. Safety and tolerability will be reviewed 
based on data entered into the eCRFs, reported SAEs, and results of laboratory assessments 
on an approximate monthly basis. The clinical stopping rules described in Section 6.5 will be 
followed. An independent DSMB will not be utilized for this study.  
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 66 of 117 
10 STATISTICAL METHODOLOGY 
10.1 Determination of Sample Size 
The sample size was computed by satisfying design assumptions for the primary endpoint of 
the study; which is to assess the PFS rate at Month 6.  
6-Month PFS rates of 70% and 55% are assumed for the XERMELO arm and historical
control arms. Simon's 2-stage design (Simon, 1989) will be used to test these rates. The null
hypothesis, that the true response rate is p0=0.55, will be tested against a 1-sided alternative.
In the first stage, n1=20 patients will be accrued. If there are r1=11 or fewer responses in
these n1=20 patients, the study will be stopped. Otherwise, 33 additional patients will be
accrued for a total n=53. The null hypothesis will be rejected if r2= 33 + 1 or more responses
are observed in 53 patients. This design yields a Type I error rate = 0.097 and statistical
power = 0.802 when the true response rate is p1= 0.70.
The target sample size of 53 patients is expected to be accrued over a period of 18 months, 
with the last enrolled patient followed for 6 months after the start of receiving study 
treatment. Under an exponential sampling process, the median follow-up time for the time-to-
event endpoints (e.g., PFS, OS) will be 15 months.  
10.2 Analysis Populations 
This is a single arm and open-label study. Safety data will be assessed periodically 
throughout the study in addition to the testing requirements of the Simon design. These 
safety-based interim analyses will not be used to assess efficacy; hence, there will be no 
inflation of the Type I error rate that would require an adjustment to the 53 patients sample 
size: 
Per-protocol (PP): A PP population will consist of those patients that 
and have no major protocol violation(s) that would interfere 
with the collection or interpretation of the efficacy data. Determination of the PP dataset will 
be made before database lock. 
Safety: The Safety population consists of all patients receiving any fraction of a dose of study 
drug. 
PK: The PK population will be made up of all patients treated with at least 1 dose of study 
drug and who have adequate samples taken to reliably estimate the parameters of interest. 
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 67 of 117 
10.3 Study Endpoints 
10.3.1 Efficacy Endpoints 
The primary efficacy endpoint is to assess the PFS rate at Month 6, where patient progression 
is defined as the time from Baseline until the first determination of PD by central radiologic 
reading using RECIST v1.1 (Eisenhauer, 2009) or death from any cause.  
Secondary efficacy endpoints include: 
•
OS
•
OS rate at Months 6 and 12
•
PFS rate at Month 12 median PFS
•
DCR; CR + PR + SD at Months 6 and 12 and EOS
•
ORR defined as CR + PR at Months 6 and 12 and EOS
•
Local radiologist’s assessment of PFS, ORR, and DCR
Exploratory efficacy endpoints include: 
•
Change from Baseline in plasma
at Months 6 and 12 and 
EOS
•
Change from Baseline in body weight at Months 6 and 12 and EOS
•
Change from Baseline in serum albumin at Months 6 and 12 and EOS
•
Subgroup analyses will be evaluated in:
o Patients with changes in liver function tests
o Patients with Biliary stents
o Location of disease (intrahepatic, extrahepatic, or gallbladder)
•
Efficacy will be evaluated by treatment cycles
 of combination treatment)
Note: Unless otherwise indicated, all radiologic endpoints will be based on RECIST v1.1 as 
determined by BICR and compared to published historical data of cis/gem alone. 
Exploratory efficacy endpoints include assessing the effect of XERMELO when used in 
combination with 1L therapy on the following endpoints: 
•
Changes in HRQoL as measured by
 items at 
Baseline, Months 6 and 12;
•
Change from Baseline in
 at Months 6 and 12 and EOS; 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 68 of 117 
•
Subgroup analysis of PFS, OS, ORR, and DCR using both BICR and local radiologist’s
assessment based on categorical group of Baseline and change from Baseline at Months 6
and 12 and EOS in:
o serum albumin
o correlation between Baseline neutrophil:lymphocyte ratio and OS
10.3.2 Safety Endpoints 
Safety endpoints are as follows: 
•
Incidence of TEAEs, TEAEs by severity, TEAEs by relationship to each of the study
drugs, TEAEs by study drugs exposure time, TEAEs leading to discontinuation from the
study, SAEs, and deaths
•
Actual and change from Baseline in clinical laboratory results including frequency of
values meeting CTCAE Grades >1 for severity
•
Actual and change from Baseline in vital signs results
•
Actual and change from Baseline in weight
•
Actual and change from Baseline in 12-lead ECG findings
10.3.3 Pharmacokinetic Endpoints 
For patients with intensive PK assessments, the following PK parameters will be estimated, 
where possible, for XERMELO and its active metabolite, LP-778902, in plasma by non-
compartmental methods: 
Cmax 
maximum concentration in the sampled matrix (ng/mL), obtained 
directly from the observed concentration versus time data  
Cmin 
minimum concentration in the sampled matrix (ng/mL), obtained 
directly from the observed concentration versus time data 
tmax 
time of maximum concentration (h), obtained directly from the 
observed concentration versus time data  
AUC(0-6) 
area under the concentration-time curve in the sampled matrix from 
zero (predose) to 6 hours after dose administration.  
AUC(0-last) 
area under the concentration-time curve in the sampled matrix from 
zero (predose) to time of last measurable concentration (ng·h/mL), 
calculated by linear up/log down trapezoidal summation. 
Kel 
apparent first-order terminal rate constant 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 69 of 117 
t½ 
apparent terminal elimination half-life 
Rac 
accumulation ratio at steady state 
PK structural models for telotristat (LP-778902) will be developed from already existing PK 
data in healthy subjects and patients. These models will be used, where possible, to develop a 
population PK analysis based on the data from this study. This analysis will include, where 
possible, an assessment of the effects of intrinsic and extrinsic factors on the PK of 
XERMELO. 
10.3.4 Characterization of Tumor Substudy Endpoint 
The endpoint of this substudy is to characterize the tumor tissue by IHC staining (i.e., 5-HT 
and TPH-1) at Baseline among patients who have consented to participate and for whom 
previously-banked tissue samples are available.  
10.4 Statistical Methods 
Demographic data, Baseline disease characteristics, prior and concomitant medications, 
treatment compliance, treatment exposure, AE, laboratory tests, vital signs, PE findings, 
12-lead ECG findings, and final disposition will be summarized descriptively.
Continuous variables will be summarized descriptively by the number of patients with non-
missing data, mean, standard deviation (SD), median, minimum, and maximum values. 
Categorical variables will be summarized descriptively by their counts and associated 
percentages. All summaries will be reported by study time point, as applicable.  
All data values will be provided in listings. 
A more detailed description of the analysis and reporting of data will be provided in the 
Statistical Analysis Plan. An overview of the main analysis strategy is provided in the 
following sections. 
10.4.1 Efficacy Analyses 
All imaging will be assessed by local radiologist and the BICR. The BICR will supersede the 
local radiologist’s assessment for the purpose of primary endpoint and all applicable key 
secondary objectives. A secondary analysis will be performed to further evaluate the primary 
and secondary efficacy endpoints using the local radiologist assessments.  
A Simon’s 2-stage design algorithm will be used to assess whether the study is successful at 
each stage of the analysis. In the Stage 1 Safety Population, if there are no clinically 
significant or unresolved Grade 3 or higher toxicities considered related to the study drug and   
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 70 of 117 
if 12 (60%) or more of the 20 patients enrolled who are deemed responders per the definition 
below after the 20th patient is censored, is alive and progression-free at the Month 6 
assessment, or has discontinued for any reason, the study will be declared successful and 
enrollment will continue in Stage 2. Efficacy will also be assessed in the PP population and 
by treatment cycle. 
Note: Patients are considered responders if they are alive and progression-free at the Month 6 
assessment; otherwise, they are considered non-responders. 
In Stage 2, an additional 33 patients will be enrolled. If 34 or more (>60%) of the 53 patients 
enrolled (Stage 1 + Stage 2) are deemed responders, the study will be considered successful. 
The primary and secondary efficacy endpoints will be analyzed based on the Safety 
population. Additional analyses for the primary and secondary efficacy endpoints will be 
performed using the PP population.  
For the primary endpoint, the Kaplan-Meier method (Kaplan, 1958) will also be used to 
estimate the survival function. The PFS rate at Month 6 and the corresponding 95% 
confidence interval (CI) will be presented. In addition, the median PFS value computed from 
this study will be compared with the historical/published median PFS time (published and 
clinically acceptable median PFS for cis/gem alone). Also, the PFS rate estimates and 95% 
CIs will be computed at Month 12. Patients without PD or death will be censored at the last 
confirmed radiographic assessment by the central reviewers prior to study completion or date 
of discontinuation from the study. The same methodology will be used to analyze the median 
OS and the OS rate at Months 6 and 12. 
Subgroup analysis may be performed based on the primary tumor site, prior therapy(ies), 
performance status, major demographic and prognostic subgroups, extent of disease, and 
Baseline biomarker levels. 
Radiographic assessments will incorporate standard and exploratory analyses. Additional 
secondary analyses will include assessment of ORR and DCR at Months 6 and 12 and EOS 
using RECIST v1.1. For binary endpoints estimated as binomial proportions, such as ORR 
and DCR, the frequency and proportion of patients assessed as responder and non-responder 
as an outcome will be presented at each assessed study time point. 
Other efficacy endpoints will be summarized descriptively by study time point. Change from 
Baseline for 
 will be summarized descriptively 
and 1-sample t-tests may be performed to test for significance.  
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 71 of 117 
10.4.2 Safety Analyses 
All safety summaries will be descriptive; no statistical significance tests will be performed on 
safety data.  
Summaries will be prepared by study time point. All safety data will be listed by patient. 
Treatment-emergent AE summaries will include the overall incidence (by System Organ 
Class [SOC] and Preferred Term [PT]), events by maximum severity, events by relationship 
to each study drug, events by length of exposure (at event onset) to each study drug, events 
leading to discontinuation from the study, and SAEs. 
Vital signs, 12-lead ECG findings, PE findings, (including height and weight) and laboratory 
parameters (hematology, chemistry, and urinalysis) will be summarized descriptively at each 
time point. For quantitative variables, both actual and change from Baseline data will be 
summarized. In addition, shift table analysis will be applied to the laboratory data. 
10.4.2.1 Adverse Events 
All AEs will be coded and listed by SOC and PT based on the Medical Dictionary for 
Regulatory Activities (MedDRA). Summaries will be provided for TEAEs, drug-related AEs, 
SAEs, TEAEs leading to study discontinuation, TEAEs by drug relationship, TEAEs by 
severity, and TEAEs by length of exposure (at event onset) to the study drugs. Treatment-
emergent AEs are those events not present at Day 1 but occurring after the first dose of study 
drug, or if existing on Day 1, increasing in severity after initiation of study drug. Summaries 
made by severity will select the event with the highest severity when multiple occurrences of 
the same event are reported for the same patient. In a similar manner, summaries prepared by 
drug relationship will select the event with the greatest degree of relationship when a patient 
reports multiple occurrences of the same event. On-study deaths will be reported for deaths 
occurring during study participation and the 30 days after stopping study drug. Also, deaths 
occurring outside the 30-day window, but secondary to an AE reported within the 30-day 
Follow-up Period, will be reported as well.  
Listings will be provided for deaths, SAEs, AESIs, and discontinuations due to AEs. 
Additional summaries or listings of AEs may also be provided. 
10.4.2.2 Clinical Laboratory Parameters 
Laboratory results will be reported in conventional units and International System of Units 
(SI) units in all tables, figures, and listings. Laboratory results falling out of the normal range 
will be marked as high or low in the listings. Actual and changes from Baseline in clinical 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 72 of 117 
laboratory results will be summarized by time point using descriptive statistics. Summaries of 
shifts from Baseline, based on CTCAE severity grades, will be provided. 
10.4.2.3 Vital Sign Measurements 
Actual and change from Baseline in vital signs results will be summarized by time point 
using descriptive statistics. 
10.4.2.4 Electrocardiogram Findings 
Clinically significant changes in ECGs compared to Baseline, as determined by the 
Investigator, will be summarized by time point using descriptive statistics. Actual and change 
from Baseline (predose values) to each time point in corrected QT (QTc) interval using 
Fridericia’s formula (QTcF) and Bazett’s formula (QTcB) will be summarized.  
10.4.2.5 Physical Examination Findings, Height, and Weight 
Physical examination findings will be listed. Weight will be analyzed as change from 
Baseline at all time points, as appropriate. 
10.4.2.6 Eastern Cooperative Oncology Group (ECOG) Performance Status 
Actual and change from Baseline in ECOG will be summarized by time point using 
descriptive statistics. 
10.4.3 Pharmacodynamic Analyses 
Actual and change from Baseline in 
 will be 
summarized by time point using descriptive statistics. 
10.4.4 Pharmacokinetic Analyses 
For patients with intensive PK assessments, descriptive statistics will be used to summarize 
the plasma concentrations of XERMELO and LP-778902 at each time of collection. All PK 
parameters for XERMELO and LP-778902 will be listed and summarized using appropriate 
descriptive statistics. 
PK data will be summarized by n, arithmetic and geometric mean, standard deviation, 
median, minimum, and maximum values at various time points. Regression models may be 
used to evaluate the type and magnitude of associations between trough concentration of 
XERMELO and LP-778902 at selected time points. 
Based on intensive PK sampling from a subset of patients and sparse PK sampling (eg, 
trough concentrations) from the study population, Population PK analyses will explore the 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 73 of 117 
effects of covariates including, but not limited to, age, sex, race, BMI on the systemic 
exposure to XERMELO and LP-778902. PK data from this study may be integrated with PK 
data from other clinical trials to further enhance the population PK analysis and/or support 
the development of an exposure-response model for safety and efficacy. Details of population 
PK analysis plan will be prepared in a separate document. 
Results from the population (overall) PK analysis will be documented in a separate report. 
10.4.5 Analysis of Health-related Quality of Life (HRQoL) 
Actual and change from Baseline for QLQ-C30 and QLQ-BIL21 total and subscale scores 
will be summarized by time point using descriptive statistics. 
10.4.6 Baseline Characteristics and Other Summaries 
Demographic data, prior and concomitant medications, treatment compliance, and final 
disposition will be summarized descriptively. 
10.4.7 Interim Analysis 
Periodic reviews of study data will be conducted as described in Section 9.6 throughout the 
study for the purposes of safety monitoring but will not serve as a formal analysis of study 
data. A Stage 1 analysis in a total of 20 patients will be conducted, Stage 1 enrollment will 
include a Safety Run-in cohort. Safety, tolerability and efficacy data of the combination 
treatment from the first 6 patients who complete at least 21 days of safety follow-up after 
the first dose of combination treatment will be evaluated. It is anticipated that a total of 20 
patients will participate in Stage 1. If there are no clinically significant or unresolved 
Grade 3 or higher toxicities considered related to the study drug, and if 12 (60%) or more 
of the 20 patients enrolled who are deemed PFS responders in the Safety population, 
enrollment will continue to Stage 2. In addition, efficacy will be assessed in the safety 
population with aim Efficacy will also be assessed in the per-protocol population and by 
treatment cycle. 
Three formal statistical interim analyses will be performed during this study as follows: 
•
Interim analysis 1: Conducted in Patients included in the Stage 1 analysis (first 20
patients enrolled) and will include safety, efficacy (PFS responder rate),
pharmacodynamic (biomarker) data and analysis by treatment cycle.
•
Interim analysis 2 added to (Stage 1+2) 6-month analysis: Conducted after all Patients
(Stage 1 + Stage 2) complete the Month 6 visit, and will include safety, efficacy (PFS
responder rate), pharmacodynamic (biomarker) data and analysis by treatment cycle.
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 74 of 117 
•
Interim Analysis 3 added to Stage (1+2) 12 month analysis: Conducted after all Patients
(Stage 1 + Stage 2) complete the Month 12 visit, and will include safety, efficacy (PFS
responder rate), pharmacodynamic (biomarker) data and analysis by treatment cycle.
These data will be used to help plan for future studies. 
10.4.8 Protocol Deviations 
Protocol deviations will be listed. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 75 of 117 
11 STUDY MANAGEMENT 
The Investigator is responsible for completing and maintaining adequate and accurate eCRFs 
and source documentation. Source documentation constitutes original records, which may 
include: progress notes, medication administration records, laboratory reports, ECG tracings, 
discharge summaries, etc.  
All data and corrections, if applicable, entered on to the eCRF must meet minimum 
requirements as specified in the case report form guidelines (CRFg). All eCRFs should be 
completed in their entirety and stored in accordance with International Council for 
Harmonisation (ICH) E6 Good Clinical Practice (GCP) guidance. The Investigator must sign 
the Investigator’s statement in each patient’s eCRF indicating that the data reported are 
accurate. 
At the study site, clinical research associates may verify up to 100% of eCRFs in their 
entirety against source documentation as specified in the Clinical Monitoring Plan. Computer 
programmed edit checks will be run against the database to check for discrepancies and 
reasonableness of the data, and the safety database will be reconciled with the clinical 
database. All issues resulting from the computer-generated checks and the safety database 
reconciliation will be resolved according to standard data management practices in 
conjunction with the Sponsor, clinical study personnel, and the study Investigator(s). 
11.1 Monitoring 
The Sponsor is responsible for ensuring the proper conduct of the study with regard to ethics, 
protocol adherence, site procedures, integrity of the data, and applicable laws and/or 
regulations. At regular intervals during the study and following completion of the study, the 
Sponsor’s study monitors will contact the study site via visits to the site, telephone calls, 
and/or letters in order to review study progress, eCRF completion, and address any concerns 
or questions regarding the study conduct. During monitoring visits, the following aspects of 
study conduct will be carefully reviewed: informed consent of patients, patient recruitment, 
patient compliance with the study procedures, source data verification, drug accountability, 
use of concomitant therapy by patients, AE and SAE documentation and reporting, and 
quality of data. Records pertaining to these aspects are expected to be kept current. 
The Investigator must make study data accessible to the clinical monitor, to other authorized 
representatives of the Sponsor, and to regulatory inspectors. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 76 of 117 
11.2 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Study 
Manual requirements. The noncompliance may be either on the part of the participant, the 
Investigator, or the study site staff. As a result of deviations, corrective actions are to be 
developed by the site and implemented promptly. 
Prospective requests to deviate from the protocol (i.e., waivers) will not be approved unless 
the approval is required to protect the health or welfare of participants enrolled in the study. 
It is the responsibility of the Investigator and site staff to use continuous vigilance to identify 
and report deviations. In addition to notifying the Sponsor, protocol deviations are to be 
reported to the Institutional Review Board (IRB) as per applicable guidelines. The site study 
staff is responsible for knowing and adhering to IRB reporting requirements. Further details 
about the handling and reporting of protocol deviations will be included in a deviation plan. 
Detailed procedures for the documentation, definition, and escalation of protocol deviations 
will be defined within a separate document. 
11.3 Audits and Inspections 
The Sponsor, regulatory authority, or IRB may visit the study site at any time during the 
study or after completion of the study to perform audits or inspections. The purpose of a 
Sponsor audit or regulatory inspection is to systematically and independently examine all 
study-related activities and documents to determine whether these activities were conducted 
according to the protocol, ICH GCP guidelines (E6), and any other applicable regulatory 
requirements. Investigators should contact the Sponsor immediately if contacted by a 
regulatory agency about an inspection at their site. 
11.4 Amendments 
Any amendments to the protocol will be written and approved by the Sponsor. All 
amendments must be submitted to the IRB for approval prior to implementing the changes. In 
some instances, an amendment may require changes to the informed consent form, which 
also must be submitted for IRB approval prior to administration to patients. If any changes to 
the eCRF are required, the Sponsor will issue supplemental or revised eCRF pages. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 77 of 117 
11.5 Record Keeping 
11.5.1 Drug Accountability  
The Investigator must maintain accurate records of XERMELO receipt, dispensing 
information, and disposition. If the Investigator cannot account for all clinical supplies at the 
termination of the study, a written explanation must be provided. 
11.5.2 Health Insurance Portability Accountability Act of 1996 and Subsequent 
Updates 
The Investigator agrees to comply with all applicable federal, state, and local laws and 
regulations relating to the privacy of patient health information, including, but not limited to, 
the Standards for Individually Identifiable Health Information, 45 CFR Parts 160 and 164 
(the Health Insurance Portability Accountability Act of 1996 [HIPAA] Privacy Regulation 
and any applicable updates). The Investigator shall ensure that study patients authorize the 
use and disclosure of protected health information (PHI) in accordance with HIPAA Privacy 
Regulation and in a form satisfactory to the Sponsor. 
The Department of Health and Human Services updated a final rule to modify HIPAA. The 
new rule has been in effect since 26 Mar 2013, and strengthens the privacy and security 
protection for individual’s health information; modifies the rule for Breach Notification for 
Unsecured PHI (Breach Notification Rule) under the HITECH Act to address public 
comment received on the interim final rule; modifies the HIPAA Privacy Rule to strengthen 
the privacy protections for genetic information by implementing section 105 of Title I of the 
Genetic Information Nondiscrimination Act of 2008 (GINA); and makes certain other 
modifications to the HIPAA Privacy, Security, Breach Notification, and Enforcement Rules 
(the HIPAA Rules) to improve their workability and effectiveness and to increase the 
flexibility for and decrease burden on the regulated entities. 
The full text of the rule can be found at: 
11.5.3 Financial Disclosure 
The Investigator shall provide to the Sponsor sufficient accurate financial information to 
allow the Sponsor to submit complete and accurate financial certification or disclosure 
statements to the FDA. The Investigator shall promptly update this information if any 
relevant changes occur in the course of the study or for 1 year following completion of the 
study. 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 78 of 117 
11.5.4 Access to Original Records 
It is an expectation of regulatory authorities that monitors, auditors, and representatives of 
national and international government regulatory agency bodies have access to original 
source documentation (see examples in Section 11) to ensure data integrity. “Original” in this 
context is defined as the first documentation of an observation and does not differentiate 
between hard copy and electronic records. 
11.5.5 Retention of Study Documents 
The new EU clinical trial regulation (Regulation (EU) No 536/2014 of the European 
Parliament and of the Council of 16 April 2014 (Article 58) mandates a new minimum 
retention period for the trial master file of 25 years after the end of the clinical trial”. This 
establishes a more specific time period than with internationally accepted practice of ICH 
GCP.  
The Investigator must not destroy any study-related records without receiving approval from 
the Sponsor. The Investigator must notify the Sponsor in the event of accidental loss or 
destruction of any study records. If the Investigator leaves the institution where the study was 
conducted, the Sponsor must be contacted to arrange alternative record storage options. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 79 of 117 
12 ADMINISTRATIVE STRUCTURE OF THE STUDY 
The study will be monitored by Sponsor personnel or the Sponsor’s representative. The 
following functions for this study will be performed by organizations designated by the 
Sponsor: data management and statistical analysis, including pharmacodynamic analysis and 
reporting. 
Specific functions designated by the Sponsor to another organization are to be defined via a 
formal transfer of obligations. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 80 of 117 
13 APPENDIX A – SCHEDULE OF EVENTS: 
Procedure 
Treatment Period2,3,4  
(1 cycle = 21 days, with Cis/Gem treatment on D1 & D8 and XERMELO treatment daily) 
Screening1 
(Up to 21 days)
C1 
D1 
C2 
D1 
C3 
D1 
C4 
D1 
C5 
D1 
C6 
D1 
C7 
D1 
C8 
D1 
C9 
D1 
C10 
D1
C11 
D1 
C12 
D1 
C13 
D1 
C14 
D1 
C15 
D1 
C16 
D1 
C17 
D1 
C18 
D1 
C19 
D1 
EOT
5,6
Window 
(days) 
NA 
NA 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
Assess IE 
criteria 
X 
X 
Medical 
history and 
demographics 
X 
Full physical 
exam7
X 
X 
X 
Symptom-
oriented, brief 
physical 
exam7 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Height 
X 
Vital signs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum 
pregnancy 
test8 
X 
Urine 
pregnancy 
test8 
X 
X 
Hematology9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X10 
Blood 
chemistry9 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X10 
Serum CA 
19-99,11
X 
X 
X 
X 
X 
X 
X 
X10 
Serum CEA9 
X 
X 
X 
X 
X 
X 
X 
X10 
Plasma 5-
HIAA9 
X 
X 
X 
X 
X 
X 
X 
X10 
PK trough 
sample9,12 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X10 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
X 
X10 
Tumor 
Assessment13 
 (CT or MRI) 
X1 
X1 
X 
X 
X 
X 
X 
X 
X10 
ECG 
X 
X 
X 
X 
X 
X 
X 
X 
X10 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 81 of 117 
Procedure 
Treatment Period2,3,4  
(1 cycle = 21 days, with Cis/Gem treatment on D1 & D8 and XERMELO treatment daily) 
Screening1 
(Up to 21 days)
C1 
D1 
C2 
D1 
C3 
D1 
C4 
D1 
C5 
D1 
C6 
D1 
C7 
D1 
C8 
D1 
C9 
D1 
C10 
D1
C11 
D1 
C12 
D1 
C13 
D1 
C14 
D1 
C15 
D1 
C16 
D1 
C17 
D1 
C18 
D1 
C19 
D1 
EOT
5,6
Window 
(days) 
NA 
NA 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
±4 
ECOG 
Performance 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Depression 
detection 
(ePRO) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
EORTC 
QLQ-30 and 
QLQ-BIL21 
(ePRO) 
X 
X 
Record 
concomitant 
medications14 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Record SAEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Record AEs 
and AESIs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense 
Xermelo4,15
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X16 
Cis/Gem 
Infusion17 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Intensive PK 
substudy18 
X 
X 
X 
X 
X 
X 
X 
Tumor 
characterizati
on substudy19 
X 
1.
The Screening Visit allows for up to 21 days prior to C1D1 if needed; however, if radiological assessments have been completed within 6 weeks prior to Day 1, they are not required to
be repeated at Day 1.
2.
All assessments, including laboratory assessments, ECGs and questionnaires should be performed prior to initiating treatment regimen.
3.
Treatment visit dates will be scheduled based on the date of enrollment.
4.
All cycles are 21 days, with Cis/Gem treatment on D1 and D8 and XERMELO treatment daily. Patients are not required to complete a specific amount of cycles, patients may continue
combination treatment for as many cycles possible until PD, unacceptable toxicity, or patient withdraws from treatment.
5.
EOT procedures should be completed once the patient has confirmed PD, unacceptable toxicity, or withdraws from combination treatment. The patient will then begin the Post-
treatment Follow-up Period (PTFP) where patients return to the site every 3 months to complete the required assessments until a new tumor directed therapy begins, the patient declines
further treatment after progression, or withdraws from any further study visits. At that time, the EOS procedures should be completed and the patient should enter the Survival Follow-
up Period (SFP) until the patient has completed a full 24 months of combination Post-treatment/Survival Follow-up.  During SFP patients are to be contacted by phone every 3 months
to obtain survival status; see Section 5.1.2.2 for details.
6.
Procedures should not be repeated if end of treatment (EOT)/end of study (EOS) occurs during scheduled study visit; however, all EOT/EOS assessments should be completed; with
those required by the scheduled visit to be recorded on the scheduled visit eCRF and additional assessments required by EOT/EOS recorded in the EOS eCRF.
7.
A complete physical examination will include, at minimum, a review of the patient’s general appearance, head, eyes, ears, nose, throat, neck, heart, lungs, abdomen, back, extremities,
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 82 of 117 
skin and general neurological system. A symptom-related brief physical exam will only occur if the patient is experiencing symptoms or AEs. If a symptom-related brief physical exam 
is required, it should include a review of all body systems that relate to the symptoms and/or AE the patient is experiencing. 
8.
Females of childbearing potential only
9.
Day 8 labs are optional (at the discretion of the Investigator) and will be analyzed by the local lab.
10. EOT assessments are not required if the last assessment occurred <3weeks prior; EOS assessments are not required if last assessment occurred ≤8weeks prior.
11. Patients should avoid multivitamins or dietary supplements containing biotin (vitamin B7) for 12 hours prior to sample collection.
12. PK trough samples are required to be drawn for ALL patients. Patients should be in a fasted state and should not have dosed prior to blood draw.
13. Tumor assessments are not required if progressive disease has been confirmed by CT/MRI at previous visit.
14. Prior medications taken within 30 days of screening will be recorded within the patient’s medical history. Any medications that are ongoing at the time of screening should be recorded
within the patient’s concomitant medication page.
15. Xermelo will be dispensed on D1 of each cycle. The patient should be reminded to bring their bottles back on D8 of each cycle in order for dosing of Xermelo to be given with the
chemotherapy infusion.
16. Xermelo can continue to be dispensed during the Post-treatment Follow-up Period, at the discretion of the Investigator, until the patient begins new tumor-directed therapy, declines
further treatment after progression, or withdraws from any further study visits.
17. Cis/Gem are not being provided by TerSera. If cisplatin is stopped, gemcitabine may be continued alone at the Investigator’s discretion.
18. Intensive PK is an optional substudy. These samples are only required for those patients who have consented to participate in this substudy and will be drawn on Day 1 and Day 8 of
each cycle where collected; refer to Appendix B for additional details.
19. Archived tissue samples can be submitted at any time during the Treatment Period. Fresh biopsies will not be collected.
20. Total duration of the 2 combined Follow-up Periods should be no more than 24 Months.
21. Follow-up visits dates should be scheduled based on the EOT date.
22. Phone call to patient or caregiver, where appropriate, to obtain survival status.
23. Patients who enter PTFP and imaging assessments are not required, or who enter SFP without entering or completing PTFP prior to having their 6-month imaging assessment in the Treatment
Period, will be asked to consent to provide their local scans and/or local scan report closest to the 6-month timepoint.  Reconsenting the patient may be required if previously prematurely
discontinued or withdrew consent from the Treatment Period of the study.
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 83 of 117 
APPENDIX A – SCHEDULE OF EVENTS 
AE = adverse event; AESI = adverse event of special interest; CT = computed tomography; Cis = cisplatin; ECG = electrocardiogram; EOS = End of Study; EOT = End of Treatment; Gem 
= gemcitabine; IE = inclusion/exclusion; MRI = magnetic resonance imaging; SAE = serious adverse event; PK = pharmacokinetic 
Procedure 
Follow-up Period20,21 
Post-treatment Follow-up 
 Survival Follow-up 
3 
Month 
6 
Month 
9 
Month 
12 
Month 
15 
Month 
18 
Month 
21 
Month 
24 
Month / 
EOS6 
3 
Month 
6 
Month
9 
Month
12 
Month
15 
Month
18 
Month
21 
Month
24 
Month
Window (days) 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
Phone patient22 
X 
X 
X 
X 
X 
X 
X 
X 
Full physical exam7
X 
Symptom-oriented brief 
physical exam7
X 
X 
X 
X 
X 
X 
X 
Weight 
X 
Vital signs 
X 
X 
X 
X 
X 
X 
X 
X 
Urine pregnancy test8 
X 
Hematology9 
X 
X 
X 
X 
X 
X 
X 
X10 
Blood chemistry9 
X 
X 
X 
X 
X 
X 
X 
X10 
Serum CA 19-99,11 
X 
X 
X 
X 
X 
X 
X 
X10 
Serum CEA9 
X 
X 
X 
X 
X 
X 
X 
X10 
Plasma 5-HIAA9 
X 
X 
X 
X 
X 
X 
X 
X10 
PK trough sample9,12 
X 
X 
X 
X 
X 
X 
X 
X10 
Urinalysis 
X10 
Tumor Assessment13
 (CT or MRI) 
X23 
X23 
X 
X 
X 
X 
X23 
X10,23 
ECG 
X10
ECOG Performance 
X 
X 
X 
X 
X 
X 
X 
X 
Depression detection 
(ePRO) 
X 
EORTC QLQ-30 and 
QLQ-BIL21 (ePRO) 
X 
X 
Record concomitant 
medications18 
X 
X 
X 
X 
X 
X 
X 
X 
Record SAEs 
X 
X 
X 
X 
X 
X 
X 
X 
Record AEs and AESIs 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense Xermelo4,15
X16
X16
X16
X16
X16
X16
X16
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 84 of 117 
1.
The Screening Visit allows for up to 21 days prior to C1D1 if needed; however, if radiological assessments have been completed within 6 weeks prior to Day 1, they are not
required to be repeated at Screening.
2.
All assessments, including laboratory assessments, ECGs and questionnaires should be performed prior to initiating treatment regimen.
3.
Treatment visit dates will be scheduled based on the date of enrollment.
4.
All cycles are 21 days, with Cis/Gem treatment on D1 and D8 and XERMELO treatment daily. Patients are not required to complete a specific amount of cycles, patients may
continue combination treatment for as many cycles possible until PD, unacceptable toxicity, or patient withdraws from treatment.
5.
EOT procedures should be completed once the patient has confirmed PD, unacceptable toxicity, or withdraws from combination treatment. The patient will then begin the
Post-treatment Follow-up Period (PTFP) where patients return to the site every 3 months to complete the required assessments until a new tumor directed therapy begins, the
patient declines further treatment after progression, or withdraws from any further study visits. At that time, the EOS procedures should be completed and the patient should
enter the Survival Follow-up Period (SFP) until the patient has completed a full 24 months of combination Post-treatment/Survival Follow-up.  During SFP patients are to be
contacted by phone every 3 months to obtain survival status; see Section 5.1.2.2 for details.
6.
Procedures should not be repeated if end of treatment (EOT)/end of study (EOS) occurs during scheduled study visit; however, all EOT/EOS assessments should be
completed; with those required by the scheduled visit to be recorded on the scheduled visit eCRF and additional assessments required by EOT/EOS recorded in the EOS
eCRF.
7.
A complete physical examination will include, at minimum, a review of the patient’s general appearance, head, eyes, ears, nose, throat, neck, heart, lungs, abdomen, back,
extremities, skin and general neurological system. A symptom-related brief physical exam will only occur if the patient is experiencing symptoms or AEs. If a symptom-
related brief physical exam is required, it should include a review of all body systems that relate to the symptoms and/or AE the patient is experiencing.
8.
Females of childbearing potential only
9.
Day 8 labs are optional (at the discretion of the Investigator) and will be analyzed by the local lab.
10. EOT assessments are not required if the last assessment occurred <3weeks prior; EOS assessments are not required if last assessment occurred ≤8weeks prior.
11. Patients should avoid multivitamins or dietary supplements containing biotin (vitamin B7) for 12 hours prior to sample collection.
12. PK trough samples are required to be drawn for ALL patients. Patients should be in a fasted state and should not have dosed prior to blood draw.
13. Tumor assessments are not required if progressive disease has been confirmed by CT/MRI at previous visit.
14. Prior medications taken within 30 days of screening will be recorded within the patient’s medical history.  Any medications that are ongoing at the time of screening should be
recorded within the patient’s concomitant medication page.
15. Xermelo will be dispensed on D1 of each cycle. The patient should be reminded to bring their bottles back on D8 of each cycle in order for dosing of Xermelo to be given
with the chemotherapy infusion.
16. Xermelo can continue to be dispensed during the Post-treatment Follow-up Period, at the discretion of the Investigator, until the patient begins new tumor-directed therapy,
declines further treatment after progression, or withdraws from any further study visits.
17. Cis/Gem are not being provided by TerSera. If cisplatin is stopped, gemcitabine may be continued alone at the Investigator’s discretion.
18. Intensive PK is an optional substudy. These samples are only required for those patients who have consented to participate in this substudy and will be drawn on Day 1 and
Day 8 of each cycle where collected; refer to Appendix B for additional details.
19. Archived tissue samples can be submitted at any time during the Treatment Period. Fresh biopsies will not be collected.
20. Total duration of the 2 combined Follow-up Periods should be no more than 24 Months.
21. Follow-up visits dates should be scheduled based on the EOT date.
22. Phone call to patient or caregiver, where appropriate, to obtain survival status.
23. Patients who enter PTFP and imaging assessments are not required, or who enter SFP without entering or completing PTFP prior to having their 6-month imaging assessment
in the Treatment Period, will be asked to consent to provide their local scans and/or local scan report closest to the 6-month timepoint.  Reconsenting the patient may be
required if previously prematurely discontinued or withdrew consent from the Treatment Period of the study.
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 85 of 117 
14 APPENDIX B – INTENSIVE PK SUBSTUDY SCHEDULE 
Schedule of Intensive PK Assessments1 
Predose 
Morning 
Dose2 
1 hr 
2 hr 
3 hr 
4 hr 
6 hr 
Midday 
Dose 
Intensive PK 
Assessments 
X 
X4 
X4 
X4 
X4 
Time of Day 
(Example) 
Predose3 
8:00 
9:00 
10:00 
11:00 
12:00 
14:00 
14:01 
1Patients who have consented to the intensive PK substudy should have PK samples collected at all 
time points shown above on Day 1 and Day 8 of all required cycles; see Appendix A. 
2With food
3Fasted 
4Samples should be collected within 15 minutes of scheduled 
collection time 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 86 of 117 
15 APPENDIX C – ESTIMATED AMOUNT OF BLOOD TO BE 
COLLECTED FROM EACH PATIENT 
Assessment 
Sample 
volume 
(mL) 
Number 
of 
samples* 
Estimated total 
volume (mL) 
Safety 
Hematology 
4 
19 
76 
Blood chemistry 
6 
19 
114 
Serum hCG 
2 
1 
2 
Pharmacokinetic 
XERMELO and LP-
788902 
4 
42 
168 
4 
16 
64 
4 
16 
64 
4 
16 
64 
Total 
552 
* Maximum number of samples is indicated.
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 87 of 117 
16 APPENDIX D – ETHICAL STANDARDS 
Ethics and Regulatory Considerations 
This study will be conducted according to GCP, 21 CFR Part 50, (Protection of Human 
Subjects), 21 CFR Part 56 (Institutional Review Boards), ICH Guidance for Industry, E6 
GCP: Consolidated Guidance, the Nuremberg Code, and the Declaration of Helsinki.  
General Instructions 
The FDA regulates studies of drugs, biologics, and medical devices. Consequently, these 
studies are patient to GCP regulations and guidance issued by the FDA and are included in, 
but not limited to, the following parts of the CFR and guideline document: 
•
21 CFR Part 11 – Electronic Records
•
21 CFR Part 50 – Protection of Human Patients
•
21 CFR Part 54 – Financial Disclosure
•
21 CFR Part 56 – Institutional Review Boards
•
21 CFR Part 312 – Investigational New Drug Application
•
Current FDA Guideline for the Monitoring of Clinical Investigations
•
Current FDA Guideline for Institutional Review Boards and Clinical Investigators
•
Current FDA Guideline for Good Clinical Practice
Copies of these materials are available from the Sponsor upon request. The purpose of these 
regulations and legal obligations is to define the standards and principles for the proper 
conduct of clinical trials that have been developed by the medical, scientific, and regulatory 
communities. They are not intended to impede or restrict clinical research.  
The ethical standards defined within GCP are intended to ensure that: 
•
human patients are provided with an adequate understanding of the possible risks of
their participation in the study, and that they have a free choice to participate or not;
•
the study is conducted with diligence and in conformance with the protocol in such a
way as to ensure the integrity of the findings;
•
the potential benefits of the research justify the risks.
TerSera Therapeutics LLC is the Sponsor of the Investigational New Drug Application 
(IND). The Sponsor is responsible for the following: 
•
selecting qualified Investigators,
•
providing Investigators with the information they need to properly conduct an
investigation,
•
ensuring proper monitoring of the investigation,
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 88 of 117 
•
ensuring that the study is conducted according to the general investigational plan and
protocols contained in the IND,
•
maintaining the IND, and
•
ensuring that FDA and all participating Investigators are properly informed of
significant new information regarding adverse effects or risks associated with the drug
being studied.
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 89 of 117 
17 APPENDIX E – INVESTIGATOR OBLIGATIONS 
Per Title 21 of the US Government Code of Federal Regulations (21 CFR) Parts 50 and 56, 
the study protocol and the final version of the patient informed consent form will be approved 
by the IRB before enrollment of any patients. The opinion of the IRB will be dated and given 
in writing. A copy of the letter of approval from the IRB and a copy of the approved informed 
consent form will be received by the Sponsor prior to shipment of XERMELO supplies to the 
Investigator. 
The Investigator will ensure that the IRB will be promptly informed of all changes in the 
research activity and of all unanticipated problems including risk to patients. The Investigator 
will also ensure that no changes will be made to the protocol without IRB approval. 
As a part of the IRB requirement for continuing review of approved research, the Investigator 
will be responsible for submitting periodic progress reports to the IRB at intervals appropriate 
to the degree of patient risk involved, but no less than once per year. 
Written informed consent must be given freely and obtained from every patient prior to 
clinical trial participation. The rights, safety, and well-being of the trial patients are the most 
important considerations and should prevail over interests of science and society. 
As described in GCP guidelines, study personnel involved in conducting this trial will be 
qualified by education, training, and experience to perform their respective task(s). Study 
personnel will not include individuals against whom sanctions have been invoked after 
scientific misconduct or fraud (eg, loss of medical licensure, debarment). Quality assurance 
systems and procedures will be implemented to assure the quality of every aspect of the 
study. 
Principal Investigators in the US must provide the Sponsor with a fully executed Form FDA 
1572 (statement of Investigator) and all updates on a new fully executed Form FDA 1572. 
Principal Investigators must provide the Sponsor with their own curriculum vitae and current 
curriculum vitae for each subinvestigator listed on the Form FDA 1572. 
Protection of Human Patients (21 CFR Part 50) 
Informed consent must be obtained from every patient before entry into a clinical study. It 
must be given freely and not under duress. Consent must be documented by use of an IRB-
approved consent form and signed by the patient or the patient’s legally authorized 
representative. The Department of Health and Human Services suggests that when minors are 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 90 of 117 
involved, a parent or guardian should sign the consent form. If the minor is an adolescent, 
their signature should also be included. Non-English-speaking patients must be presented 
with a consent form written in a language that they understand. A copy of the signed consent 
form must be given to the patient signing it. Another copy must be kept in the Investigator’s 
files and made available to FDA representatives upon request. If, for any reason, patient risk 
is increased as the study progresses, a revised, IRB-approved consent form must be signed by 
the patient. Before the study begins, a sample of the consent form must be provided to the 
Sponsor for review. The FDA may reject otherwise scientifically valid studies if proper 
informed consent has not been obtained from all patients. 
Only in the case of a life-threatening incident may an investigational product be used without 
prior signed consent. In such an emergency situation, separate certifications must be written 
both by a physician not participating in the study and by the Investigator. The certifications, 
along with the protocol and informed consent, must be sent to the IRB within 5 working 
days. In this situation, the Investigator may not administer any subsequent product to that 
patient until informed consent and IRB approval are obtained. 
Informed Consent 
Written informed consent must be obtained from each patient prior to entry in the study. One 
copy of the signed informed consent document will be given to the patient, and another will 
be retained by the Investigator. Additionally, the participant must be allowed adequate time to 
consider the potential risks and benefits associated with his/her participation in the study.  
In situations where the participant is not legally competent to provide consent (i.e., mentally 
incapacitated), written consent must be obtained from a parent, legal guardian, or legal 
representative. In these situations, the consent must be signed and dated by a witness. 
The informed consent document must have been reviewed and approved by the Sponsor and 
by the Investigator’s IRB prior to the initiation of the study. The document must contain the 8 
basic elements of informed consent and may contain the 6 additional elements described in 
21 CFR Part 50. Every consent form must include the following 8 elements: 
•
A statement that the study involves research, an explanation of the purpose of the
research and the expected duration of the patient’s participation, a description of the
procedures to be followed, and identification of any procedures that are experimental
•
A description of any reasonably foreseeable risks or discomforts to the patient
•
A description of any benefits to the patient or to others that may reasonably be
expected from the research
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 91 of 117 
•
A disclosure of appropriate alternative procedures or course of treatment, if any, that
might be advantageous to the patient
•
A statement describing the extent, if any, to which confidentiality of records
identifying the patient will be maintained and noting the possibility that the FDA and
representatives may inspect the records
•
An explanation as to whether any compensation or medical treatments are available if
injury occurs for research involving more than minimal risk. The explanation should
involve a description of the compensation or treatment available, or a statement
describing where further information may be obtained
•
An explanation of whom to contact for answers to pertinent questions about the
research and the patient’s rights and whom to contact in the event of a research related
injury
•
A statement that participation is voluntary, that refusal to participate will involve no
penalty or loss of benefits to which the patient is otherwise entitled, and that the
patient may discontinue participation at any time without penalty or loss of benefits to
which the patient is otherwise entitled.
When appropriate, 1 or more of the following elements of information shall also be included 
in the consent form: 
•
A statement that the particular treatment or procedure may involve risks to the patient
(or to the embryo or fetus, if the patient is or may become pregnant), which are
currently unforeseeable
•
Anticipated circumstances under which the patient’s participation may be terminated
by the Investigator without regard to the patient’s consent
•
Any additional costs the patient may incur from participation in the research
•
The consequences of a patient’s decision to withdraw from the research and
procedures for orderly termination of participation by the patient
•
A statement that significant new findings developed during the course of the research
that may relate to the patient’s willingness to continue participation will be provided
to the patient
•
The approximate number of patients involved in the study
The Declaration of Helsinki includes further details regarding the specific requirements for 
informed consent.  
Nothing in these regulations is intended to limit the authority of a physician to provide 
emergency medical care to the extent the physician is permitted to do so under applicable 
federal, state, or local laws. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 92 of 117 
The informed consent requirements in these regulations are not intended to preempt any 
applicable federal, state, or local laws that require additional information to be disclosed in 
order that informed consent be legally effective. Some states, such as California and Oregon, 
require further action on the Investigator’s part concerning patient consent. 
Study Documentation 
The protocol and informed consent form(s) for this study, including advertisements used to 
recruit participants, must be reviewed and approved by an appropriate IRB/Ethics Review 
Committee (ERC) prior to enrollment of participants in the study. It is the responsibility of 
the Investigator to assure that all aspects of the ethical review are conducted in accordance 
with the current Declaration of Helsinki, ICH GCP, and/or local laws, whichever provide the 
greatest level of protection. A letter documenting the IRB/ERC approval, which specifically 
identifies the study/protocol and a list of the committee members, must be received by the 
Sponsor prior to initiation of the study. Amendments to the protocol will be subject to the 
same requirements as the original protocol. 
A progress report with a request for reevaluation and reapproval will be submitted by the 
Investigator to the IRB/ERC at intervals required by the IRB/ERC, and not less than 
annually. A copy of the report will be sent to the Sponsor.  
When the Sponsor provides the Investigator with a Safety Report, the Investigator must 
promptly forward a copy to the IRB/ERC. 
After completion or termination of the study, the Investigator will submit a final report to the 
IRB/ERC and to the Sponsor, if required. This report should include: deviations from the 
protocol, the number and types of participants evaluated, the number of participants who 
discontinued (with reasons), results of the study, if known, and significant AEs, including 
deaths. 
Study Files 
The Investigator is required to maintain complete and accurate study documentation in 
compliance with current GCP standards and all applicable federal, state, and local laws, rules, 
and regulations related to the conduct of a clinical study. Study documents include, but are 
not limited to, the IB, drug accountability records, Sponsor/Investigator correspondence, IRB 
correspondence, protocol and amendments, information regarding monitoring activities, 
patient exclusion records, eCRFs, and data queries. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 93 of 117 
Confidentiality 
The anonymity of participating patients must be maintained. Patients will be identified by an 
assigned patient number on eCRFs and other documents submitted to the clinical monitor. 
Documents that will be submitted to the clinical monitor and that identify the patient (eg, the 
signed informed consent document) must be maintained in strict confidence by the Principal 
Investigator, except to the extent necessary to allow auditing by the FDA, the clinical 
monitor, or Sponsor personnel. 
All information regarding the nature of the proposed investigation provided by the Sponsor to 
the Investigator (with the exception of information required by law or regulations to be 
disclosed to the IRB, the patient, or the FDA) must be kept in confidence by the Investigator. 
Drug Accountability 
The Investigator or designee is responsible for accountability of XERMELO at the site. The 
Investigator or designee must maintain records of the product’s delivery to the site, inventory 
at the site, use by each patient, and return to the Sponsor or alternative disposition of any 
unused product. These records must include dates, quantities, batch/serial/lot numbers, and 
expiration dates (if applicable). 
The Investigator should ensure that XERMELO is used only in accordance with the protocol. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 94 of 117 
18 APPENDIX F – CALCULATIONS 
Cockcroft-Gault equation: 
The equation for calculation of creatinine clearance, as an estimation of glomerular filtration 
rate, using the method of Cockcroft and Gault is: 
     [(140-age) x weight (in kg)]___ 
[72 x serum creatinine (in mg/dL)]  
If the patient is female, multiply the above by 0.85  
For an online calculator, please use: http://www.nephron.com/cgi-bin/CGSI.cgi. 
Source:  Cockcroft D, Gault MD. Prediction of Creatinine Clearance from Serum Creatinine. 
Nephron. 1976;16:31-41. 
Body Mass Index equation: 
For an online calculator, please use: 
From the Centers for Disease Control and Prevention site: 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 95 of 117 
Reference: 
National Cancer Institute – Cancer Therapy Evaluation Program. Clinical Data Update System (CDUS) 
Instructions and Guidelines version 3.0 Release 4. Capital Technology Information Services, Inc. 15 January 
2008. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 96 of 117 
20 APPENDIX H – NATIONAL CANCER INSTITUTE (NCI) 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS 
(CTCAE) V5.0 
The NCI CTCAE v5.0 can be found at: 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 97 of 117 
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 98 of 117 
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 99 of 117 
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 100 of 117 
22 APPENDIX J – RESPONSE EVALUATION CRITERIA IN SOLID 
TUMORS (RECIST) 
The RECIST Guidelines can be found at: 
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 101 of 117 
23 APPENDIX K - DETAILED SUMMARY OF PROTOCOL CHANGES 
Section 
Former Text 
New Text (in Bold) 
Rationale 
Cover Page 
Added Amendment 3 Date: 
15 November 2020 
Cover Page 
Sponsor 
Lexicon Pharmaceuticals, Inc. 
8800 Technology Forest Place 
The Woodlands, TX 77381-1160 
Sponsor 
TerSera Therapeutics LLC 
 520 Lake Cook Road, Suite 500 
Deerfield, IL 60015 
Investigator 
Signature 
Page 
Added Amendment 3 Date: 
15 November 2020 
Investigator 
Signature 
Page 
Sponsor 
Lexicon Pharmaceuticals, Inc. 
8800 Technology Forest Place 
The Woodlands, TX 77381-1160 
Sponsor 
TerSera Therapeutics LLC 
 520 Lake Cook Road, Suite 500 
Deerfield, IL 60015 
Investigator 
Signature 
Page 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 102 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
Protocol 
Amendment 
Changes 
Added: 
Protocol Amendment Summary Of Key Changes 
Synopsis-
Primary 
Objective 
Section 4.1-
Primary 
Objective 
The primary objective of the study is to 
assess the safety and efficacy (progression-
free survival rate at Month 6) of XERMELO 
in combination with cisplatin (cis) plus 
gemcitabine (gem) 
The primary objective of the study is to assess the 
safety and efficacy (PFS rate at Month 6) in the 
Safety population receiving the combination of 
XERMELO plus 1L treatment with cis/gem 
combination chemotherapy. Efficacy (PFS rate at 
Month 6) will also be evaluated in the Per 
Protocol Population (PP) and by treatment cycle. 
Synopsis-
Second 
Objectives 
Section 4.2-
Secondary 
Objective 
Section 10.3-
Study 
Endpoints 
•
PFS rate at Month 12 and median PFS
•
PFS rate at Month 12 and median PFS at
Month 12
Synopsis-
Exploratory 
Objectives 
Section 4.3-
Exploratory 
Objectives 
Section 10.3-
Study 
Endpoints 
•
Change from Baseline in
•
Subgroup analyses of PFS, OS, ORR,
and DCR using both BICR and local
radiologist’s assessment, based on
categorical group of Baseline and
change from Baseline
•
Change from Baseline in
 at 
Months 6 and 12 and EOS; 
•
Subgroup analyses of PFS, OS, ORR, and
DCR using both BICR and local
radiologist’s assessment, based on
categorical group of Baseline and change
from Baseline at Months 6 and 12 and
EOS in:
Added the following new objectives: 
•
Subgroup analyses in:
o
Patients with changes in liver
function tests
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 103 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
o
Patients with Biliary stents
o
Location of disease (intrahepatic,
extrahepatic, or gallbladder)
•
Efficacy analyses by treatment cycles
(such as in patients who completed
 with combination
treatment)
Synopsis-
Methodology 
Section 
5.1.2.1-
Treatment 
Period 
If 12 or more patients have survived and 
remain progression-free at Month 6, Stage 1 
of the study will be considered successful 
and enrollment will continue in Stage 2. 
From a total of 53 accrued patients from 
Stage 1 + Stage 2, if 34 or more responses 
are observed (ie, patients are alive and 
progression-free at Month 6) the study will 
be declared successful 
Added: 
Note: Efficacy (PFS rate at Month 6) will also 
be assessed in the Per Protocol population and 
by treatment cycle. 
Note: For statistical purposes and most 
analyses, Cycle 1 Day 1 is intended as 
Baseline, Cycle 10 Day 1 is intended as 
Month 6, and Cycle 19 Day 1 is intended 
as Month 12.  
If there are no clinically significant or 
unresolved Grade 3 or higher toxicities 
considered related to the study drug, and if 
efficacy in 12 (60%) or more of the 20 patients 
are deemed responders, in the Safety 
population, enrollment will continue to Stage 2. 
In addition, efficacy will be assessed in the Per-
Protocol (PP) population and by treatment 
cycle. 
From a total of 53 accrued patients from Stage 1 + 
Stage 2, if 34 (>60%) or more responses are 
observed (i.e., patients are alive and progression-
free at Month 6) in the Safety population, the 
study will be declared successful. Efficacy will 
also be assessed in the PP population and by 
treatment cycle. 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 104 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
Section 
5.1.2.2-
Follow-up 
Periods 
Note: If a radiological assessment has not 
been performed within 6 weeks prior to Day 
1, an assessment at Screening will also be 
required. 
All patients are expected to be followed for a 
total duration of 24 months after the 
Treatment Period unless they voluntarily 
withdraw consent from future study visits or 
assessments. 
Patients will complete scheduled study visits 
every 3 months for a total of 24 months or 
until the patient begins a new tumor-directed 
therapy, declines further treatment after 
progression, or withdraws consent from 
future study visits or assessments. 
Note: If a radiological assessment has 
performed within 6 weeks prior to Day 1, a 
Day 1 assessment will not be required. 
All patients are expected to be followed for a total 
duration of 24 months after the Treatment Period 
unless they prematurely discontinue or 
voluntarily withdraw consent from future study 
visits or assessments. 
Patients will complete scheduled study visits 
every 3 months for a total of 24 months or until 
the patient begins a new tumor-directed therapy, 
prematurely discontinues, declines further 
treatment after progression, or withdraws consent 
from future study visits or assessments. 
Added: 
Note: For those patients who enter PTFP prior 
to having their 6-month imaging assessment in 
the Treatment Period, will be asked to consent 
to provide their local scans and/or local scan 
report closest to the Treatment Period 6-month 
timepoint. This includes the possible 
reconsenting of patients previously 
prematurely discontinued or withdrew consent 
from the Treatment Period of the study. 
Note: Patients who enter SFP without entering 
or completing PTFP and who entered SFP 
prior to having their 6-month imaging 
assessment in the Treatment Period, will be 
asked to consent to provide their local scans 
and/or local scan report closest to the 
Treatment Period 6-month timepoint. This 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
CONFIDENTIAL 
Page 105 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
includes the possible reconsenting of patients 
previously prematurely discontinued or 
withdrew consent from the Treatment Period 
of the study. 
Synopsis-
Direction of 
Treatment 
Added: 
Note: Patients may continue to receive 
treatment for as many cycles possible, until 
progressive disease (PD) (up to 19 cycles 
during the Treatment Period), and during the 
Post Treatment Follow-up Period (up to an 
additional 24 months) at the discretion of the 
Investigator. 
Synopsis-
Interim 
Analysis 
New Section: 
A formal statistical interim analysis will be 
performed on patients included in the Stage 1 
analysis. The interim analysis results will include 
safety, efficacy (PF responder rates), and 
pharmacodynamic (biomarker) data. These data 
will be used to help plan for future studies. 
Interim Analysis will be conducted: 
•
In addition to (Stage 1 + Stage 2) analysis,
after all 53 patients complete Month 6
In addition to (Stage 1 + Stage 2) analysis after, 
all 53 patients complete Month 12 
Synopsis-
Statistical 
Methods 
In Stage 1, if 12 or more of the 20 patients 
enrolled are deemed responders per the 
clinically significant or unresolved Grade 3 or 
higher toxicities considered related to the study 
drug and if 12 or more (≥60%) of the 20 
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 106 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
definition below after the 20th patient is 
censored, is alive and progression-free at the 
Month 6 assessment, or has discontinued for 
any reason, the first stage of the study will be 
declared successful and enrollment will 
continue in Stage 2. 
In Stage 2, an additional 33 patients will be 
enrolled. If 34 or more of the 53 patients 
enrolled (Stage 1 + Stage 2) are deemed 
responders, the study will be considered 
successful. 
patients enrolled are deemed responders per the 
definition below after the 20th patient is censored, 
is alive and progression-free at the Month 6 
assessment, or has discontinued for any reason, 
the first stage of the study will be declared 
successful and enrollment will continue in Stage 
2. Efficacy will also be assessed in the PP
populations and by treatment cycle.
In Stage 2, an additional 33 patients will be 
enrolled. If 34 (>60%) or more of the 53 patients 
enrolled (Stage 1 + Stage 2) are deemed 
responders, the study will be considered 
successful. Efficacy will also be assessed in the 
PP populations and by treatment cycle. 
Synopsis-PK 
Analysis 
Section 
10.4.4-PK 
Analyses 
PK data will be summarized by n, mean, 
standard deviation, median, minimum, and 
maximum values at various time points. 
PK data will be summarized by n, arithmetic and 
geometric mean, standard deviation, median, 
minimum, and maximum values at various time 
points. 
Abbreviations 
C1D1 Cycle 1, Day 1; Baseline 
C1D1 Cycle 1, Day 1; Baseline (Baseline value 
is defined as the last non-missing data on or 
before the first dose of the study drug, unless 
otherwise specified) 
Added: 
C10D1 Cycle 10, Day 1 is intended as Month 6  
C19D1 Cycle 19 Day 1 is intended as Month 12 
Section 5.1.1-
Screening 
Note: If radiological assessments have been 
completed within 6 weeks prior to Day 1, 
they are not required to be repeated during 
the Screening Period 
Note: If radiological assessments have been 
completed within 6 weeks prior to Day 1, they are 
not required to be repeated at Day 1. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 107 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
Section 
5.1.2.2-
Follow-up 
Periods 
Added: 
Reconsent 
In cases when a patient has prematurely 
discontinued from the study and/or withdrawn 
consent from conducting further study 
assessments, these patients may be asked to re-
consent to provide permission for their local 
imaging and imaging reports to be submitted to 
BICR.  
Section 
6.3.1.1-End-
of-Treatment 
Procedures 
Added: 
For those patients who enter PTFP prior to having 
their 6-month imaging assessment in the 
Treatment Period, will be asked to consent to 
provide their local scans and/or local scan report 
closest to the 6-month timepoint. 
Section 
6.3.1.2-End-
of-Study 
Procedures 
In addition, if a patient voluntarily ends 
participation in the study, it must be recorded 
on the eCRF the extent of withdrawal (eg, 
Does the patient agree to attend future study 
visits, allow contact by study personnel, 
and/or continued access to information about 
potential SAEs?). The date the patient 
discontinues participation and the primary 
reason for termination of participation (eg, 
AE, PD, protocol deviation, withdrawal of 
consent, lost to follow-up, death), must be 
recorded on the eCRF. 
Added: 
Patients who enter PTFP prior to having their 6-
month imaging assessment in the Treatment 
Period, will be asked to consent to provide their 
local scans and/or local scan report closest to the 
6-month timepoint.
In addition, if a patient voluntarily ends 
participation in the study at any time, the 
primary reason for discontinuation (e.g., AE, 
PD, protocol deviation, withdrawal of consent, 
lost to follow-up, death) must be recorded on the 
eCRF and document whether the patient agrees 
to attend future study visits, allow contact by 
study personnel, and/or continued access to 
information and/or images about disease status 
and potential SAEs. The date the patient 
discontinues participation and the primary reason 
for discontinuation of participation (eg, AE, PD, 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 108 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
After the EOS visit occurs, patients who 
have not completed 24 months of follow-up 
will enter the SFP where all patients (or 
caregivers, where appropriate) will be 
contacted by phone every 3 months to obtain 
their survival status until death, withdrawal 
of consent, loss to follow-up, or for a total 
duration of 24 months after the last dose of 
chemotherapy (including the duration of the 
PTFP), whichever occurs first. 
protocol deviation, withdrawal of consent, lost to 
follow-up, death), must be recorded on the eCRF. 
After the EOS visit occurs, patients who have not 
completed 24 months of follow-up will enter the 
SFP where all patients (or caregivers, where 
appropriate) will be contacted by phone every 3 
months to obtain their survival status until death, 
premature discontinuation, withdrawal of 
consent, loss to follow-up, or for a total duration 
of 24 months after the last dose of chemotherapy 
(including the duration of the PTFP), whichever 
occurs first. 
Added: 
Note: Patients who enter SFP without entering 
or completing PTFP and who entered SFP 
prior to having their 6-month imaging 
assessment in the Treatment Period, will be 
asked to consent to provide their local scans 
and/or local scan report closest to the 6-month 
timepoint. This includes the possible 
reconsenting of patients previously 
prematurely discontinued or withdrew consent 
from the Treatment Period of the study. 
Section 7-
Treatment 
Lexicon 
TerSera 
Section 7.3-
Prohibited 
Medication or 
Concomitant 
Therapy 
(Lexicon Pharmaceuticals, Inc., 2017), 
(TerSera Therapeutics LLC. 2020)), 
Added: 
•
Chronic treatment with corticosteroids, ≥5
mg/day of prednisone (or equivalent), or other
immunosuppressive agent(s)
Section 8-
Study 
Procedures 
(Lexicon Pharmaceuticals, Inc., 2017), 
(TerSera Therapeutics LLC, 2020). 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 109 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
Section 
8.2.1.1.1-
CT/MRI 
For the purpose of this study, C1D1 will be 
referred to as Baseline. 
For the purpose of this study, images submitted 
to BICR within 6 weeks prior to and including 
C1D1, i.e., which ever set was closest to C1D1 
will be referred to as Baseline imaging. 
Section 8.2.2-
Clinical 
Laboratory 
Assessments 
Added: 
In rare cases, laboratory results obtained from 
the local laboratory may be used to assess 
eligibility when the central laboratory lab 
result is unavailable. Authorization to use local 
laboratory results for determining eligibility 
must be obtained from the Sponsor prior to 
initiating study drug. 
Section 9.4-
Reporting of 
SAEs and 
Pregnancies 
If paper report forms are used, the form(s) 
should be sent to:  
Safety Data Facsimile: (832) 442-5462 or  
Email address (in case of fax failure): 
In case of failure of/lack of access to eCRF, 
email, or fax, the event should be reported 
using Safety Hotline:
If an SAE is reported via telephone, the 
telephone report should be followed by a 
written report using a reporting method 
described above (ie, completion of eCRF of 
paper form).  
For questions on safety reporting, the Safety 
Physician of the study should be contacted 
at: 
 Pharmacovigilance and 
Drug Safety 
Email: 
Phone: 
Added: 
All SAEs, pregnancies, and other special 
situations should be recorded on the study 
participant’s eCRF page for AEs. 
Moved: 
Where applicable, information from relevant 
hospital records and autopsy reports should be 
obtained. 
If paper report forms are used or to provide 
redacted supporting documents, they, should be 
sent to:  
Safety Data Facsimile:
 or 
Email address (in case of fax failure): 
In case of failure of/lack of access to eCRF, email, 
or fax, the event can be reported to the TerSera 
Call Center
If an SAE is reported via telephone, the telephone 
report should be followed by a written report 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 110 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
For questions on study participant 
management related to AE, the Medical 
Monitor of the study should be contacted. 
All SAEs, pregnancies, and other special 
situations should also be recorded on the 
study participant’s eCRF page for AEs. 
using a reporting method described above (i.e., 
completion of eCRF or paper form).  
For questions on safety reporting, please contact 
Section 
10.4.1-
Efficacy 
Analyses 
A Simon’s 2-stage design algorithm will be 
used to assess whether the study is successful 
at each stage of the analysis. In the Stage 1 
Safety Population, if there are no clinically 
significant or unresolved Grade 3 or higher 
toxicities considered related to the study drug 
and   if 12 (60%) or more of the 20 patients 
enrolled who are deemed responders per the 
definition below after the 20th patient is 
censored, is alive and progression-free at the 
Month 6 assessment, or has discontinued for 
any reason, the study will be declared 
successful and enrollment will continue in 
Stage 2. Efficacy will also be assessed in the 
PP population and by treatment cycle. 
In Stage 2, an additional 33 patients will be 
enrolled. If 34 or more (>60%) of the 53 
patients enrolled (Stage 1 + Stage 2) are 
deemed responders, the study will be 
considered successful. 
A Simon’s 2-stage design algorithm will be used 
to assess whether the study is successful at each 
stage of the analysis. In the Stage 1 Safety 
Population, if there are no clinically significant 
or unresolved Grade 3 or higher toxicities 
considered related to the study drug and   if 12 
(60%) or more of the 20 patients enrolled who are 
deemed responders per the definition below after 
the 20th patient is censored, is alive and 
progression-free at the Month 6 assessment, or has 
discontinued for any reason, the study will be 
declared successful and enrollment will continue 
in Stage 2. Efficacy will also be assessed in the 
PP population and by treatment cycle. 
In Stage 2, an additional 33 patients will be 
enrolled. If 34 or more (>60%) of the 53 patients 
enrolled (Stage 1 + Stage 2) are deemed 
responders, the study will be considered 
successful. 
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 111 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
Section 
10.4.7-Interim 
Analysis 
Periodic reviews of study data will be 
conducted as described in Section 9.6 
throughout the study for the purposes of 
safety monitoring but will not serve as a 
formal analysis of study data. No formal 
interim analysis will be performed. 
Periodic reviews of study data will be conducted 
as described in Section 9.6 throughout the study 
for the purposes of safety monitoring but will not 
serve as a formal analysis of study data: 
Added: 
A Stage 1 analysis in a total of 20 patients will 
be conducted.  Stage 1 enrollment will include 
a Safety Run-in cohort. Safety, tolerability and 
efficacy data of the combination treatment 
from the first 6 patients who complete at least 
21 days of safety follow-up after the first dose 
of combination treatment will be evaluated. It 
is anticipated that a total of 20 patients will 
participate in Stage 1. If there are no clinically 
significant or unresolved Grade 3 or higher 
toxicities considered related to the study drug, 
and if 12 (60%) or more of the 20 patients 
enrolled who are deemed PFS responders in 
the Safety population, enrollment will continue 
to Stage 2. In addition, efficacy will be assessed 
in the safety population with aim Efficacy will 
also be assessed in the per-protocol population 
and by treatment cycle. 
Three formal statistical interim analyses will be 
performed during this study as follows: 
•
Interim analysis 1: Conducted in Patients
included in the Stage 1 analysis (first 20
patients enrolled) and will include safety,
efficacy (PFS responder rate),
pharmacodynamic (biomarker) data and
analysis by treatment cycle.
•
Interim analysis 2 added to (Stage 1+2) 6-
month analysis: Conducted after all
Patients (Stage 1 + Stage 2) complete the
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 112 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
Month 6 visit, and will include safety, 
efficacy (PFS responder rate), 
pharmacodynamic (biomarker) data and 
analysis by treatment cycle.  
•
Interim Analysis 3 added to Stage (1+2) 12
month analysis: Conducted after all
Patients (Stage 1 + Stage 2) complete the
Month 12 visit, and will include safety,
efficacy (PFS responder rate),
pharmacodynamic (biomarker) data and
analysis by treatment cycle.
These data will be used to help plan for future 
studies. 
Appendix A-
Schedule of 
Events 
#1: The Screening Visit allows for up to 21 
days prior to C1D1 if needed; however, if 
radiological assessments have been 
completed within 6 weeks prior to Day 1, 
they are not required to be repeated at 
Screening 
#17: Lexicon 
#22 Phone call to patient or caregiver, where 
appropriate, to obtain survival status. 
Added footnotes to tumor assessment 
First table 
#1: The Screening Visit allows for up to 21 days 
prior to C1D1 if needed; however, if radiological 
assessments have been completed within 6 weeks 
prior to Day 1, they are not required to be 
repeated at Day 1. 
#17:TerSera 
Added: 
#23 Patients who enter PTFP and imaging 
assessments are not required, or who enter SFP 
without entering or completing PTFP prior to 
having their 6-month imaging assessment in the 
Treatment Period, will be asked to consent to 
provide their local scans and/or local scan report 
closest to the 6-month timepoint.  Reconsenting 
the patient may be required if previously 
prematurely discontinued or withdrew consent 
from the Treatment Period of the study. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 113 of 117 
Section 
Former Text 
New Text (in Bold) 
Rationale 
Second Table 
Added: 
#22. Phone call to patient or caregiver, where 
appropriate, to obtain survival status. 
#23. Patients who enter PTFP and imaging 
assessments are not required, or who enter SFP 
without entering or completing PTFP prior to 
having their 6-month imaging assessment in the 
Treatment Period, will be asked to consent to 
provide their local scans and/or local scan report 
closest to the 6-month timepoint.  Reconsenting 
the patient may be required if previously 
prematurely discontinued or withdrew consent 
from the Treatment Period of the study. 
Appendix D-
Ethical 
Standards 
Lexicon Pharmaceuticals, Inc. 
TerSera Therapeutics LLC 
Appendix K-
Summary of 
Changes 
New Section 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 114 of 117 
24 REFERENCES 
Alpini G, Invernizzi P, Gaudio E, et al. Serotonin metabolism is dysregulated in 
cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 
2008;68(22):9184-9193. 
American Psychiatric Association. DSM-5 Criteria for Substance-Related Disorders. Criteria 
for Substance Dependence Use (LEVEL 2 – Substance Abuse – Adult), 2013. 
Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin 
Gastroenterol. 2015;29(2):221-232. 
Bristol-Myers Squibb Company, Princeton, New Jersey. Platinol® (cisplatin for injection, 
USP) package insert. September 2010. 
Caplin ME, Pavel M, Ćwikła JB, et al. for the CLARINET Investigators. Lanreotide in 
metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233. 
Caplin ME, Pavel ME, Ruszniewski P, et al. Exploratory analysis of tumor growth rate 
(TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors 
(NETs) from the CLARINET study. J Clin Oncol. 2016; 34(15):suppl 4096-4096.  
Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron 
emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a 
single institution with imatinib mesylate: proposal of new computed 
tomography response criteria. J Clin Oncol. 2007; 25(13):1753-1759. 
Cives M, Simone V, Rizzo FM, Silvestris F. NETs: organ-related epigenetic derangements 
and potential clinical applications. Oncotarget. 2016; 7(35):57414-57429. 
Cockcroft D, Gault MD. Prediction of Creatinine Clearance from Serum Creatinine. 
Nephron. 1976;16:31-41. 
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & 
Co; 1994:253-256.  
Dasari A, Shan C, Halerin D, et al. Trends in the Incidence, Prevalence, and Survival 
Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 
2017;3(10):1335-1342. 
Dierks J, Gaspersz MP, Belkouz A, et al. Translating the ABC-02 trial into daily practice: 
outcome of palliative treatment in patients with unresectable biliary tract cancer treated with 
gemcitabine and cisplatin.  Acta Oncol. 2018;57(6):807-812. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 115 of 117 
Drozdov I, Kidd M, Gustafsson BI, et al. Autoregulatory effects of serotonin on proliferation 
and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer. 
2009;115(21):4934-4945. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. 
Food and Drug Administration. Code of Federal Regulations Title 21, volume 5. Food and 
Drugs. Chapter I - Food and Drug Administration. Department of Health and Human 
Services. Subchapter D -- Drugs for Human Use. Part 312 -- Investigational New Drug 
Application. Subpart B--Investigational New Drug Application (IND). Sec. 312.32 IND 
safety reporting. 
Published April 01, 2017. Accessed May 16, 2018. 
International Conference on Harmonisation. ICH Harmonized Tripartite Guideline. ICH 
Topic E6 Good Clinical Practice. CPMP/ICH/135/95. 17 January 1997 
Huang L, Frampton G, Rao A, et al. Monoamine oxidase A expression is suppressed in 
human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest. 
2012;92(10):1451-1460. 
Kanthan R, Senger JL, Ahmed S, Kanthan SC. Gallbladder Cancer in the 21st Century. J 
Oncol. 2015;2015:967472. 
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Ann Stats 
Assoc. 1958;53(282):457-481. 
Kulke, MH, Horsch, D, Caplin, ME, et al. Telotristat Ethyl, a Tryptophan Hydroxylase 
Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017;35(1):14-23. 
Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340(11):858-868. 
Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine 
tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical 
Trials Planning Meeting. J Clin Oncol. 2011;29(7):934-943. 
Kunz PL. Carcinoid and Neuroendocrine Tumors: Building on Success. J Clin Onc. 
2015;33(16):1855-1863. 
Lexicon Pharmaceuticals, Incorporated, The Woodlands, TX. XERMELO® (telotristat ethyl) 
package insert. February 2017. 
Lexicon Pharmaceuticals, Incorporated, The Woodlands, TX. Telotristat Etiprate (LX1606 
Hippurate) Investigator Brochure. July 2017. 
CCI
CCI
CCI
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 116 of 117 
Lilly USA, LLC, Indianapolis, IN. GEMZAR® (gemcitabine for injection) package insert. 
1996, 2018. 
Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma. 
World J Gastroenterol. 2016;22(4):1335-1347. 
Masab M, Saif MW. Telotristat ethyl: proof of principle and the first oral agent in the 
management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome 
diarrhea. Cancer Chemother Pharmacol. 2017; 80(6):1055-1062. 
National Comprehensive Cancer Network®. NCCN Guidelines® v 1.2018 Neuroendocrine 
and Adrenal Tumors. March 29, 2018. 
Öberg K, Knigge U, Kwekkeboom D, Perren A; ESMO Guidelines Working Group. 
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii124-vii130. 
Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with 
cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J 
Cancer. 2010;103(4):469-474. 
Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-2179. 
Rinke A, Müller HH, Schade-Brittinger C, et al; PROMID Study Group. Placebo-controlled, 
double-blind, prospective, randomized study on the effect of octreotide LAR in the control of 
tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the 
PROMID Study Group. J Clin Oncol. 2009;27(28):4656-4663.  
Sahai V, Catalano, PJ, Zalupski, MM, et al. Nab-Paclitaxel and Gemcitabine as First-Line 
Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA 
Oncol. 2018;4(12):1707-1412. 
Sarrouilhe D, Clarhaut J, Defamie N, Mesnil M. Serotonin and cancer: what is the link? Curr 
Mol Med. 2015;15(1):62-77. 
Simon, R, 1989, Optimal Two-Stage Designs for Phase II Clinical Trials, Controlled Clinical 
Trials, Vol. 10, Issue 1, March, 1–10.   
Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of 
gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2011;61(2):113-132. 
Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract 
cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391-398. 
Valle J, Wasan H, Palmer D, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary 
tract cancer. N Engl J Med. 2010; 362:1273-1281. 
CCI

XERMELO® Protocol No. LX1606.207 
15 November 2020 
Page 117 of 117 
Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in 
patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a 
multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 
2009;101(4):621-627. 
Wu, J. Sample size calculation for the one-sample log-rank test. Pharm Stat.2015;12(1):26-
33. 
van der Horst-Schrivers AN, Post WJ, Kema IP, et al. Persistent low urinary excretion of 5-
HIAA is a marker for favourable survival during follow-up in patients with disseminated 
midgut carcinoid tumours. Eur J Cancer. 2007; 43(18):2651-2657. 
Yao JC, Fazio N, Singh S, et al, for the RAD001 in Advanced Neuroendocrine Tumours, 
Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-
functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a 
randomised, placebo-controlled, phase 3 study. Lancet 2016.387(10022):968-977. 
Zhao DY, Lim KH. Current biologics for treatment of biliary tract cancers. J. Gastrointest 
Oncol. 2017;8(3):430-440. 
CCI